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Abstract 
This thesis is concerned with the development and application of methods for the 
diastereoselective synthesis of substituted cyclopropanes. The methodology described in this 
dissertation is based on the addition of nucleophiles to highly reactive cyclopropene 
intermediates, to which a variety of oxygen and nitrogen-based nucleophiles can be efficiently 
employed in this transformation. The presented methodology provides easy access to di-, tri- and 
tetrasubstituted cyclopropanes which is divided into three chapters and describes not only the 
methodology developed in our research group but also other synthetic routes to densely 
substituted cyclopropanes. 
 Chapter one is a review of synthetic methodologies for the preparation of densely 
substituted chirally-rich cyclopropanes with three stereocenters. The first part of the chapter will 
describe the stereoselective addition of zinc carbenoids to substituted alkenes. The following 
section will cover recent advances in the field of transition-metal-catalyzed carbene chemistry. 
Other methods including Michael-initiated ring closure and C-H activation reactions will be 
discussed in the final part of chapter one. 
 Chapter two focuses on intermolecular formal nucleophilic substitution of 
bromocyclopropanes with azoles and anilines. The developed methodology aims for the 
construction of stereodefined di- and trisubstituted cyclopropanes. Formal substitution of 
bromocyclopropanes proceeds via the dehydrohalogenation of bromocyclopropane generating 
cyclopropene in situ followed by subsequent addition of a nitrogen-based nucleophile with  
 
iv 
	  
Abstract (Continued) 
efficient selectivity control achieved by thermodynamically driven epimerization of enolizable 
carboxamides or directing effect of a substituent on a three-membered cycle. 
 Chapter three describes a highly efficient and diastereoselective synthesis of 
tetrasubstituted donor-acceptor cyclopropanes that can be obtained in a homochiral form from 
corresponding bromocyclopropyl carboxylic acids. A single chiral center on bromocyclopropane 
dictates the configuration of the other two stereocenters that are successively installed via a 
sterically controlled addition of a nucleophile to a chiral trisubstituted cyclopropene, followed by 
a thermodynamically driven epimerization of the resulting enolate intermediate. This new “dual-
control” strategy was successfully employed to the synthesis of densely substituted 
cyclopropanes in inter- and intramolecular fashion.  
 
 
 
 
 
Keywords: cyclopropene, cyclopropane, bromocyclopropanes, donor-acceptor cyclopropanes, β-
aminocyclopropanecarboxylic acid, activated C=C bond, aza-Michael, oxa-Michael, directing 
groups, cyclopropyl acid.   
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Chapter 1. Synthesis of Densely Substituted Cyclopropanes with Three 
Stereocenters 
 This thesis is concerned with the synthesis of chiral densely functionalized 
cyclopropanes. For this reason, in the introductory chapter, it is appropriate to provide an 
overview of synthetic methods, which have been used in their preparation.  
1.0. Introduction 
 Cyclopropane-based scaffolds are attractive and versatile targets due their innate 
rigidity, unusual geometry, compact size, and metabolic stability. 1 The cyclopropane unit 
is an extremely useful tool for controlling the conformation of molecules as the rigid 
carbon backbone allows the substituents to be organized in three-dimensional space. 
Despite the importance of this target, the synthesis of enantiomerically and 
diastereomerically pure cyclopropane derivatives still remains a considerable challenge. 
Efficient asymmetric assembly of cyclopropanes is often limited to di- and trisubstituted 
cyclopropanes. Thus, more effort is required in developing new methods to synthesize 
highly substituted cyclopropanes, especially in intermolecular fashion. 2 
1.1. Occurrence in Nature and Applications 
 Substituted cyclopropanes are attractive targets because of their biological and 
pharmaceutical applications. 3 While the cyclopropane ring is highly strained, it is still 
found in a large number of natural products and biologically active compounds. 4  There is 
a number of multisubstituted cyclopropanes with impressive biological profiles (Scheme	  
1). Fumarranol 1 is a member of fumagillin family of natural products and selectively 
inhibits type 2 methionine aminopeptidase (MetAP2) and endothelial cell proliferation  
	   2	  
and is also active in a mouse model of angiogenesis in vivo.5 The polyketide Ambruticin 
2 is an attractive candidate for drug development as an antifungal agent, which was 
isolated from the fermentation of Polyangium cellusum var. fulvum. 6 This trisubstituted 
trans-divinylcyclopropane compound exhibits unprecedented oral activity against 
histoplasmosis and coccidiomycosis fungal infections. Ambruticin also displays potent 
inhibitory activity against the yeast strain Hansenula anomala. 7 Crispatene 3 is a mild 
cytotoxic agent, a member of polypropionate natural products which has been isolated 
from the saccoglossan mollusc Elysia crispate8. Eglumetad 4 (LY 354740) is a highly 
potent agonist selective for group II (mGluR2/3) receptors (EC50 = 5.1 and 24.3 nM at  
Scheme	  1 
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mGlu2 and mGlu3 receptors respectively). Eglumetad is widely used in studies of 
addiction, epilepsy, schizophrenia, hyperactivity, and sleep. 9 Cyclopropyl benzofuran 5 
exhibits good GPR40 agonistic activity with EC50 = 0.1nM and is used to treat type 2 
diabetes. 10 Cyclopeptide 6 is a novel high-affinity αv β3/ αv β5 integrin binder with EC50 
= 0.02 µM inhibition of human integrin αv β3 receptor and EC50 = 1.5 μM αv β5 receptor 
inhibition. DCG-IV 7 is a research drug which acts as a group-selective agonist for the 
group II metabotropic glutamate receptors (mGluR2/3). DCG-IV has potent 
neuroprotective and anticonvulsant effects in animal studies, anti-Parkinsonian effects, 
but also impairs the formation of memories.11 
1.2. Synthetic Approach Towards Densely Substituted Cyclopropanes  
   There have been numerous synthetic studies in the literature, new and more 
efficient methods for the preparation of trisubstituted cyclopropanes in enantiomerically 
pure form are still evolving. 12 Several distinct approaches for the construction of densely 
substituted cyclopropanes include: carbenoid addition to alkenes, also known as the 
Simmons-Smith cyclopropanation; transition-metal-catalyzed carbene [2+1] 
cycloaddition, Michael-initiated ring closure (MIRC); Kishner synthesis, pyrolysis and 
photolysis of pirazolines; functional group manipulation/C-H activation of existing 
cyclopropanes and cyclopropene functionalization (Scheme	  2).  
1.3. Simmons-Smith Cyclopropanation 
 Discovered more than 50 years ago, 13 Simmons-Smith cyclopropanation is the 
reaction of alkenes with diiodomethane in the presence of activated zinc, affording  
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Scheme	  2 
 
cyclopropanes. Despite the tremendous progress that was done since its discovery in 
1958, the asymmetric Simmons–Smith reaction was only introduced in 1992 by 
Kobayashi et al.14 on allylic alcohols 8 in the presence of chiral disulfonamide catalyst 9. 
(Scheme	  3).  
 The Simmons-Smith reaction remains one of the most important reactions for the 
synthesis of cyclopropanes, however the use of Simmon-Smith cyclopropanation to 
generate 1,2,3-trisubstituted cyclopropanes in enantioselective fashion is very rare.15 The 
most common zinc carbenoid reagents derived from diiodomethane are typically used to  
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Scheme	  3 
 
install a methylene group on an alkene substrate. Alternatively, α-substituted (α-halo, α-
alkyl and α-arylzinc) zinc carbenoids16 can be used to prepare substituted cyclopropanes. 
α-alkylzinc carbenoids may partially decompose via a β-hydride elimination pathway, a 
careful temperature control and a large excess of reagent is needed to obtain high yields 
of the cyclopropane. 
Scheme	  4 
 
cat 12 mol% Et2Zn, CH2I2, -23oC
R1
R2
OH
H
R2
R1 H
OHcat = NHSO2Ar
NHSO2Ar
R1 , R2 = Ph, PhCH2CH2, TrtOCH3, H
Ar = Ph, o-O2N-C6H4, m-O2N-C6H4, p-O2N-C6H4
8
9
10
71 - 99 %
66 - 82 %ee
Ph OH
Me
Ph OH
Me
Ph OH
O
B
O
Me2NOC CONMe2
Bu
2.2 equiv Zn(CHIMe)2
1.1 equiv
>95% ee
> 50 : 111
12
13a 13b
Ph OH Ph OH Ph OH
O
B
O
Me2NOC CONMe2
Bu
2.2 equiv Zn(CHICH2CH2OTIPS)2
1.1 equiv
>95% ee
> 20 : 111
12
14a 14b
TIPSO TIPSO
	   6	  
 In 1997 Charette et al.17 demonstrated a new method to generate 1,2,3-substituted 
cyclopropanes 13 and 14 with excellent diastereo- and enantiocontrol by using 
substituted zinc carbenoids in the presence of the chiral dioxaborolane-derived ligand 12 
(Scheme	   4). High diastereoselectivities and enantioselectivities were obtained with a 
variety of allylic alcohols, treated with the zinc carbenoid reagents formed by mixing 1,1-
diiodoethane and diethylzinc. It was also shown that functionalized 1,1-diiodoalkanes can 
be used in this reaction, cyclopropane 13a can be obtained by treating cinnamyl alcohol 
11 with zinc-based reagent prepared from l-triisopropylsiIyloxy-3,3-diiodopropanaen and 
Et2Zn) in the presence of chiral ligand 12. These examples clearly show the potential of 
this methodology as a convergent synthesis of structurally complex cyclopropanes. 
 An alternative methodology for the synthesis of 1,2,3-substituted cyclopropanes 
was developed by Charette et al. in 2002.18 The new method is based on the preparation 
of a gem-dizinc carbenoid reagent from iodoform and diethylzinc, which is further 
transformed into cyclopropylzinc 16 that is easily derivatized into  substituted species 17 
by quenching the intermediate with a suitable electrophile (Scheme	   5). When allylic 
alcohol is used, the formation of the cyclopropylzinc and the subsequent electrophilic 
quench are highly diastereoselective. 
Scheme	  5 
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 Protected alcohols can be used as directing groups in this transformation and the 
methodology can be applied to the cyclopropanation of enantiopure allylic alcohols 
(Scheme	  6). 19 Zinco-cyclopropanation with gem-dizinc carbenoid 19 of enantioenriched 
trans-alkene 18 and quenching with iodine provided with syn,cis-iodocyclopropane 20. 
Scheme	  6	  
	  
 Similarly, 1,2,3-syn-cis-substituted potassium cyclopropyl trifluoroborates 2320 
can be synthesized from allylic alcohols, readily prepared gem-dizinc carbenoids, 
trimethylborate and KHF2. This reaction proceeds through a zincboron exchange, by 
quenching the cyclopropylzinc intermediate with an electrophilic boron source giving 22, 
which can be converted into trifluoroborates 23 with KHF2. Under optimized conditions 
the reaction is quite general for Z-alkenes, however the yields for E-alkenes are generally 
lower.	   Potassium cyclopropyl trifluoroborates can be used in Suzuki–Miyaura cross-
coupling reactions,21 1,2,3-trisubstituted cyclopropane 24 can be obtained in high yield 
starting from cyclopropane 23 and 1-(4-bromophenyl)ethan-1-one in the presence of 
palladium acetate (Scheme	  7).  
 Highly enantio- and diastereoselective tandem generation of iodocyclopropyl 
alcohols with four contiguous stereocentres was reported by Walsh et al.22 Instead of  
Scheme	  7 
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direct enantioselective cyclopropanation, a tandem reaction was designed involving an 
asymmetric addition to an aldehyde as the first step in the presence of a catalytic amount 
of Nugent’s (-)-MIB.23 The initial enantioselective C–C bond formation was followed by 
a diastereoselective cyclopropanation performed with CF3CH2OZnCHI2 reagent, derived 
from iodoform, giving rise to the corresponding iodocyclopropyl alcohol with up to 99% 
ee (Scheme	  8). 
Scheme	  8	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1.4. Transition-metal-catalysed decomposition of diazoalkanes 
 Transition-metal-catalysed cyclopropanation of olefins with diazoalkanes is a 
very powerful tool in an organic chemist’s arsenal.24 Diazocompounds 28 are first reacted 
with transition metal compounds forming metal carbenoids complexes 29 with 
concomitant release of nitrogen. These compounds undergo [2+1] cycloaddition with 
olefins 30, giving cyclopropanes 31 (Scheme	   9).  Highly enantioselective syntheses of  
functionalized cyclopropanes have been achieved, in particular, with catalysts based on 
copper, rhodium, ruthenium, palladium and other metals. Enantiocontrol in the carbine-
transfer step may be achieved by chiral auxiliary tethered to a substrate by chiral ligands 
surrounding the metal center of the catalyst.  
Scheme	  9	  
	  
1.5. Intramolecular cyclopropanation  
 Copper-based catalysts. 1,2,3-Trisubstituted cyclopropanes can be obtained 
starting from chiral alkene substrates. High stereochemical control in the ethyl 
diazoacetate (EDA) cyclopropanation reaction of a chiral cyclobutene 32, using 
Cu(Acac)2 as the catalyst is observed (Scheme	  10).25 
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Scheme	  10 
 
 Chiral ligands such as bidentate C2-symmetric bisoxazolines are one of the most 
widely used copper-catalyzed enantioselective cyclopropanation reactions. Electron-rich 
furans 34 successfully react with EDA as reported by Reiser et al.26 in the presence of 
bisoxazoline ligands 35, provide the corresponding cyclopropanes 36 with high diastereo- 
and enantioselectivities. This methodology was applied to the total syntheses of paraconic 
acids27, and other natural products containing bicyclic and tricyclic γ-butyrolactones 
(Scheme	  11). 28 
Scheme	  11	  
	  
 In 2003, Landais et al.29 reported a synthesis of densely substituted cyclopropanes 
bearing a useful allylsilane moiety 39. The process is based on Cu-catalysed 
cyclopropanation/	   desymmetrization of cyclopentadienylsilane 37 in the presence of a 
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PyBox ligand 38 providing the corresponding cyclopropanes 39 as a mixture of 
diasteremers in high enantiomeric excess (Scheme	  12).  
Scheme	  12 
 
 In 2007 Tang et al.30 introduced a new type of ligand, a bisoxazoline moety with a 
pendant oxazoline 42. This structural modification of the ligand greatly improved both 
the yield and enantioselectivity of the copper-catalyzed cyclopropanation of alkenes 40 
with ethylphenyldiazoacetate 41. This methodology provides an easy access for tri- and 
tetra-substituted cyclopropane derivatives 43 with high yields and impressive diastereo- 
and enantioselectivities (Scheme	  13). 
Scheme	  13 
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 Rhodium-based catalysts. Rhodium catalysts have also been extensively used and 
proveт to be effective catalysts for cyclopropanation using diazo compounds.  
Scheme	  14 
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Dirhodium tetrakis((R)-(N-dodecylbenzenesulfonyl)prolinate) catalyst Rh2[(R)-DOSP]4 
was used by Davies et al.31 to cyclopropanate aromatic nitrogen and oxygen heterocycles. 
Rhodium catalyst is used to induce the decomposition of aryldiazoacetates in the 
presence of heterocycles, resulting in the formation of mono- or biscyclopropanes of the 
furans and pyrroles. An interesting effect was observed, in these reactions the 
enantioselectivity was heavily influenced by the structure of the substrate. Upon initial 
coordination of the carbenoid and the heterocycle, and depending upon which bond of the 
substrate interacted with the rhodium complex first, either face of the heterocycle can be 
attacked (Scheme	  14). 
 Iridium-based catalysts. Asymmetric cyclopropanations of alkenes with diazo 
compounds have also been reported, involving chiral iridium complexes as catalysts. As 
an example, Katsuki et al. 32   have recently developed highly cis-diastereo- and 
enantioselective cyclopropanations of cyclic olefins such as indene 53 and benzofuran 55 
with diazoacetates using chiral aryliridium–salen complex 57 (Scheme	  15).  
Scheme	  15	  
	  
NN
O O
PhPh
Ir
L
Cat =
L = p-Tol
Cat
N2
t-BuO2C
CO2t-Bu
H
H
O Cat
N2
t-BuO2C
O
CO2t-Bu
H
H
53
54
55
56
57
51%, de > 98%, ee = 97%
46%, de > 98%, ee = 99%
	   14	  
1.6. Intramolecular cyclopropanation 
	   Highly	   functionalized	   synthetically	   versatile	   [n.1.0]bicycloalkanes	   can	   be	  
assembled	   via	   the	   transition-­‐metal-­‐catalysed	   intramolecular	   cyclopropanation	   of	  
alkenes.	  33	  When	  both	  functionalities,	  the	  diazo	  unit	  and	  the	  alkene,	  are	  in	  the	  same	  
molecule,	   an	   intramolecular	   cyclopropanation	   is	   possible	   in	   the	   presence	   of	   an	  
appropriate	  catalyst,	  thus	  producing	  bicyclic	  structures.	   
 Rhodium-based catalysts. Rh-Catalyzed intramolecular cyclopropanation of 3-
substituted-2-propenyl cyanodiazoacetates 58 was reported by Charette et al. 34 
Cyclopropanation occurred cleanly to form the corresponding cyclopropane derivatives 
in high yields. Chiral dirhodium catalyst Rh2[(4S)-FBNAZ]4 was used to introduce 
chirality to cyanolactones. Yield and the level of enantioselection were shown to be 
heavily dependent on the structure of the starting material. 
Scheme	  16	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Copper-based catalysts. When developing the copper-catalyzed asymmetric 
intramolecular cyclopropanation of substituted fluoroacrylate diazoacetates 60, Wong et 
al. 35 synthesized highly functionalized and enantioenriched fluorocyclopropanes 6236 
(Scheme	  17). Copper triflate catalyst promoted the intramolecular cyclopropanation of the 
fluorodiazoketone 60 in the presence of a bisoxazoline ligand 61. 
Scheme	  17 
 
Ruthenium-based catalysts. Ruthenium complexes recently have been introduced in the  
field of enantioselective cyclopropanation.37 Ruthenium is a direct neighbor of rhodium  
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  18 
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in the periodic table and offers an advantage because it currently costs roughly one-tenth 
the price of rhodium. In both inter- and intramolecular cyclopropanation reactions, where 
ruthenium catalysts work successfully, they often rival established rhodium catalysts in 
terms of overall effectiveness. Chiral ruthenium D4-symmetric porphyrin complex 64 has 
been used to catalyze the intramolecular cyclopropanation of allyl diazoacetates 63, 
leading to the corresponding lactones in moderate-to-high enantioselectivitiesis, which is 
largely dependent on the substitution of the alkene (Scheme	  18).38  
 Several types of chiral salen ligands 7039 were demonstrated by Katsuki et al.40 
proved to be efficient to induce chirality for the intramolecular cyclopropanation of 
various alkenyl α–diazoacetates 66, 68.  It was shown that the cyclization outcome is 
strongly affected by several factors including the olefin substitution pattern, length and 
the nature of the linker connecting the olefin and diazomethyl moieties (Scheme	  19). 
Scheme	  19	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1.7. Michael-Initiated Ring Closure (MIRC) 
 The nucleophilic conjugated addition reaction  to an α,β-unsaturated carbonyl 
compound 71 bearing a γ-leaving group is a common method to prepare densely 
substituted cyclopropanes. The process is commonly refered as  the  “Michael-induced 
ring-closure” reaction (MIRC). Typically, stereospecific cyclopropanations using the 
MIRC reaction are observed only when the ring-closure process is faster than the rotation 
around the single С-С bond in the first intermediate formation 72 (Scheme	  20). 
Scheme	  20 
 
 Tang et al.41 reported a method to prepare a series of chiral 1,3-disubstituted-2-
vinyl- cyclopropanes based on the addition of chiral sulfur ylides 77.  Camphor-derived 
sulfur ylides when in the presence of a variety of α,β -unsaturated carbonyl compounds 
reacted cleanly giving highly substituted cyclopropanes with great enantio- and 
diastereoselectivities. Interestingly, when the corresponding endo-type sulfonium ylides 
were used, the diastereoselectivities were not changed, but the absolute configurations of 
the products became opposite to those of the reactions of exo-type sulfonium ylides 
(Scheme	  21). 
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Scheme	  21 
 
 LY354740 analogue 80 can be synthesized via the cyclopropanation of a chiral 
cyclopentenone 79 with sulfur ylide (Scheme	   22)42. It is important to point out that 
bicyclic structure 80 was obtained as a single diastereomer, due to the addition of the 
ylide being directed by boc-protected amino group. 
Scheme	  22 
 
 Catalytic methods to generate chiral cyclopropanes via Michael-initiated ring-
closure reactions are highy desired, and have obvious advantages compared to the MIRC 
cyclopropanations discussed above. A new class of catalytic asymmetric 
cyclopropanations have been developed with the use of chiral organocatalysts.  In 2006, 
Gaunt et al. reported the first example of enantioselective intramolecular 
cyclopropanation based on the use of a chiral ammonium ylide as an organocatalyst 
(Scheme	   23Scheme	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OH
S R3R1
R2+
t-BuOK/THF R
2
R1 R3
+
Br
78a, R1 = R3 = Ph, R2 = CO2Me: 77% de > 98% ee = 99% 
78b, R1 = R3 = Ph, R2 = Bz: 83% de = 94% ee = 94% 
78c, R1 = p-ClC6H4, R2 = COt-Bu, R3 = Ph: 91% de = 90% ee = 98%
78d, R1 = R3 = Ph, R2 = CON(CH2)4: 98% de > 98% ee = 94% 
78e, R1 = R3 = Ph, R2 = CON(CH2)2O: 99% de > 98% ee = 98% 
78f, R1 = Ph, R2 = CO2Me, R3 = TMS: 85% de > 98% ee = 97%
78g, R1 = Ph, R2 = CO2Et, R3 = TMS: 75% de > 98% ee = 97%
76 77
O
BocHN Me2S+-CH2CO2Et, DBU O
BocHN
EtO2C
H
H
79 80 73%
	   19	  
range of chiral functionalized cyclopropanes possessing excellent diastereo- and enantio- 
selectivities can be produced using this methodology. The method relies heavily on the 
organocatalyst derived from cinchona alkaloids and offers several advantages, e.g. 
transition metals are absent, inexpensive starting materials and a large pool of known 
chiral amines from which potential catalysts can be selected. 
Scheme	  23	  
	  
 An asymmetric cyclopropanation of α,β -unsaturated aldehydes was reported by 
MacMillan et al. using a novel class of iminium organocatalysts based upon directed 
electrostatic activation.44 A chiral 2-carboxylic acid dihydroindole 86 was found to be a 
efficient catalyst for the reaction between a sulfonium ketone ylide 85 and an α,β 
unsaturated aldehyde 84, providing the corresponding cyclopropanes 87 with excellent 
enantioselectivity and yields. It was demonstrated that the organocatalyst and the ylide 
were engaged in electrostatic association via their pendant carboxylate and thionium 
substituents (Scheme	  24). 
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Scheme	  24	  
	  
 An excellent example of a one-step enantioselective nitrocyclopropanation was 
reported by Ley et al.45 Using chiral 5-(pyrrolidin-2-yl)-1H-tetrazole as an organo- 
catalyst, the asymmetric nitrocyclopropanation of α,β -unsaturated ketone 88 has been 
achieved in high yield and with good enantioselective control (Scheme	  25). 
Scheme	  25	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 The synthesis of cyclopropanes by decomposition of pyrazolines is a well-known 
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amount of olefin product may be formed as well. The addition of Bronsted or Lewis acids 
significantly increases the proportion of cyclopropanes and lowers the temperature 
required for denitrogenation.  
 Ruano et al. have described a completely stereoselective denitrogenation of chiral 
sulfinylpyrazolines 92 into the corresponding cyclopropanes, performed in the presence 
of  Yb(OTf)3 under very mild conditions and in almost quantitative yields with complete 
retention of the configuration at both carbons flanking the nitrogen atoms (Scheme	  26).47 
The metal forms a chelated species with the sulfinyl and carbonyl oxygens, which 
increases the electronic deficiency at C6 and provokes the concerted migration with 
extrusion of nitrogen. Raney-Ni desulfinylation of sulfinyl cyclopropanes 93 yielded 
optically pure bicyclic lactones 94 in good yields. 
Scheme	  26	  
	  
1.9. C–H Activation of Cyclopropanes 
 The catalytic C(sp3)–H functionalization is a continuously growing field in 
organic synthesis due to the ubiquity of C–H bonds in nature.48 However, the direct 
functionalization of the cyclopropyl unit is via C-H activation chemistry is still in its 
infancy. The rigidity of the cyclopropyl subunit and orbital hybridization leads to a more 
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sp2-like character for its carbon atoms, which should facilitate the C-H activation 
reactions.  
 To facilitate cyclopropane C(sp3)−H cleavage Yu and coworkers49 installed an 
acidic N-arylamide directing group 95 enabling Pd(II)-catalyzed C−H/R−BXn cross-
coupling under mild conditions. After systematic examination of structurally diverse 
array of amino acid ligands for stereoinduction, chiral ligand 96 was found to be the most 
efficient. This method is compatible with aryl-, vinyl-, and alkylboron reagents and 
tolerates a number of different substituents at the α- position (Scheme	  27). 
Scheme	  27 
 
 In 2013 Charette and coworkers 50  demonstrated a highly selective C-H 
functionalization of cyclopropanes employing a picolinamide auxiliary. A Pd-catalyzed, 
picolinamide-enabled C-H activation of cyclopropanes 98 employing aryl iodides as 
coupling partners was developed. Various aryl iodides can be employed as coupling 
partners, providing exclusively cis-substituted cyclopropylpicolinamides 99, however a 
minor product is obsevered. Along with monoarylated cyclopropane 99, a product of 
diarylation 100 is formed as a mixture of cis and trans (Scheme	  28). 
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Scheme	  28	  
 
  A highly diastereoselective synthesis of di- and trisubstituted 
cyclopropanecarboxamides was reported by Babu et al. 51  using a N-(quinolin-8-
yl)carboxamide as a directing group. The C-H functionalization reaction of 
cyclopropanecarboxamide 101 occurs in the presence of palladium acetate, installation of 
aryl groups is performed with various aryl iodides. The arylation of 
cyclopropanecarboxamide 101 with aryl iodides having electron-donating or -
withdrawing groups at the para-position gave the corresponding trisubstituted 
cyclopropanes as single diastereomers in moderate to good yields (Scheme	  29). 
Scheme	  29	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1.10. Cyclopropene Functionalization 
 Functionalization of cyclopropenes constitutes an attractive alternative to the 
more mainstream routes to chiral cyclopropanes. 52  Examples of enantioselective 
synthesis of trisubstituted cyclopropanes from cyclopropene precursors are still rare. 
  Fox et al. 53  reported the enantioselective carbomagnesation of cyclopropenes 
103 performed in the presence of N-methylprolinol 104 as a chiral ligand. 
Carbometalation is facially selective and the nucleophile is delivered by a hydroxyl 
functional group, the cyclopropylmetals can be trapped with a variety of electrophiles to 
generate highly substituted cyclopropanes 105. The process is highly diastereoselective, 
only one out of four isomers is formed, and the reaction proceeds with high levels of 
enantioselectivity and in a good yield (Scheme	  30). 
Scheme	  30	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 A similar strategy was suggested by the same researchers which was applied to a 
chiral cyclopropene substrate: Cu-catalyzed addition of aryl Grignard reagents to 
cyclopropene 106 and subsequent trapping with a suitable electrophile, generating highly 
substituted cyclopropanes 107. The reaction proceeds with high regio- and 
diastereoselectivity (Scheme	  31).54 
Scheme	  31 
 
 Stereoselective intermolecular Pauson–Khand reaction was demonstrated on 
chiral cyclopropenes 108 and 110.55 (Scheme	  32). Enantiomerically pure cyclopentenone 
derivatives 109 and 111 were isolated in each of the reactions performed in the presence 
of a dialkylsulfide (n-BuSMe) or a N-oxide (N-methylmorpholine N-oxide (NMO)). The 
cyclopropane ring strongly influences the stereochemistry of the reaction at the enone and 
the three-membered ring can subsequently be cleaved under mild conditions. 
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Scheme	  32 
 
1.11. Conclusions 
 1,2,3-Trisubstituted cyclopropanes are basic structural moieties in a wide range of 
natural and biologically active compounds as well as important building blocks in organic 
synthesis. Synthetic utility and application in medicinal chemistry resulted in the 
development of many strategies for their preparation in their optically pure form. 
However, there are much fewer methods for preparing enantiomerically pure densely 
substituted cyclopropanes compared to less substituted cyclopropanes. 
 Helping to address the lack of methods for the synthesis of stereodefined densely 
substituted cyclopropanes, we have developed a diastereoselective protocol for the 
additions of nucleophiles to chiral cyclopropropenes in an inter- and intramolecular 
fashion.  
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Chapter 2. Formal Nucleophilic Substitution of Bromocyclopropanes with 
Azoles and Anilines 
 In this chapter a highly diastereoselective protocol toward N-cyclopropyl azoles 
and anilines will be described. These amino-substituted cyclopropanes belong to an 
important class of molecules - β-Aminocyclopropanecarboxylic acid derivatives (β-
ACCs). 56	  
 2.0.  Introduction.  
  β-Aminocyclopropanecarboxylic acid derivative sare important members of a 
versatile and synthetically challenging family of donor−acceptor cyclopropanes (DAC).57 
β-ACCs have been recognized for their ability to produce surprisingly stable secondary 
structures in short peptides58 and serve as useful tools for conformational analysis.59 They 
have also been used as key elements in natural products,60 organocatalysts,61 prospective 
drug candidates,62 including potent antiviral,63 antitumor,64 and antihypertensive agents.65 
In contrast to a plethora of natural and synthetic analogues of α-
aminocyclopropanecarboxylic acid (α-ACC), which have been extensively exploited in 
medicinal, chemical, and agricultural research,66 synthesis of many β-ACC analogues 
face a number of difficulties and limitations. The problem associated with the stability of 
the three-membered ring in heteroatom-substituted “push−pull” cyclopropanes,67 limits 
access to these structural motifs and limits their further use in the assembly of complex 
architectures.68 As a result, substituted aminocyclopropane carboxylic acids possessing 
an additional stabilizing carboxylic acid group in the three-membered unit have been 
commonly used as more available β-ACC surrogates.  
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 2.1. General Approach 
 Stereochemically defined and densely substituted cyclopropanes are readily 
available from the corresponding cyclopropenes via a number of highly diastereoselective 
additions of various entities across the strained double bond. This area of research has 
received major attention during the past decade, particularly due to the recent advances in 
transition metal-catalyzed transformations of cyclopropenes.  At the same time, only a 
limited number of cyclopropenes can boast a long shelf life most are relatively short-
living species and require special handling. This, in part, explains the lack of enthusiasm 
by the pharmaceutical industry in adopting these novel synthetic tools.  
 The methodology described in this chapter heavily relies on the addition of 
pronucleophiles to cyclopropenes, in which the highly reactive cyclopropene 
intermediates 113 are generated in situ from a stable bromocyclopropane precursor 112, 
and reacted with nitrogen-based nucleophiles. The described reaction can be also seen as 
a formal nucleophilic substitution of bromocyclopropanes (Scheme	  33).  
Scheme	  33	  
	  
 Because standard substitution protocols used in larger ring chemistry are 
prohibitive in cyclopropane analogs due to significant ring strain and high s-character, a 
sequential dehydrobromination/nucleophile addition has served as a nucleophilic 
substitution surrogate for these strained substrates. This reaction operates via initial base-
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assisted dehydrobromination, followed by the strain-release-driven addition of a 
pronucleophile to the double bond of a highly reactive cyclopropene intermediate.69,70	  
 The Rubin group has previously disclosed efficient diastereoselective protocols 
for the formal nucleophilic substitution of structurally diverse bromocyclopropanes with 
oxygen- and sulfur-based pronucleophiles.71 At the same time, attempts to employ 
amines as nitrogen-based pronucleophiles 72 , 73  have failed, which was surprising, 
considering the power and versatility of the analogous aza-Michael reaction.74  The lack 
of reactivity was rationalized due to ineffective deprotonation of the N-H bond of 1° or 2° 
amine using relatively weak bases typically used in this reaction (KOH, t-BuOK). This 
renders this moiety less nucleophilic as compared to anionic species derived from more 
acidic alcohols and thiols. 
 2.2. Formal Nucleophilic Substitution of Bromocyclopropanes with 
Azoles 
	   Efficient overlap of the cyclopropane’s Walsh orbitals with the π-system of the 
adjacent aromatic substituent allows cyclopropyl(het)arenes with unique conformational 
features. It has been demonstrated that arylcyclopropanes can efficiently mimic active 
conformations of the bis-aryl 75  or benzylaryl moieties 76  producing remarkable 
pharmacological effects. Successful employment of cyclopropyl(het)arenes as 
bioisosteres is evidenced by a growing number of aryl- and hetarylcyclopropanes with 
impressive biological profiles, including antimalarial, 77  anti- cancer, 78  anti-HIV, 79 
antidepressant,80 immunemodulatory,76 antibiotic,81 and analgesic82 activity. Assembly of 
hetarylcyclopropanes possessing a cyclopropyl−NHetAr bond is a challenging task and thus 
far has been only achieved via Cu-catalyzed coupling of azoles to cyclopropylboronic 
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acids (eq. 1)83 and cyclopropylbismuth reagents (eq. 2),84 and the reaction of magnesium 
cyclopropylidene with N-lithioarylamines (eq. 3) (Scheme	  34).85  
Scheme	  34	  
	  
	   It is also important to note that due to vulnerability of cyclopropyl bromide to ring 
opening, the coupling reactions of azoles with cyclopropyl bromide using a palladium, 
nickel, or copper catalyst result in the formation of N-allylated product (Scheme	  35).83 
Scheme	  35	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2.2.1. Azoles as Nitrogen-Based Nucleophiles: Mode A 
 Directed Addition of Nucleophiles, Convergent Approach to 
Conformationally Constrained cis-Cyclopropyl Amino Acid Derivatives 
 The N−H bond acidity of azoles, whose pKa fall in the same range as values for 
carboxamides and comparable to many O- based pronucleophiles makes them good 
candidates for the formal nucleophilic substitution reaction. The lack of success in 
previous attempts on N-alkylation of azoles via the formal nucleophilic substitution of 
bromocyclopropane by other groups86,87 can be attributed to the unstable, electron-rich 
intermediate - unsubstituted cyclopropene - which undergoes rapid concurrent  
Scheme	  36	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polymerization. Indeed, it was previously shown by the Rubin group that analogous 
transformation proceeding via a stable, isolable cyclopropene 116a88,89  produced N-
pyrrolyl cyclopropane 117aa71a in good yield (Scheme	  36). Nucleophilic attack of pyrrole 
118a was efficiently directed by the carboxamide function affording predominantly cis 
diastereomer (Figure	  1). 
Figure	  1	  
  
 Likewise, trans products were obtained selectively, albeit in slightly lower yields, 
in the reactions of pyrrole 118a or indole 118b with tertiary cyclopropylamides - 
derivatives of N-methylpiperazine 115c and morpholine 115b. In contrast, cyclopropyl 
bromide 115d bearing a secondary carboxamide moiety provided adduct 117da with poor 
diastereoselectivity. This result was rather surprising as we previously demonstrated that 
the secondary carboxamide function served as superior directing group in reactions with 
O- based nucleophiles.71bc 
2.2.2. Azoles as Nitrogen-Based Nucleophiles: Mode B. 
 Nucleophilic Addition Followed by Thermodynamically Driven Base-
Assisted Epimerization, Convergent Approach to Conformationally Constrained 
trans-Cyclopropyl Amino Acid Derivatives  
 It was shown earlier that conjugation of the strained C=C bond with an electron-
withdrawing functionality can enhance the affinity of the cyclopropene intermediate 
O
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toward soft nucleophiles, such as phenoxides and thiolates.71 However, the corresponding 
rather acidic pronucleophiles reduce the overall basicity of the media leading, to 
inefficient epimerization at the α-carbon and, consequently, lower diastereoselectivities. 
Along these lines, 1,2-dehydrobromination of bromocyclopropane 119 in the presence of 
pyrrole 118a (mode B) afforded the corresponding cyclopropyl pyrrole 121aa in high 
yield but poor diastereomeric ratio (dr), which was addressed by our standard 
postreaction treatment of a crude mixture with a stronger base (Table	  1, entry 1) to give a 
98:2 trans selectivity with perfect material balance (Table	  1, entry 1). Likewise, reaction 
of 119a with 2-cyanopyrrole 118b, followed by base-assisted epimerization, afforded the 
corresponding trans adduct 121ab in high yield and excellent diastereoselectivity (Table	  
1, entry 2). Indoles reacted cleanly, in spite of their susceptibility to Friedel−Crafts 
alkylation, dimerization, and polymerization.90 As expected, skatole 118d, possessing a 
substituent at the vulnerable C3 position, provided the best yield in the series (entry 3−7). 
When imidazole 118g was used as a nucleophilic component, we stumbled upon isolation 
issue. Although the corresponding adduct 121ag was produced in reasonable yield (50% 
as judged by 1H NMR analysis of crude reaction mixture), chromatographic purification 
of the product proved inefficient due to its partial decomposition on silica gel (27% 
isolated yield, entry 8). In contrast, reactions in the presence of its fused analogues 
benzimidazoles 118h, 118i, 118j proceeded cleanly to afford the corresponding trans 
products in high yields and excellent diastereoselectivities (entries 9−11). Similarly, 
pyrazole 118k was engaged in a very efficient transformation with cyclopropyl bromides 
119a and 119b, providing good yields of N-cyclopropylpyrazoles 119ak and 119bk,  
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Table	  1 
 
no. R1, R2, 119 Azole, 118 121 crude 
drb 
Yield,a % (dr) 
upgradedb 
1 tBu, H, 119a pyrrole, 118a 121aa 72:28 66 (98:2) 
2 tBu, H, 119a 2-cyanopyrrole, 118b 121ab 85:15 82 (95:5) 
3 tBu, H, 119a indole, 118c 121ac 73:27 66 (97:3) 
4 Bn, H, 119b indole, 118c 121bc 75:25 48 (97:3) 
5 tBu, H, 119a skatole, 118d 121ad 75:25 73 (99:1) 
6 tBu, H, 119a 5-methoxy-1H-indole, 
118e 
121ae 75:25 61 (97:3) 
7 tBu, H, 119a 5-bromo-1H-indole, 118f 121af 58:42 48 (97:3) 
8 tBu, H, 119a imidazole, 118g 121ag 87:13 50 (100:0)c 
9 tBu, H, 119a 1H-benzo[d]imidazole, 
118h 
121ah 87:13 66 (100:1) 
10 tBu, H, 119a 2-methyl-1H-benzo[d] 
imidazole, 118i 
121ai 93:7 84 (95:5) 
11 tBu, H, 119a 5,6-dimethyl-1H-
benzo[d]imidazole, 118j 
121aj 95:5 72 (97:3) 
12 tBu, H, 119a pyrazole, 118k 121ak 86:14 85 (99:1) 
13 Bn, H, 119b pyrazole, 118k 121bk 88:12 73 (97:3) 
aIsolated yields, unless specified otherwise. bDiastereomeric ratio (trans:cis) determined by GC or 
1H NMR analyses of crude reaction mixtures. cNMR yield.	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respectively (entries 12 and 13). The trans configuration of the carboxamide and azole 
substituents was unambiguously confirmed by X-ray analysis of 119bk.  
 It should be mentioned that the scope of this reaction is generally limited to 
weakly acidic azoles with pKa ∼ 16−23. Nonetheless, a more acidic N-heterocycle 
benzotriazole (118l, pKa 11.9) was also reactive, producing two regioisomers, 121al and 
122al resulting from two tautomeric forms (Scheme	   37).91,92 Attempts on addition of 
tetrazoles 118m and 118n (pKa ∼ 8.2) were unsuccessful (Scheme	   38), which was 
expected for such poor aza-Michael donors.93 
 
Scheme	  37	  
	  
Scheme	  38	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Figure	  2	  ORTEP	  drawing	  of	  121bk	  showing	  50%	  probability	  amplitude	  displacement	  ellipsoids.	  
	  
	  
2.3. Formal Nucleophilic Substitution of Bromocyclopropanes with Anilines 
 The higher N−H acidity of anilines as compared to alkylamines makes them 
attractive N-based nucleophiles for the formal substitution reaction. However, our initial 
test using anilines as nucleophiles proved unsuccessful: reaction of N-methylaniline 123a 
with 119a produced aldehyde 124 as the only isolable compound. Formation of the latter 
can be envisioned via a formal addition of water to cyclopropene 120a, followed by a 
base-assisted cleavage of the intermediate cyclopropanol 125a; yet product 124 was 
never observed in our reactions in the absence of the secondary aniline, suggesting an 
alternative mechanism (Scheme	  39). 
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Scheme	  39	  
	  
  We believe the reaction begins with a base-assisted conjugate addition of aniline 
species 123a across the C=C bond of cyclopropene 120a. The resulting donor−acceptor 
cyclopropane 126aa undergoes ring-opening to give the iminium intermediate 127a, 
which upon base-assisted hydrolysis produces aldehyde 124 (Scheme	   40). It should be 
emphasized that, mechanistically, this ring-opening process is related to the small cycle 
cleavage observed in the attempted additions of primary carboxamides.73 The propensity 
of the donor−acceptor cyclopropane toward ring-opening depends on the extent of 
polarization of the C−C bond between the electron-donating (EDG) and electron-with- 
drawing groups (EWG). Polarization is commonly achieved through installation of strong 
EWGs, typically two ester functions, additionally activated by a Lewis acid (“pull” 
strategy).57 In our case polarization is realized through installation of an EDG with 
increased electron density, such as anionic N-moiety or a neutral N-group bearing an 
electron- donating substituents (“push” strategy).94 
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 Scheme	  40	  
	  
 Accordingly, the aptitude toward small ring cleavage was significantly reduced in 
cyclopropylanilines possessing electron-deficient nitrogen. Thus, reaction of p-
nitroaniline 123b with 119a in the presence of tBuOK and 18-crown-6 proceeded 
smoothly providing a single diastereomer of cyclopropylaniline 126ab in nearly 
quantitative yield. (Scheme	   41). Several other electron- deficient N-benzyl protected 
anilines, possessing cyano-, trifluoromethyl- , and nitro-  groups in para positions, reacted 
in a similar manner affording the corresponding aminocyclopropanes in good to excellent 
yields. Regardless of the yield, the diastereoselectivity of addition was perfect in all these 
examples.95 
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Scheme	  41 
 
 It should be mentioned that no product 126ac was obtained in the reaction with 
primary aniline 123c despite complete consumption of the bromocyclopropane 119a. We 
failed to detect any reasonable amounts of cyclopropane-containing products in this 
reaction. We propose the following rationale to account for the distinct reactivity of 
primary anilines (Scheme	   42). Addition of primary aniline pronucleophile 123c to 
cyclopropene 120a produces aminocyclopropane 126ac, the high N− H acidity of which 
is additionally enhanced by the adjacent electron-deficient aromatic ring. As a result, it 
undergoes facile base-assisted deprotonation under our typical reaction conditions to give 
an activated DAC species with relatively high electron density on the nitrogen atom. 
Subsequent facile cleavage of the small ring gives rise to 127ac and can undergo various 
side reactions. In contrast, adducts of secondary anilines pronucleophiles do not possess 
acidic N−H bond and therefore are stable toward ring-opening.  
 It should be also mentioned that diphenylamine 123d and 10H-phenothiazine 
123e did not require electron- withdrawing substituents to furnish trans-diastereomers of 
the corresponding cyclopropylamine derivatives 126ad and 126ae in good yields and 
with high diastereoselectivity (Scheme	  43). 
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Scheme	  42 
 
  
Scheme	  43 
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2.4. Conclusions 
 An efficient diastereoselective synthesis of β-aminocyclopropylcarboxylic acid 
derivatives via the formal nucleophilic substitution of bromocyclopropanes with N-based 
nucleophiles has been developed. This transformation proceeds via dehydrobromination 
followed by addition of a nucleophilic N-moiety across the strained C=C bond of a 
cyclopropene intermediate. Strong influence of steric and electronic factors on the 
efficiency of the formal substitution reaction has been demonstrated. N-Based 
pronucleophiles, including azoles and secondary anilines, have been successfully 
employed in the featured transformation. The trans selectivity of the addition is 
controlled by a thermodynamically driven base assisted epimerization, while cis 
selectivity is governed by a directed effect of the functional group. This methodology 
addresses some of the long-standing challenges in the synthesis of DAC and β-ACC 
derivatives through the synergism of strain release-powered thermodynamics and 
chelation-enforced selectivity. The diastereoconvergent approach allows for efficient 
installation of N-substituents in the last step, making the described method very attractive 
for the diversity oriented synthesis. 
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2.5. Experimental 
 2.5.1. General Information 
NMR spectra were recorded on a Bruker Avance DPX-400 instrument, equipped 
with a quadruple-band gradient probe (H/C/P/F QNP) or a Bruker Avance DRX-500 with 
a dual carbon/proton cryoprobe (CPDUL).  13C NMR spectra were registered with broad-
band decoupling.  The (+) and (-) designations represent positive and negative intensities 
of signals in 13C DEPT-135 experiments.  Column chromatography was carried out 
employing silica gel (Selecto Scientific, 63-200 µm).  Pre-coated silica gel plates (Merck 
Kieselgel 60 F-254) were used for thin-layer chromatography.  GC/MS analyses were 
performed on a Shimadzu GC-2010 gas chromatograph interfaced to a Shimadzu GCMS 
2010S mass selective detector, and equipped with an AOC-20i auto-injector and an 
AOC-20S auto-sampler tray (150 vials).   30 m × 0.25 mm × 0.25 mm capillary column, 
SHR5XLB, polydimethylsiloxane, 5% Ph was employed.  Helium (99.96%), additionally 
purified by passing consecutively through a CRS oxygen/ moisture/hydrocarbon trap 
(#202839) and VICI oxygen/moisture trap (P100-1), was used as a carrier gas.  High 
resolution mass-spectra were obtained using a LCT Premier (Micromass Technologies) 
instrument using electrospray ionization and time of flight detection techniques.   IR 
spectra were recorded on a Shimadzu FT-IR 8400S instrument.   
Glassware employed in moisture-free syntheses was flame-dried in vacuum prior 
to use.  Water was purified by dual stage deionization, followed by dual stage reverse 
osmosis.   Anhydrous THF was obtained by passing degassed commercially available 
HPLC-grade inhibitor-free solvent consecutively through two columns filled with 
activated alumina (Innovative Technology).   Anhydrous Et3N was obtained by 
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distillation of ACS-grade commercially available materials over calcium hydride in a 
nitrogen atmosphere. All commercially available reagents were purchased from Sigma-
Aldrich, TCI America or Acros Organics and used as received. Synthesis, physical 
properties and spectral data of all new compounds obtained in a frame of these studies are 
described below.  All manipulations with t-BuOK and 18-crown-6 ether were conducted 
under inert atmosphere (<8 ppm residual oxygen and moisture) using a combination of 
glovebox and standard Schlenk techniques.  After quench the reaction mixtures and 
compounds were treated on air.  All the obtained materials were moisture and oxygen 
stable at ambient temperatures.  
 2.5.2. Synthesis of bromocyclopropane derivatives 
2-Bromo-1-methylcyclopropylcarbonyl chloride (127): 2-Bromo-1-
methylcyclopropane- carboxylic acid (128,88 mixture of diastereomers, 1.1:1) 
(51.8 g, 400 mmol) and freshly distilled thionyl chloride (100 mL) were 
stirred at room temperature overnight. Excess thionyl chloride was distilled off at 
ambient pressure. The residue was distilled in vacuum, b.p. 50–53 °C (10 mm Hg). Yield 
75.8 g (384 mmol, 96%). This material was used as is in further acylations of primary 
and secondary amines as described below.  
(2-Bromo-1-methylcyclopropyl)(piperidin-1-yl)methanone (115a): 
Typical procedure: To a stirred solution of freshly distilled piperidine 
(7.7 mL, 6.6 g, 85 mmol) under an atmosphere of N2 in anhydrous 
THF (20 mL) was added the acid chloride 127 (5.10 g, 25.8 mmol) in dry THF (35 mL) 
dropwise. After ~1 hr of stirring at room temperature, the starting materials were 
consumed as judged by GCMS analysis; then the precipitate formed in the reaction 
O
Cl
Br
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mixture was removed by suction filtration and the filter cake was rinsed with THF (2 x 20 
mL). Then the precipitate was dissolved in water (20 mL) and extracted with EtOAc (2 x 
20 mL). The combined organic phases were washed with brine (20 mL), dried with 
Mg2SO4, combined with the THF filtrate and concentrated in vacuum. Kugelrohr vacuum 
distillation (oven temperature 150 °C/0.4 Torr) of the resulting residue afforded a mixture 
of trans- and cis-isomers of 115a (1:1) as colorless oil. Yield: 6.26 g (98%). 1H NMR 
(400 MHz, CDCl3): d = [3.70–3.57 (m), 3.49–3.35 (m), S4 H], [3.11 (dd, J = 8.1 Hz, 4.8 
Hz), 2.94 (dd, J = 8.1 Hz, 4.8 Hz), S1 H], 1.65–1.45 (m, 7 H), [1.38 (s), 1.30 (s), S3 H], 
[1.10 (ps t, J = 8.6 Hz, 5.3Hz), 0.82 (pst, J=6.8 Hz, 4.8 Hz), S1H]. 13C NMR (100 MHz, 
CDCl3): d = 170.1, 168.8, 46.9, 43.2, 27.9, 27.5, 26.5, 26.1, 26.0, 25.7, 25.6, 24.6, 24.5, 
21.9, 21.7, 21.3, 19.5. IR (film, cm-1): 2934, 2854, 1641, 1431, 1207, 1151, 1014, 854. 
ESI-HRMS (TOF): m/z [M–Br]+ calcd for C10H16NO: 166.1232; found: 166.1233. 
 
 (2-bromo-1-methylcyclopropyl)(morpholino)methanone (115b) : 
Cyclopropanecarboxamide 115b was prepared according to the 
typical procedure from acyl chloride 127 (5.00 g, 25.3 mmol) and 
freshly distilled morpholine (6.60 mL, 6.62 g, 76 mmol). Kugelrohr vacuum distillation 
(oven temperature 133 °C/0.6 Torr) of the resulting residue afforded a mixture of trans- 
and cis-isomers of 115b (1.1:1) as a colorless oil. Yield: 5.52 g (88%). 1H NMR (400 
MHz, CDCl3): δ 3.67–3.64 (m, 8 H), [3.15 (dd, J = 8.3 Hz, 5.1 Hz), 2.98 (dd, J = 7.6 Hz, 
4.8 Hz), Σ1H], [1.70 (ps t, J = 8.1), 1.58 (dd, J = 6.8 Hz, 4.8 Hz), Σ1H], [1.45 (s), 1.37 
(s), Σ3H], [1.20 (ps t, J = 7.3 Hz), 0.91 (dd, J = 6.6 Hz, 4.8 Hz), Σ1 H]. 13C NMR (100 
MHz, CDCl3): δ 170.6, 168.9, 67.1 (–), 66.9 (–), 66.7 (–, 2C), 46.4 (–), 42.6 (–), 27.5 (+), 
O
N
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27.1, 25.6, 25.4 (+), 21.6 (–), 21.4 (+), 21.2 (–), 19.4 (+). IR (film, cm-1): 2962, 2922, 
2854, 2897, 1643, 1460, 1429, 1281, 1207, 1153, 1115, 1032, 851, 623, 505. ESI-HRMS 
(TOF): m/z [M–Br]+ calcd for C9H14NO2: 168.1025; found: 168.1026.  
 
 (2-Bromo-1-methylcyclopropyl)(4-methylpiperazin-1-
yl)methanone (115c): 
Cyclopropanecarboxamide 115c was prepared according to the 
typical procedure from acyl chloride 127 (5.10 g, 25.8 mmol) and freshly distilled 
piperidine (7.7 mL, 6.6 g, 85 mmol). Kugelrohr vacuum distillation (oven temperature 
150 °C/0.4 Torr) of the resulting residue afforded a mixture of trans- and cis-isomers of 
115c (1:1) as a colorless oil. Yield: 6.26 g (98%). 1H NMR (400 MHz, CDCl3): δ  [3.70–
3.57 (m), 3.49–3.35 (m), Σ4H], [3.11 (dd, J = 8.1 Hz, 4.8 Hz), 2.94 (dd, J = 8.1 Hz, 4.8 
Hz), Σ1H], 1.65–1.45 (m, 7 H), [1.38 (s), 1.30 (s), Σ3H], [1.10 (ps t, J = 8.6 Hz, 5.3Hz), 
0.82 (pst, J=6.8Hz, 4.8Hz), Σ1H]. 13C NMR (100 MHz, CDCl3): δ  170.1, 168.8, 46.9, 
43.2, 27.9, 27.5, 26.5, 26.1, 26.0, 25.7, 25.6, 24.6, 24.5, 21.9, 21.7, 21.3, 19.5. IR (film, 
cm–1): 2934, 2854, 1641, 1431, 1207, 1151, 1014, 854. ESI-HRMS (TOF): m/z [M– Br]+ 
calcd for C10H16NO: 166.1232; found: 166.1233. 
 
2-Bromo-N-tert-butyl-1-methylcyclopropanecarboxamide (115d): 
Cyclopropanecarboxamide 115d was prepared according to the typical 
procedure from acyl chloride 127 (5.10 g, 25.8 mmol) and freshly 
distilled tert-butylamine (1.52 mL, 1.06 g, 14.4 mmol). Vacuum distillation in a 
Kugelröhr at 150 °C at 0.6 mm Hg gave the product as a pale-yellow oil. Yield 845 mg 
(3.61 mmol, 75%). 1H NMR (CDCl3, 400.13 MHz) δ [5.66 (br.s) & 5.41 (br.s), Σ1H], 
O
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[3.47 (dd, J = 8.1 Hz, 5.1 Hz) & 3.10 (dd, J = 7.6 Hz, 5.8 Hz), Σ1H], [1.91 (dd, J = 6.8 
Hz, 5.8 Hz) & 1.84 (dd, J = 8.1 Hz, 5.8 Hz), Σ1H], [1.59 (s) & 1.47 (s), Σ3H], [1.39 (s) & 
1.35 (s), Σ9H], [1.16 (dd, J = 7.6 Hz, 6.8 Hz) & 0.86 (ps.-t, J = 5.8 Hz, 5.1 Hz), Σ1H]; 
13C NMR (CDCl3, 100.67 MHz) δ 171.2, 169.3, 51.9, 51.5, 29.0 (+), 28.8 (+, 3C), 28.7 
(+, 3C), 28.2, 25.9 (+), 24.9 (-), 24.4, 23.9 (-), 21.1 (+), 17.6 (+); HRMS (TOF ES) found 
234.0494, calcd for C9H17BrNO (M+H) 234.0493 (0.4 ppm). 
 
2,2-Dibromocyclopropanecarboxylic acid (129): 10.0 g (44.2 mmol) 
of the 2,2-dibromo-1-vinylcyclopropane 13071b was added to a three 
necked flask equipped with a reflux condenser and magnetic stir bar. 340 mL of glacial 
acetic acid and 170 mL of formic acid were then added to the flask which was then 
placed in an oil bath.  While stirring, ozone was bubbled into the solution for ca. two 
hours.  Bubbling was stopped after disappearance of starting material by GC. 120 mL of 
30% hydrogen peroxide was then added to the solution which was then refluxed for ca. 
two hours.  The solution was then allowed to cool after disappearance of the intermediate. 
The solution was then extracted with chloroform (5x300 mL; chloroform was recovered 
from rotovap and reused for each extraction), the solvent was then removed by rotary 
evaporation and the product was then placed under a high vacuum overnight, yielding a 
white crystalline solid, identical to the material previously described in literature. Yield 
7.04 g (30.9 mmol; 70%).71a 
 
 (1S*,2R*)-2-Bromocyclopropanecarbonyl chloride (131): Flame-
dried 3000 mL three neck round bottom flask was charged with solution 
of 2,2-dibromocyclopropanecarboxylic acid (129) (27.0 g, 111 mmol) in anhydrous ether 
Br
O
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(1300 mL) under nitrogen atmosphere.  The mixture was vigorously stirred (500-650 
rpm) at -20 oC, and methyl lithium solution (1.6M in ether, 95 mL, 152 mmol, 1.37 
equiv) was added dropwise.  For safety reasons it is essential to add methyl lithium 
directly to a solution rather than draining along the flask wall to minimize the amount of 
solid precipitate, which might ignite during the following work up.  An aliquot of 
solution (1 mL) was withdrawn from the flask with a syringe, quenched consecutively 
with brine (2-3 drops) and 5% aqueous HCl (2-3 drops) in 10 mL test tube.  The aqueous 
layer was saturated with NaCl, and extracted with EtOAc (3 x 0.5 mL).  The combined 
organic phases collected with Pasteur pipet were dried with MgSO4 and concentrated.  
The conversion was measured based on 1H NMR analysis of this probe, and additional 
amount of MeLi necessary to complete the transformation was assessed (35 mL, 56 
mmol).  The mixture was quenched at -20 oC by adding brine (100 mL) and 5% aqueous 
HCl (100 mL).  (It is essential to perform the quenching at low temperature and to 
maintain inert atmosphere to avoid ignition of the mixture).  The mixture was allowed to 
warm up to rt, then aqueous layer was saturated with NaCl.  Ethereal layer was separated, 
and then aqueous phase was extracted with EtOAc (6 x 100 mL).  Combined organic 
phases were dried with MgSO4, filtered and concentrated, yield 8.79 g (53.3 mmol, 48%).  
This material was charged into a 25 mL round bottomed flask equipped and thionyl 
chloride (11.5 g, 110 mmol) was added.  The mixture was stirred at room temperature 
overnight, then an excess of thionyl chloride was distilled off, and the residue was 
fractionated in vacuum to obtain the title compound as clear oil, bp 56 oC at 15 torr.  
Yield 9.19 g (50.1 mmol, 94%). 
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(1S*,2R*)-2-Bromo-N-tert-butylcyclopropanecarboxamide 
(119a): Typical procedure. To a stirred solution of acyl chloride 131 
(1.0 g, 5.5 mmol) in dry THF (40 mL) was added tert-butylamine (3.90 mL, 2.74 g, 45.8 
mmol). The mixture was stirred at room temperature overnight, then partitioned between 
water (100 mL) and EtOAc (50 mL). The organic layer was separated; the aqueous phase 
was extracted with EtOAc (2 x 50 mL). Combined organic extracts were washed with 
brine (50 mL), dried with MgSO4, filtered, and concentrated. The residue was purified by 
vacuum distillation on Kugelröhr (oven temp. 120 oC at 0.4 torr) to afford a white 
crystalline material, mp 87-89 oC Yield 1.13 g (5.12 mmol, 93%).  1H NMR (500.19 
MHz, CDCl3) δ 5.87 (br. s., 1H), 3.17 (ddd, J = 7.7 Hz, 4.0 Hz, 3.2 Hz, 1H), 1.81–1.72 
(m, 1H), 1.58–1.51 (m, 1H), 1.35 (s, 9H), 1.24–1.20 (m., 1H); 13C NMR (125.76 MHz, 
CDCl3) δ 169.1, 51.6, 28.8 (+, 3C), 26.2 (+), 18.9 (+), 17.2 (-);IR (film, cm-1): 3315, 
3080, 2966, 2932, 1641, 1555, 1454, 1391, 1364, 1277, 1225; HRMS (TOF ES): found 
220.0340, calculated for C8H15BrNO (M+H) 220.0337 (1.4 ppm). 
 
N-Benzyl-2-bromocyclopropanecarboxamide (119b): The 
reaction was performed according to the typical procedure, 
employing benzylamine (1.10 g, 10.0 mmol, 2.50 equiv.) and 2-bromo-
cyclopropanecarbonyl chloride (730 mg, 4.0 mmol).   Yield 910 mg (3.57 mmol, 89%).   
1H NMR (400.13 MHz, CDCl3) δ ppm 7.37–7.23 (m, 5H), 6.89 (br.  s., 1H), 4.42–4.31 
(m, 2H), 3.18 (ddd, J = 7.6 Hz, 4.7 Hz, 3.0 Hz, 1H), 1.91 (ddd, J = 9.2 Hz, 5.9 Hz, 3.0 
Hz, 1H), 1.58 (dt, J = 7.6 Hz, 5.9 Hz, 1H), 1.27 (dt, J = 9.2 Hz, 5.4 Hz, 1H);  13C NMR 
(100.67 MHz, CDCl3) δ 170.2, 137.7, 128.6 (+, 2C), 127.6 (+, 2C), 127.5 (+), 43.8 (-), 
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25.3 (+), 19.0 (+), 17.5 (-);  FT IR (NaCl, film, cm-1): 3296, 3088, 3063, 2930, 1634, 
1553, 1454, 1213, 1034, 746, 696, 515;  HRMS (TOF ES): found 254.0176, calculated 
for C11H13BrNO (M+H) 254.0181 (2.0 ppm). 	  
2.5.3. Synthesis of Cyclopropylazoles 
	  
 ((1R*,2S*)-2-(1H-Indol-1-yl)-1-methylcyclopropyl)(mor- 
pholino)-methanone (117bb): Typical Procedure. An oven-
dried 10 mL Wheaton vial equipped with a magnetic stir bar 
was loaded under N2 with potassium tert-butoxide (168 mg, 1.5 mmol), 18-crown-6 (13 
mg, 0.05 mmol), (2-bromo-1-methylcyclopropyl) (morpholino)methanone 115b (124 mg, 
0.50 mmol), indole 118c (117 mg, 1.00 mmol), and THF (5 mL). The mixture was stirred 
at 80 °C for 12 h, then filtered through a fritted funnel, and concentrated. Preparative 
column chromatography on silica gel afforded the title compound as an amber oil, Rf 0.46 
(CH2Cl2:MeOH 20:1). Yield: 58 mg (0.25 mmol, 50%, dr >25:1). 1H NMR (400.13 
MHz, CDCl3): δ ppm 7.63 (d, J = 7.7 Hz, 1H), 7.45 (d, J = 7.7 Hz, 1H), 7.23 (dd, J = 8.2, 
7.0 Hz, 1H), 7.14 (dd, J = 8.0, 7.0Hz, 1H), 6.95 (d, J = 3.4Hz, 1H), 6.45 (d, J = 3.3 Hz, 
1H), 3.84 (dd, J = 8.8, 5.4 Hz, 1H), 3.79−3.69 (br s, 1H), 3.61−3.44 (br s, 2H), 3.19 (br s, 
2H), 2.97 (m, 3H), 2.22 (dd, J = 6.9, 5.4 Hz, 1H), 1.49 (s, 3H), 1.29 (dd, J = 8.7, 6.8 Hz, 
1H). 13C NMR (100.61 MHz, CDCl3): δ ppm 168.8, 137.2, 129.1, 123.8 (+), 121.8 (+), 
121.4 (+), 120.0 (+), 108.6 (+), 101.5 (+), 46.1 (−), 42.4(−), 41.0 (+), 28.8, 21.0 (+), 16.1 
(−). FT IR (KBr, cm−1): 2962, 2921, 2856, 1635, 1512, 1464, 1223, 847. HRMS (TOF 
ES): found 284.1530, calculated for C17H20N2O2 (M+) 284.1525 (1.8 ppm). 
N
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 ((1R*,2S*)-2-(1H-Pyrrol-1-yl)-1-methylcyclopropyl)(mor-
pholino)-methanone (117ba): This compound was synthesized 
according to typical procedure, employing (2-bromo-1-
methylcyclopropyl)- (morpholino)methanone 115b (124 mg, 0.50 mmol), pyrrole 118a 
(60 mg, 1.00 mmol), potassium tert-butoxide (168 mg, 1.50 mmol), and 18-crown-6 (13 
mg, 0.05 mmol) to afford after purification the title compound as yellow oil, Rf 0.34 
(hexane/EtOAc 1:1), 72 mg (0.31 mmol, 61%, dr >25:1). 1H NMR (400.13 MHz, 
CDCl3): δ ppm 6.59 (t, J = 2.1 Hz, 2H), 6.11 (t, J = 2.1 Hz, 2H), 3.81 (br s, 1H), 3.58 (br 
s, 1H), 3.49 (dd, J = 8.6, 5.4 Hz, 1H), 3.36 (br s, 1H), 3.46 (br s, 1H), 3.27 (br s, 2H), 
3.15 (br s, 1H), 2.59 (br s, 1H), 1.93 (dd, J = 6.9, 5.5 Hz, 1H), 1.39 (s, 3H), 1.15 (dd, J = 
8.6, 7.0 Hz, 1H). 13C NMR (100.61 MHz, CDCl3): δ ppm 168.9, 119.1 (+), 108.7 (+), 
66.1 (−, 2C), 46.0 (−), 44.5 (+), 42.4 (−), 28.7, 21.3 (+), 16.7 (−). FT IR (KBr, cm−1): 
2962, 2925, 2901, 2856, 1634, 1494, 1464, 1230, 851. HRMS (TOF ES): found 
235.1448, calculated for C13H19N2O2 (M+) 235.1447 (0.4 ppm). 
 
 ((1R*,2R*)-2-(1H-Pyrrol-1-yl)-1-methylcyclopropyl)(4-
methylpiperazin-1-yl)methanone (117cb): This compound 
was synthesized according to typical procedure, employing (2-
bromo-1- methylcyclopropyl)(4-methylpiperazin-1-yl)methanone 115c (78 mg, 0.30 
mmol), pyrrole 118a (40 mg, 0.60 mmol), potassium tert- butoxide (101 mg, 0.90 mmol), 
and 18-crown-6 (8 mg, 0.03 mmol) affording after purification the title compound as 
yellow oil, Rf = 0.23 (CH2Cl2/MeOH 20:1). Yield: 39 mg (0.16 mmol, 52%, dr 10:1). 1H 
NMR (400.13 MHz, CDCl3): δ ppm 6.58 (t, J = 2.1 Hz, 2H), 6.08 (t, J = 2.2 Hz, 2H), 
N
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3.73 (br s, 1H), 3.51−3.46 (dd, J = 7.8, 5.3 Hz, 1H), 3.40 (br s, 1H), 3.27 (br s, 2H), 2.33 
(br s, 1H), 2.23 (br s, 2H), 2.15 (s, 1H), 2.01 (br s, 1H), 1.90 (dd, J = 6.9, 5.4 Hz, 1H), 
1.39 (s, 3H), 1.14 (dd, J = 8.6, 6.9 Hz, 1H). 13C NMR (125.76 MHz, CDCl3): δ ppm 
168.8, 119.2 (+, 2C), 108.6 (+, 2C), 54.0 (−, 2C), 45.6 (+), 44.5 (+), 41.8 (−, 2C), 28.8, 
21.6 (+), 16.9 (−). FT IR (KBr, cm−1): 2935, 2856, 1630, 1492, 1437, 1227, 827. HRMS 
(TOF ES): found 247.1690, calculated for C14H21N3O (M+) 247.1685 (2.0 ppm). 
 
 ((1R*,2S*)-2-(1H-Indol-1-yl)-1-methylcyclopropyl)(4-
methylpiper- azin-1-yl)methanone (117cb): This 
compound was synthesized according to typical procedure, 
employing (2-bromo-1- methylcyclopropyl)(4-methylpiperazin-1-yl)methanone 115c (78 
mg, 0.30 mmol), indole 118c (70 mg, 0.60 mmol), potassium tert-butoxide (101 mg, 0.90 
mmol), and 18-crown-6 (10 mg, 0.03 mmol) affording after purification the title 
compound as yellow oil, Rf 0.23 (CH2Cl2:MeOH 20:1). Yield: 46 mg (0.15 mmol, 52%, 
dr >25:1). 1H NMR (500.13 MHz, CDCl3): δ ppm 7.61 (d, J = 7.9 Hz, 1H), 7.49 (d, J = 
8.3 Hz, 1H), 7.23 (dd, J = 8.0, 7.7 Hz, 1H), 7.13 (dd, J =8.1, 7.9 Hz, 1H), 6.96 (d, J = 3.4 
Hz, 1H), 6.43 (d, J =3.3 Hz, 1H), 3.84 (dd, J = 8.7, 5.4 Hz, 1H), 3.70 (br, 1H), 3.16 (br, 
3H), 2.50−2.26 (m, 1H), 2.25−2.16 (dd, 7.3, 5.4, Hz, 1H), 1.95 (s, 3H), 1.85 (br, 3H), 
1.51 (s, 3H), 1.30 (dd, J = 10.5, 5.1 Hz, 1H). 13C NMR (125.76 MHz, CDCl3): δ 168.7, 
137.4, 129.2, 123.9 (+), 121.7 (+), 121.2 (+), 119.9 (+), 108.8 (+), 101.5 (+), 54.0 (−), 
45.5 (+), 41.9 (−), 41.0 (+), 28.8, 21.4 (+), 16.4 (−). FT IR (KBr, cm−1): 3325, 2966, 
2934, 2874, 1647, 1549, 1508, 1462, 1225, 795. HRMS (TOF ES): found 297.1840, 
calculated for C18H23N3O (M+) 297.1841 (0.3 ppm). 
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  ((1R*,2S*)-N-(tert-Butyl)-1-methyl-2-(1H-pyrrol-1-yl)- 
cyclopropanecarboxamide (117da). This compound was 
synthesized according to typical procedure employing 2-bromo-N-
(tert-butyl)-1-methylcyclopropanecarboxamide (115d) (214 mg, 0.91 mmol), pyrrole 
(118a) (112 mg, 1.82 mmol), potassium tert-butoxide (307 mg, 2.74 mmol), and 18-
crown-6 (24 mg, 0.09 mmol) to afford after purification the title compound as a light 
brown solid, mp 80 °C, Rf 0.34 (hexane/EtOAc 1:1), 133 mg (0.61 mmol, 67%, dr 3:1). 
1H NMR (400.13 MHz, chloroform-d): δ 6.70 (t, J = 2.1 Hz, 2H), 6.14 (t, J = 2.1 Hz, 
2H), 4.78 (s, 1H), 3.45 (dd, J = 7.9, 5.0 Hz, 1H), 1.86 (dd, J = 6.0, 5.3 Hz, 1H), 1.41 (s, 
3H), 1.23 (dd, J = 7.8, 6.4 Hz, 1H), 1.12 (s, 9H). 13C NMR (125.76 MHz, CDCl3): δ 
169.4, 121.4 (+, 2C), 109.0 (+, 2C), 50.9, 42.6 (+), 28.3 (+, 3C), 20.8 (+), 19.3 (−). FT IR 
(NaCl, cm−1): 3393, 2966, 2929, 1653, 1526, 1495, 1456, 1392, 1364, 1258, 1238, 1221, 
725. HRMS (TOF ES): found 220.1577, calculated for C13H20N2O (M+) 220.1576 (0.5 
ppm). 
	  
(1R*,2R*)‐N‐(tert‐Butyl)‐2‐(1H‐pyrrol‐1‐yl)cyclopropane 
carboxamide (121aa):  Typical procedure: An oven‐dried 10 
mL Weaton vial was charged with 18‐crown‐6 (6.6 mg, 25 µmol, 10 mol %), powdered 
KOH (42 mg, 0.75 mmol, 3.0 equiv), pyrrole 118a (26 µL, 0.38 mmol, 1.5 equiv) and 
anhydrous THF (5.0 mL). The mixture was stirred at room temperature for 1 minute and 
bromocyclopropane 119a (55 mg, 0.25 mmol, 1.0 equiv) was added in a single portion. 
The reaction mixture was stirred overnight at 55 oC, then filtered through a short plug of 
silica gel eluting with CH2Cl2. The filtrate was concentrated in vacuum, and the residue 
N
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(a mixture of diastereomers, trans:cis 72:28) was dissolved in THF (3.0 mL) and 
transferred via cannula into another 10 mL Wheaton vial, pre‐charged with potassium 
tert‐butoxide (56 mg, 0.5 mmol, 2.0 equiv). The mixture was stirred at 80 oC overnight 
when GC analysis showed the epimerization was complete (final trans:cis ratio 98:2). 
Flash column chromatography on Silica gel afforded the title compound as a yellow 
solid, Rf 0.20 (hexane‐EtOAc 4:1), mp 109.3‐110.2 oC. Yield 34 mg (66%). 1H NMR 
(500.13 MHz, CDCl3) δ ppm 6.73 (t, J = 2.2 Hz, 2 H), 6.15 (t, J = 2.0 Hz, 2 H), 5.54 (br. 
s., 1 H), 3.80 (ddd, J = 7.8, 4.8, 2.8 Hz, 1 H), 1.73 (ddd, J = 9.0, 5.8, 2.8 Hz, 1 H), 1.55 
(dt, J = 7.9, 5.5 Hz, 1 H), 1.45 (dt, J = 9.6, 5.0 Hz, 1 H), 1.41 (s, 9 H); 13C NMR (125.76 
MHz, CDCl3) δ ppm 169.4, 120.5 (+, 2C), 108.5 (+, 2C), 51.6, 37.0 (+), 28.9 (+, 3C), 
24.6 (+), 13.7 (‐); FT IR (KBr, cm‐1): 3317, 2966, 2930, 1645, 1549, 1495, 1456, 1394, 
1364, 1339, 1286, 1256, 1225, 1198, 1115, 1074, 1053, 1036, 989, 955, 932, 910, 872, 
854, 822, 791, 723, 656, 636, 602; HRMS (TOF ES): found 213.1578, calculated for 
C12H18N2OLi (M+Li) 213.1579 (0.5 ppm).  
(1R*,2R*)‐N‐(tert‐Butyl)‐2‐(2‐cyano‐1H‐pyrrol‐1‐
yl)cyclopropanecarboxamide (121ab): This compound was 
obtained according to a typical procedure employing pyrrole‐2‐carbonitrile 118b (42.5 µl, 
0.5 mmol, 2.0 equiv) as pronucleophile. Epimerization was carried out in the presence of 
potassium tert‐butoxide (84 mg, 0.75 mmol, 3 equiv) to improve initial 85:15 dr 
(trans:cis) to the final value of 95:5. The subsequent chromatographic purification 
afforded title compound as a yellowish solid, Rf 0.28 (hexanes/EtOAc 4:1), mp 93.5−93.8 
oC. Yield 47 mg (0.20 mmol, 82%). 1H NMR (500.13 MHz, CDCl3) δ ppm 6.87−6.91 
(m, 1 H), 6.78 (dd, J = 4.0, 1.3 Hz, 1 H), 6.11−6.17 (m, 1 H), 5.90 (br. s., 1 H), 3.65 (ddd, 
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J = 7.6, 4.6, 3.0 Hz, 1 H), 1.97 (ddd, J = 9.2, 6.1, 2.9 Hz, 1 H), 1.76 (dt, J = 7.5, 5.7 Hz, 1 
H), 1.38−1.43 (m, 1 H), 1.41 (s, 9 H); 13C NMR (125.76 MHz, CDCl3) δ ppm 168.1, 
143.1, 127.1 (+), 120.7 (+), 114.3, 109.6 (+), 51.8, 36.0 (+), 28.7 (+, 3C), 24.8 (+), 13.0 (‐
); FT IR (KBr, cm‐1): 2218, 1651, 1541, 1526, 1458, 1437, 1396, 1364, 1312, 1256, 1225, 
1151, 1076, 1059, 1026, 974, 912, 891, 860, 785, 737, 692, 679, 648, 602, 579; HRMS 
(TOF ES): found 232.1449, calculated for C13H18N3O (M+H) 232.1450 (0.4 ppm). 
 (1R*,2R*)‐N‐(tert‐Butyl)‐2‐(1H‐indol‐1‐yl)cyclopro-
panecarboxamide (121ac): This compound was obtained 
according to a typical procedure from bromocyclopropane 119a (110 mg, 0.50 mmol, 
1.00 equiv), employing indole 118c (88 mg, 0.75 mmol, 1.50 equiv) as pronucleophile. 
Epimerization was carried out in the presence of potassium tert‐butoxide (112 mg, 1.00 
mmol, 2.00 equiv) to improve initial 73:27 dr (trans:cis) to the final value of 97:3. The 
subsequent chromatographic purification afforded 85 mg (0.33 mmol, 66%) of the title 
compound as a light orange solid, Rf 0.37 (hexanes/EtOAc 4:1), mp 106.0−106.5 oC. 1H 
NMR (500.13 MHz, CDCl3) δ ppm 7.65 (d, J = 7.9 Hz, 1 H), 7.48 (d, J = 8.2 Hz, 1 H), 
7.29 (t, J = 7.6 Hz, 1 H), 7.18 (t, J = 7.6 Hz, 1 H), 7.09 (d, J = 3.2 Hz, 1 H), 6.48 (d, J = 
3.2 Hz, 1 H), 5.79 (br. s., 1 H), 3.81 (ddd, J = 7.6, 4.4, 2.8 Hz, 1 H), 1.66−1.81 (m, 2 H), 
1.52 (dt, J = 8.7, 4.5 Hz, 1 H), 1.47 (s, 9 H); 13C NMR (125.76 MHz, CDCl3) δ ppm 
169.5, 137.1, 128.8, 126.9 (+), 121.8 (+), 121.0 (+), 120.0 (+), 109.8 (+), 101.5 (+), 51.6, 
34.2 (+), 28.9 (+, 3C), 24.4 (+), 13.7 (‐); FT IR (KBr, cm‐1): 3396, 3198, 3086, 3057, 
2966, 2930, 2868, 2359, 2341, 1645, 1612, 1549, 1512, 1475, 1464, 1400, 1364, 1340, 
1317, 1256, 1225, 1153, 1126, 1094, 1080, 1059, 1032, 1011, 960, 928, 910, 883, 856, 
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764, 741, 717, 683, 650, 617; HRMS (TOF ES): found 257.1652, calculated for 
C16H21N2O (M+H) 257.1654 (0.8 ppm). 
 (1R*,2R*)‐N‐benzyl‐2‐(1H‐indol‐1‐yl)cyclopro-
panecarboxamide (121bc): This compound was 
obtained according to a typical procedure from 
bromocyclopropane 119b (63.5 mg, 0.25 mmol, 1.00 equiv), employing indole 118c (44 
mg, 0.38 mmol, 1.5 equiv) as pronucleophile. Epimerization was carried out in the 
presence of potassium tert‐butoxide (84 mg, 0.75 mmol, 3.0 equiv) to improve initial 
75:25 dr (trans:cis) to the final value of 97:3. NMR yield of 82% was determined by 
integration of 1H NMR spectrum of the obtained crude mixture, which was recorded in 
the presence of CH2Br2 as internal standard. Subsequent chromatographic purification 
was accompanied by partial decomposition of the product and afforded the title 
compound as a colorless solid, Rf 0.17 (hexanes/EtOAc, 3:1), mp: 122.3−124.2 oC. Yield 
35 mg (0.12 mmol, 48%). 1H NMR (500.13 MHz, CDCl3) δ ppm 7.63 (d, J = 7.9 Hz, 1 
H), 7.46 (d, J = 8.2 Hz, 1 H), 7.32−7.44 (m, 5 H), 7.24 (t, J = 7.6 Hz, 1 H), 7.11−7.19 (m, 
1 H), 7.05−7.11 (m, 1 H), 6.47 (d, J = 3.2 Hz, 1 H), 6.19 (br. s., 1 H), 4.51−4.62 (m, 2 H), 
3.84−3.93 (m, 1 H), 1.77−1.88 (m, 2 H), 1.57−1.65 (m, 1 H); 13C NMR (125.76 MHz, 
CDCl3) δ ppm 170.3, 138.0, 137.2, 128.8, 128.8 (+, 2C), 127.8 (+, 2C), 127.7 (+), 126.9 
(+), 121.9 (+), 121.1 (+), 120.1 (+), 109.9 (+), 101.8 (+), 44.0 (‐), 34.7 (+), 23.8 (+), 14.2 
(‐); FT IR (KBr, cm‐1): 3298, 3061, 2926, 1717, 1645, 1614, 1556, 1512, 1495, 1475, 
1454, 1447, 1404, 1383, 1352, 1339, 1317, 1225, 1198, 1126, 1107, 1082, 1030, 1013, 
960, 947, 764, 741, 698, 673, 663, 636, 621, 602, 581, 571, 507, 484, 428, 411; HRMS 
(TOF ES): found 297.1570, calculated for C19H18N2OLi (M+Li) 297.1579 (3.0 ppm). 
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 (1R*,2R*)‐N‐(tert‐Butyl)‐2‐(3‐methyl‐1H‐indol‐1‐
yl)cyclopropanecarboxamide (121ad): This compound was 
obtained according to a typical procedure employing 3‐
methylindole 118d (49 mg, 0.38 mmol, 1.5 equiv) as pronucleophile. Epimerization was 
carried out in the presence of potassium tert‐butoxide (56 mg, 0.50 mmol, 2.0 equiv) to 
improve initial 75:25 dr (trans:cis) to the final value of 99:1. The subsequent 
chromatographic purification afforded the title compound as a light brown solid, Rf 0.40 
(hexanes/EtOAc 4:1), mp: 181.0−181.9 oC. Yield 49 mg (0.18 mmol, 73%). 1H NMR 
(400.13 MHz, CDCl3) δ ppm 7.57 (d, J = 7.8 Hz, 1 H), 7.42 (d, J = 8.1 Hz, 1 H), 
7.23−7.30 (m, 1 H), 7.12−7.20 (m, 1 H), 6.87 (s, 1 H), 5.66 (br. s., 1 H), 3.71−3.79 (m, 1 
H), 2.31 (s, 3 H), 1.66−1.75 (m, 2 H), 1.48−1.54 (m, 1 H), 1.45 (s, 9 H); 13C NMR 
(100.67 MHz, CDCl3) δ ppm 169.6, 137.4, 129.1, 124.5 (+), 121.8 (+), 119.3 (+), 119.1 
(+), 110.8, 109.7 (+), 51.7, 34.1 (+), 29.0 (+, 3C), 24.5 (+), 13.8 (‐), 9.5 (+); FT IR (KBr, 
cm‐ 1): 3321, 3055, 2966, 2930, 1645, 1614, 1545, 1522, 1466, 1456, 1439, 1402, 1364, 
1312, 1256, 1236, 1227, 1207, 1122, 1013, 739, 550, 494, 471, 455, 413, 401; HRMS 
(TOF ES): found 271.1494, calculated for C17H23N2O (M+H) 271.1810 (2.2 ppm). 
 (1R*,2R*)‐N‐(tert‐Butyl)‐2‐(5‐methoxy‐1H‐indol‐1‐
yl)cyclopropanecarboxamide (121ae): This 
compound was obtained according to a typical procedure employing 5‐methoxylindole 
118e (55 mg, 0.38 mmol, 1.5 equiv) as pronucleophile. Epimerization was carried out in 
the presence of potassium tert‐ butoxide (56 mg, 0.50 mmol, 2.0 equiv) to improve initial 
75:25 dr (trans:cis) to the final value of 97:3. The subsequent chromatographic 
purification afforded the title compound as a light orange solid, Rf 0.25 (hexanes/EtOAc 
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4:1), mp: 124.2−124.8 oC. Yield 44 mg (0.15 mmol, 61%). 1H NMR (500.13 MHz, 
CDCl3) δ ppm 7.33 (d, J = 8.8 Hz, 1 H), 7.08 (d, J = 2.5 Hz, 1 H), 7.04 (d, J = 2.8 Hz, 1 
H), 6.91 (dd, J = 8.8, 2.5 Hz, 1 H), 6.37 (d, J = 3.2 Hz, 1 H), 5.65 (br. s., 1 H), 3.86 (s, 3 
H), 3.73−3.80 (m, 1 H), 1.66−1.74 (m, 2 H), 1.46−1.54 (m, 1 H), 1.44 (s, 9 H); 13C NMR 
(125.76 MHz, CDCl3) δ ppm 169.4, 154.5, 132.5, 129.2, 127.4 (+), 112.1 (+), 110.4 (+), 
102.9 (+), 101.2 (+), 55.9 (+), 51.7, 34.4 (+), 29.0 (+, 2C), 24.5 (+), 13.8 (‐); FT IR (KBr, 
cm‐1): 3323, 2966, 2934, 1647, 1622, 1549, 1516, 1483, 1448, 1400, 1364, 1288, 1246, 
1227, 1150, 1030, 800, 754, 717, 455, 428; HRMS (TOF ES): found 293.1848, calculated 
for C17H22N2O2Li (M+Li) 293.1841 (2.4 ppm). 
 
 (1R*,2R*)‐N‐(tert‐butyl)‐2‐(1H‐imidazol‐1‐yl)cyclopro-
panecarboxamide (121ag): This compound was obtained 
according to a typical procedure employing imidazole 118g (34 mg, 0.50 mmol, 2.0 
equiv) as pronucleophile. Epimerization was carried out in the presence of potassium tert‐
butoxide (56 mg, 0.50 mmol, 2.0 equiv) to improve initial 87:13 dr (trans:cis) to the final 
value of 100:0. NMR yield of 50% was determined by integration of 1H NMR spectrum 
of the obtained crude mixture, which was recorded in the presence of CH2Br2 as internal 
standard. Since chromatographic purification was accompanied by partial decomposition 
of the product, isolation was carried out by crystallization from the mixture cyclohexane‐
EtOH, which afforded the title compound as a light yellow solid, Rf 0.15 (CH2Cl2/MeOH 
20:1), mp: 101.5−101.9 oC. Yield 14 mg (0.068 mmol, 27%). 1H NMR (500.13 MHz, 
CDCl3) δ ppm 7.49 (s, 1 H), 6.99 (s, 1 H), 6.94 (s, 1 H), 6.25 (br. s., 1 H), 3.75 (ddd, J = 
N
N O
H
N
	   58	  
7.9, 4.7, 3.2 Hz, 1 H), 1.81 (ddd, J = 9.2, 5.9, 2.8 Hz, 1 H), 1.58 (dt, J = 7.9, 5.7 Hz, 1 H), 
1.33−1.38 (m, 1 H), 1.39 (s, 9 H); 13C NMR (125.76 MHz, CDCl3) δ ppm 168.6 (s), 
137.0 (s), 129.2 (s), 119.4 (s), 51.7 (s), 34.3 (s), 28.8 (s), 24.0 (s), 13.4 (s); FT IR (KBr, 
cm‐ 1): 3302, 3065, 2966, 2928, 1651, 1556, 1504, 1456, 1404, 1393, 1364, 1256, 1227, 
1200, 1107, 1078, 1061, 1045, 1022, 914, 737, 663, 613, 494, 484, 453; HRMS (TOF 
ES): found 207.1376, calculated for C11H17N3O (M+) 207.1372 (1.9 ppm). 
 
 (1R*,2R*)‐2‐(1H‐benzo[d]imidazol‐1‐yl)‐N‐(tert‐
butyl)cyclopropanecarb‐ oxamide (121ah): This compound 
was obtained according to a typical procedure employing benzimidazole 118h (59 mg, 
0.50 mmol, 2.0 equiv) as pronucleophile. Epimerization was carried out in the presence 
of potassium tert‐butoxide (84 mg, 0.75 mmol, 3.0 equiv) to improve initial 83:17 dr 
(trans:cis) to the final value of 100:0. The subsequent chromatographic purification 
afforded the title compound as a colorless solid, Rf 0.21 (CH2Cl2/MeOH 20:1), mp: 
182.0‐182.6 oC. Yield 42 mg (0.16 mmol, 66%). 1H NMR (500.13 MHz, CDCl3) δ ppm 
7.89 (s, 1 H), 7.80 (d, J = 7.6 Hz, 1 H), 7.49 (d, J = 8.2 Hz, 1 H), 7.29−7.37 (m, 2 H), 
5.78 (br.s.,1H), 3.80−3.87 (m, 1H), 1.75−1.83 (m, 2H), 1.53 (dt, J = 8.4, 4.3 Hz, 1H), 
1.45 (s, 9H); 13CNMR (125.76 MHz, CDCl3) δ ppm 168.7, 155.8 (+), 143.8, 142.4, 123.3 
(+), 122.7 (+), 120.6 (+), 110.0 (+), 51.9, 32.3 (+), 29.0 (+, 3C), 23.7 (+), 13.3 (‐); FT IR 
(KBr, cm‐1): 3082, 3067, 2966, 2928, 1651, 1614, 1556, 1497, 1479, 1460, 1441, 1402, 
1393, 1364, 1313, 1286, 1259, 1236, 1227, 1150, 1132, 1095, 1084, 1055, 1034, 970, 
949, 893, 800, 783, 766, 744, 700, 683, 660, 629, 613, 594, 573, 542, 527, 501, 463, 420, 
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401; HRMS (TOF ES): found 257.1519, calculated for C15H19N3O (M+) 257.1528 (3.5 
ppm). 
 (1R*,2R*)‐N‐(tert‐butyl)‐2‐(2‐methyl‐1H‐benzo[d]imi-
dazol‐1‐yl)cyclopropanecarboxamide (121ai): This 
compound was obtained according to a typical procedure 
employing 2‐methylbenzimidazole 118i (66 mg, 0.50 mmol, 2.0 equiv) as 
pronucleophile. Epimerization was carried out in the presence of potassium tert‐butoxide 
(84 mg, 0.75 mmol, 3.0 equiv) to improve initial 93:7 dr (trans:cis) to the final value of 
95:5. The subsequent chromatographic purification afforded the title compound as a 
colorless solid, Rf 0.17 (CH2Cl2/MeOH 20:1), mp: 150.0−150.5 oC. Yield 57 mg (0.21 
mmol, 84%). 1H NMR (400.13 MHz, CDCl3) δ ppm 7.66−7.71 (m, 1 H), 7.41 (dt, J = 
5.1, 2.0 Hz, 1 H), 7.23−7.27 (m, 2 H), 5.82 (s, 1 H), 3.66 (ddd, J = 7.3, 4.8, 3.0 Hz, 1 H), 
2.66 (s, 3 H), 1.80−1.88 (m, 2 H), 1.49−1.54 (m, 1 H), 1.47 (s, 9 H); 13C NMR (125.76 
MHz, CDCl3) δ ppm 168.8, 152.9, 142.2, 135.7, 122.3 (+), 122.1 (+), 119.1 (+), 109.7 
(+), 51.9, 31.7 (+), 28.9 (+, 3C), 24.2 (+), 14.7 (+), 14.6 (‐); FT IR (KBr, cm‐1): 3281, 
3055, 2966, 2928, 1651, 1556, 1524, 1460, 1443, 1404, 1364, 1344, 1315, 1285, 1256, 
1227, 1200, 741, 467; HRMS (TOF ES): found 278.1847, calculated for C16H21N3OLi 
(M+Li) 278.1845 (0.7 ppm). 
  (1R*,2R*)‐N‐(tert‐butyl)‐2‐(5,6‐dimethyl‐1H‐benzo- 
[d]imidazol‐1‐ yl)cyclopropanecarboxamide (121aj): 
This compound was obtained according to a typical 
procedure employing 5,6‐dimethylbenzimid‐azole 118j (73 mg, 0.50 mmol, 2.0 equiv) as 
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pronucleophile. Epimerization was carried out in the presence of potassium tert‐ butoxide 
(84 mg, 0.75 mmol, 3.0 equiv) to improve initial 95:5 dr (trans:cis) to the final value of 
97:3. The subsequent chromatographic purification afforded the title compound as a 
colorless solid, Rf 0.19 (CH2Cl2/MeOH 20:1), mp: 200−201 oC. Yield 51 mg (0.18 mmol, 
72%). 1H NMR (500.13 MHz, CDCl3) δ ppm 7.75 (s, 1 H), 7.53 (s, 1 H), 7.24 (s, 1 H), 
5.93 (br. s., 1 H), 3.77 (ddd, J = 7.7, 4.7, 3.2 Hz, 1 H), 2.41 (s, 3 H), 2.38 (s, 3 H), 1.71− 
1.83 (m, 2 H), 1.49 (dt, J = 9.2, 4.7 Hz, 1 H), 1.45 (s, 9 H); 13C NMR (125.76 MHz, 
CDCl3) δ ppm 168.9, 142.3, 141.6 (+), 133.4, 132.5, 131.6, 120.5 (+), 110.2 (+), 51.9, 
32.4 (+), 29.0 (+, 3C), 23.8 (+), 20.6 (+), 20.2 (+), 13.3 (‐); FT IR (KBr, cm‐1): 3261, 
3211, 3070, 3028, 2966, 2935, 2866, 1651, 1556, 1495, 1472, 1454, 1404, 1393, 1364, 
1339, 1308, 1261, 1227, 1175, 1161, 1136, 1086, 1068, 1051, 1022, 999, 970, 947, 930, 
910, 866, 843, 800, 766, 737, 702, 646, 615, 586, 569, 548, 528, 467, 417, 403; HRMS 
(TOF ES): found 308.1749, calculated for C17H23N3ONa (M+Na) 308.1739 (3.2 ppm). 
  (1R*,2R*)‐N‐(tert‐butyl)‐2‐(1H‐pyrazol‐1‐yl)cyclopropane- 
carboxamide (121ak): This compound was obtained according 
to a typical procedure employing pyrazole 118k (26 mg, 0.38 mmol, 1.5 equiv) as 
pronucleophile. Epimerization was carried out in the presence of potassium tert‐butoxide 
(84 mg, 0.75 mmol, 3.0 equiv) to improve initial 86:14 dr (trans:cis) to the final value of 
99:1. The subsequent chromatographic purification afforded the title compound as a light 
orange solid, Rf 0.24 (CH2Cl2/MeOH 20:1), mp: 155.5−155.9 oC. Yield 44 mg (0.21 
mmol, 85%). 1H NMR (400.13 MHz, CDCl3) δ ppm 7.47 (d, J = 2.3 Hz, 1 H), 7.44 (d, J 
= 1.5 Hz, 1 H), 6.21 (t, J = 2.1 Hz, 1 H), 6.01 (br. s., 1 H), 3.94 (ddd, J = 7.8, 4.9, 2.8 Hz, 
1 H), 2.04 (ddd, J = 9.1, 6.1, 3.0 Hz, 1 H), 1.51−1.62 (m, 2 H), 1.34 (s, 9 H); 13C NMR 
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(100.67 MHz, CDCl3) δ ppm 169.1, 139.2 (+), 129.8 (+), 105.7 (+), 51.5, 39.1 (+), 28.8 
(+, 3C), 23.8 (+), 13.6 (‐); FT IR (KBr, cm‐1): 3313, 2966, 2932, 1651, 1553, 1516, 1474, 
1456, 1400, 1364, 1273, 1254, 1227, 1205, 1094, 1082, 1053, 987, 955, 937, 910, 752, 
644, 611, 500, 434, 403; HRMS (TOF ES): found 214.1531, calculated for C11H17N3OLi 
(M+Li) 214.1532 (0.5 ppm).  
 (1R*,2R*)‐N‐benzyl‐2‐(1H‐pyrazol‐1‐yl)cyclopro-
panecarboxamide (121bk): This compound was obtained 
according to a typical procedure from bromocyclopropane 119b (63.5 mg, 0.25 mmol, 
1.00 equiv), employing pyrazole 118k (34 mg, 0.50 mmol, 2.0 equiv) as pronucleophile. 
Epimerization was carried out in the presence of potassium tert‐butoxide (84 mg, 0.75 
mmol, 3.0 equiv) to improve initial 88:12 dr (trans:cis) to the final value of 97:3. 
Subsequent chromatographic purification afforded the title compound as a colorless solid, 
Rf 0.27 (CH2Cl2/MeOH, 20:1), mp: 125.0−125.5 oC. Yield 44 mg (0.18 mmol, 73%). 1H 
NMR (400.13 MHz, CDCl3) δ ppm 7.48 (d, J = 2.3 Hz, 1 H), 7.44 (d, J = 1.5 Hz, 1 H), 
7.24−7.38 (m, 5 H), 6.76 (br. s., 1 H), 6.24 (t, J = 2.0 Hz, 1 H), 4.50 (dd, J = 14.7, 5.8 Hz, 
1 H), 4.42 (dd, J = 14.7, 5.6 Hz, 1 H), 4.01 (ddd, J = 7.8, 4.9, 2.9 Hz, 1 H), 2.17 (ddd, J = 
9.2, 6.1, 2.9 Hz, 1 H), 1.59−1.73 (m, 2 H); 13C NMR (100.67 MHz, CDCl3) δ ppm 170.0, 
139.3 (+), 137.9, 129.9 (+), 128.7 (+, 2C), 127.8 (+, 2C), 127.5 (+), 105.8 (+), 43.9 (‐), 
39.4 (+), 23.3 (+), 13.9 (‐); FT IR (KBr, cm‐1): 3242, 3113, 3097, 3069, 3030, 2961, 
2928, 2872, 1728, 1632, 1605, 1556, 1514, 1495, 1454, 1404, 1339, 1273, 1238, 1223, 
1202, 1122, 1082, 1051, 993, 953, 752, 696, 523, 422, 415, 403; HRMS (TOF ES): found 
248.1367, calculated for C14H15N3OLi (M+Li) 248.1375 (3.2 ppm).  
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 (1R*,2R*)-2-(5-Bromo-1H-indol-1-yl)-N-(tert-butyl)- 
cyclopropanecarboxamide (121ae): This compound 
was obtained according to a typical procedure from bromocyclopropane 119a (55 mg, 
0.25 mmol, 1.00 equiv), employing 5-bromo-1H-indole 118e (147 mg, 0.75 mmol, 3.0 
equiv) as pronucleophile. Epimerization was carried out in the presence of potassium tert‐
butoxide (84 mg, 0.75 mmol, 3.0 equiv) to improve initial 42:58 dr (trans:cis) to the final 
value of 97:3. Subsequent chromatographic purification afforded the title compound as an 
amber oil, Rf 0.27 (hexane/EtOAc 6:1). Yield 40 mg (0.12 mmol, 48%). 1H NMR 
(400.13 MHz, CDCl3): δ ppm 7.74 (dd, J = 1.7, 0.8 Hz, 1H), 7.34−7.32 (m, 2H), 7.09 (d, 
J = 3.3 Hz, 1H), 6.39 (dd, J = 3.2, 0.7 Hz, 1H), 5.68 (s, 1H), 3.84−3.73 (m, 1H), 
1.79−1.68 (m, 2H), 1.56−1.48 (m, 1H), 1.45 (s, 9H). 13C NMR (100.61 MHz, CDCl3): δ 
ppm 169.3, 135.8, 130.3, 128.2 (+), 124.8 (+), 123.6 (+), 113.3, 111.3 (+), 101.2 (+), 
51.8, 34.3 (+), 29.0 (+, 3C), 24.4 (+), 13.9 (−). FT IR (KBr, cm−1): 3325, 2966, 2934, 
2874, 1647, 1549, 1508, 1462, 1225, 795. HRMS (TOF ES): found 357.0570, calculated 
for C16H19BrN2ONa (M + Na) 357.0578 (2.2 ppm).  
Reaction with benzotriazole 118l: The reaction was carried out according to a standard 
procedure employing bromocyclopropane 119a (110 mg, 0.50 mmol, 1.0 equiv) and 
benzotriazole 118l (90 mg, 0.76 mmol, 1.5 equiv.) as pronucleophile. Epimerization was 
carried out in the presence of potassium tert‐butoxide (84 mg, 0.75 mmol, 3.0 equiv) to 
improve initial ratio of 65:35 dr (121al, trans:cis) and 70:30 dr (122al, trans:cis) to the 
final values of 96:4 and 99:1, respectively. The subsequent chromatographic purification 
afforded two fractions: yellowish solid 121al, mp 132‐133 oC, Rf 0.33 (hexane/EtOAc 
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6:1) (yield 49 mg, 0.19 mmol, 38%), and colorless solid 122al, mp 170−172 oC, Rf 0.29 
(hexane/EtOAc 6:1) (yield 36 mg, 0.14 mmol, 28%). 
 
 (1R*,2R*)‐2‐(1H‐benzo[d][1,2,3]triazol‐1‐yl)‐N‐(tert‐
butyl)cyclopropanecarboxamide (121al): 1H NMR 
(400.13 MHz, CDCl3) δ 8.02 (d, J = 8.3 Hz, 1 H), 7.65 (d, J 
= 8.3 Hz, 1 H), 7.48−7.60 (m, 1 H), 7.36−7.41 (m, 1 H), 6.41 (s, 1 H), 4.23 (ddd, J = 2.8, 
4.7, 7.7 Hz, 1 H), 2.47 (ddd, J = 3.0, 6.1, 9.3 Hz, 1 H), 1.87 (ddd, J = 5.8, 7.6 Hz, 1 H), 
1.71 (ddd, J = 4.9, 9.5 Hz, 1 H), 1.44 (s, 9 H); 13C NMR (101MHz , CDCl3) δ 168.8, 
145.9, 134.0, 127.7 (+), 124.4 (+), 119.9 (+), 109.7 (+), 77.4, 77.1, 76.8, 51.9, 35.3(+), 
28.9 (+, 3C), 23.5 (+), 13.9 (‐); FT IR (KBr, cm‐1): 3306, 3071, 2968, 2932, 1652, 1456, 
1258, 1177, 1095, 909, 745; HRMS (TOF ES): found 257.1405, calculated for 
C14H17N4O (M−H) 257.1402 (1.2 ppm). 
 
(1R*,2R*)‐2‐(2H‐benzo[d][1,2,3]triazol‐2‐yl)‐N‐(tert‐
butyl)cyclopropanecarboxamide (122al): 1H NMR (400.13 
MHz, CDCl3) δ 7.83 (dd, J = 3.0, 6.6 Hz, 2 H), 7.39 (dd, J = 3.2, 6.7 Hz, 2 H), 5.69 (br. 
s., 1 H), 4.72 (ddd, J = 3.0, 4.9, 8.0 Hz, 1H), 2.38 (ddd, J = 3.0, 6.4, 9.5 Hz, 1 H), 2.00 
(ddd, J = 4.3, 5.1, 9.4 Hz, 1 H), 1.85 ‐ 1.93 (m, 1 H), 1.39 (s, 9 H); 13C NMR (100.67 
MHz, CDCl3) δ 168.1, 144.1, 126.5 (+), 117.7 (+), 77.4, 77.0, 76.7, 51.8, 43.5 (+), 28.8 
(+), 25.7 (+), 14.8 (‐); FT IR (KBr, cm‐1): 3324, 2966, 1644, 1455, 1392, 1364, 1326, 
NN
N O
H
N
N
N N O
H
N
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1290, 1266, 1256, 1224, 1008, 745; HRMS (TOF ES): found 258.1484, calculated for 
C14H18N4O (M+) 258.1481 (1.2 ppm).  
2.5.4. Synthesis of Cyclopropylanilines 
 
(1R*,2R*)-N-(tert-Butyl)-2-(methyl(4-nitrophenyl)amino)cyclo-
propanecarboxamide (126ab): Typical Procedure: 10 mL 
Wheaton vial equipped with a magnetic stir bar, under dry nitrogen 
atmosphere was charged with THF (5 mL), powdered KOH (112 
mg, 2.00 mmol), N-methyl-4-nitroaniline 123b (228 mg, 1.50 mmol), 18-crown-6 (13 
mg, 0.050 mmol) and 2-bromo-N-(tert-butyl)cyclopropanecarboxamide 119a (110 mg, 
0.50 mmol).  This solution was stirred at 55 oC for 12h, then filtered through a fritted 
funnel and concentrated in vacuum.  Purification by flash chromatography on silica gel 
(eluent hexane:EtOAc 3:1) afforded the title compound as yellow solid (Rf 0.18), yield 
142 mg (0.49 mmol, 98%). 1H NMR (400.13 MHz, CDCl3) δ ppm 8.07 (d, J = 9.4 Hz, 
2H), 6.76 (d, J = 9.4 Hz, 2H), 5.86 (s, 1H), 3.09 (s, 3H), 3.06 (ddd, J = 7.6, 4.8, 3.1 Hz, 
1H), 1.56 (m, 2H), 1.44 (s, 9H), 1.22 (ddd, J = 4.4, 4.9, 9.4 Hz, 1H); 13C NMR (CDCl3, 
100.61 MHz) δ 169.5, 154.6, 138.1, 125.6 (+, 2C), 111.8 (+, 2C), 51.7, 40.6 (+), 38.0 (+), 
29.0 (+, 3C), 27.1  (+), 16.3 (-); FT IR (NaCl, cm-1): 3325, 2966, 2930, 2874, 1643, 1547, 
1493, 1396, 1315, 1113, 831, 754; HRMS (TOF ES): found 290.1504, calculated for 
C15H20N3O3 (M−H) 290.1505 (0.3 ppm). 
(1R*,2R*)-N-(tert-Butyl)-2-(diphenylamino)cyclopro-
panecarboxamide (126ad): This compound was synthesized 
according to the typical procedure employing 2-bromo-N-
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(tert-butyl)cyclopropanecarboxamide 119a (55 mg, 0.25 mmol), powedered KOH (56 
mg, 1.0 mmol), 18-crown-6 (6.6 mg, 0.025 mmol), THF (5 mL), and diphenyl amine 
123d (126 mg, 0.75 mmol).   Crude mixture (dr 1.1:1) was concentrated in vacuum and 
treated with potassium tert-butoxide (112 mg, 1.0 mmol) in anhydrous THF (5 mL) at 80 
oC for 12h, to improve the dr to 25:1. Flash column chromatography on silica gel 
afforded the title compound as white solid, mp 111.3 oC, Rf 0.27 (hexane/EtOAc 6:1).   
Yield 74 mg (0.24 mmol, 96%).   1H NMR (400.13 MHz, CDCl3) δ ppm 7.36–7.29 (m, 
4H), 7.08–6.99 (m, 6H), 5.50 (s, 1H), 3.20 (ddd, J = 7.5, 4.8, 2.9 Hz, 1H), 1.04 (ddd, J = 
8.6, 4.8 Hz, 1H), 1.43–1.39 (m, 9H), 1.53 (ddd, J = 7.2, 5.4 Hz, 1H), 1.50–1.46 (m, 1H);  
13C NMR (100.61 MHz, CDCl3) δ 170.1, 147.3, 129.2 (+, 4C), 122.3 (+, 2C), 121.4 (+, 
4C), 51.5, 40.6 (+), 29.0 (+, 3C), 27.6 (+), 16.5 (-).   FT IR (NaCl, cm-1): 3325, 3057, 
3044, 2966, 2930, 1647, 1591, 1500, 1456, 1394, 1364, 1313, 1248, 1224, 748; HRMS 
(TOF ES): found 308.1880, calculated for C20H24N2O (M+) 308.1889 (2.9 ppm). 
 (1R*,2R*)-N-(tert-butyl)-2-(10H-phenothiazin-10-
yl)cyclopropanecarboxamide (126ae): This compound was 
prepared according to the typical procedure employing 2-
bromo-N-(tert-butyl)cyclopropanecarboxamide 119a (55 mg, 0.25 mmol), powdered 
KOH (56 mg, 1.0 mmol), 18-crown-6 (6.6 mg, 0.025 mmol), THF (5 mL), and 10H-
phenothiazine 123e (149 mg, 0.75 mmol).  Crude reaction mixture (dr 3.5:1) was 
concentrated in vacuum and treated with potassium tert-butoxide (112 mg, 1.00 mmol) in 
anhydrous THF (5 mL) at 80 oC for 12h to improve dr to 49:1.   Purification by flash 
chromatography on silica gel (eluent hexane:EtOAc 8:1) afforded the title compound as 
white solid, mp 187−188 oC, Rf 0.52.   Yield 50 mg (0.148 mmol, 59%). 1H NMR 
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(400.13 MHz, CDCl3) δ ppm 7.24–7.12 (m, 4H), 6.98 (t, J = 8.0 Hz, 2H), 5.57 (s, 1H), 
3.29 (ddd, J = 7.2, 4.7, 2.9 Hz, 1H), 1.83 (ddd, J = 6.7, 5.8, 4.9 Hz, 1H), 1.57 (ddd, J = 
5.8, 2.9 Hz, 1H), 1.20 (ddd, J = 9.3, 4.8 Hz, 1H). 13C NMR (100.61 MHz, CDCl3) δ ppm 
169.8, 127.2, 127.1, 122.93, 51.6, 35.4, 29.0, 28.5, 18.1; FT IR (NaCl, cm-1): 3358, 2992, 
2961, 1649, 1542, 1461, 1374, 1367, 1250, 1129, 825, 750;  HRMS (TOF ES): found 
339.1528, calculated for C20H23N2OS (M+H) 339.1531 (0.9 ppm). 
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 Chapter 3. Dual Control of the Selectivity in the Formal Nucleophilic 
Substitution of Bromocyclopropanes 
 3.0. Introduction 
   Densely functionalized, chirally rich cyclopropanes have been the focus of 
rapidly growing interest, as both advanced synthons9697 and important pharmacophores,98 
as evident from the vast number of emerging publications. Despite impressive 
achievements in the development of powerful methods for di- and trisubstituted 
cyclopropanes, and use thereof in the synthesis of complex biologically relevant targets,99 
there is still a significant demand for complementary approaches to analogs with denser 
substitution patterns and an expanded functional group scope. 
 In our continuing efforts to develop the diastereoselective formal nucleophilic 
substitution reaction of halocyclopropanes with heteroatom nucleophiles, we aimed at 
expanding the scope of this reaction to include multisubstituted substrates. We have 
shown previously that 1,2-dehydrohalogenation of 1,2-di- and 1,2,2-trisubstitued 
cyclopropylbromides 132a, 132b produces achiral cyclopropenes 133a and 133b, which 
upon in situ addition of a nucleophile furnish heterosubstituted cyclopropanes (modes 1 
and 2, Scheme	   44). Three alternative means of controlling the diastereoselectivity of 
addition have been demonstrated: a thermodynamically driven epimerization (mode 1), 
and a steric or directing effect of the substituents in the cyclopropene (mode 2, Scheme	  
44). In both of these modes, the generation of cyclopropene intermediates 133a and 133b 
was accompanied by a complete loss of the inherent chiral information and its subsequent 
reinstallation during the nucleophilic attack at either the prochiral face (mode 1) or 
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prochiral site (mode 2). Thus, nonracemic products could only be obtained via a 
diastereoselective addition of an enantiomerically pure nucleophilic reagent. 
Scheme	  44	  
 
 Extension of this methodology beyond trisubstituted substrates amplifies the 
challenge of controlling the stereo- selectivity of addition. Indeed, both modes 1 and 2 
required control of a single center only, since the two forming chiral centers were linked 
to each other. The new mode 3 (Scheme	  44) realized in this work utilizes tetrasubstituted 
substrates 132, in which installation of two stereogenic centers is synchronized and is 
controlled by both means (Scheme	  45). 
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Scheme	  45	  
	  
	  
 We envisioned that chiral α-bromocyclopropylcarboxamides 132 (easily available 
from corresponding α-bromocyclopropyl carboxylic acids) would provide convenient 
probes for this transformation, because the chirality of the β-quaternary center in these 
substrates would be preserved during the dehydrohalogenation/addition sequence, which 
would allow for carrying over the asymmetric information from the substrate to the 
product 134. The chiral center at C-2 in bromocyclopropane 132 dictates the 
configuration of the other two stereocenters that are successively installed via a sterically 
controlled addition of a nucleophile (Steric control), followed by a thermodynamically 
driven epimerization (Thermodynamic control) of the resulting enolate intermediate 135. 
3.1. Synthesis of Homochiral α-Bromocyclopropyl Carboxylic Acids  
 Homochiral α-bromocyclopropyl carboxylic acids (α-BCA) 136 can be obtained 
in multigram quantaties via an efficient chiral resolution protocol and later converted into 
corresponding α-bromocyclopropylcarboxamides 132 (Scheme	  47). The preparation of  α-
BCA’s commences with the synthesis of α-substituted styrenes. Previously, Rubin et al.  
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Scheme	  46	  
 
disclosed an efficient protocol for the synthesis of styrenes 134 from the readily available 
alkyl benzoates or acetophenones 133 via a two-step sequence including addition of 
Grignard reagent followed by the acid-catalyzed dehydration of the resulting tertiary 
alcohols 137 (Scheme	   46). It was observed that the rate of the dehydration varies 
significantly depending on the electronic properties of the substituents at the aromatic 
ring of styrenes. Thus, electron-poor substrates react very slowly, whereas reaction times 
for electron-rich alcohols are significantly shorter. It should also be noted that some of 
the olefins 134 are highly susceptible to acid-catalyzed cationic polymerization, thus in 
order to avoid the decomposition of the olefin, the preparation of styrenes 134 was 
carried out via the Wittig olefination (Scheme	  47).  
Scheme	  47	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 Dibromocyclopropanes 135 were prepared by cyclopropanation of the obtained 
olefins 134 with dibromocarbene generated under modified Makosza’s PTC 
conditions.100 Racemic bromoacids 136 were obtained by treatment of gem-dibromides 
135 with butyl lithium at -61°C in THF, and exposure of the formed cyclopropyl lithium 
species to freshly condensed dry carbon dioxide. Carboxylation of gem-
dibromocyclopropanes 135 under optimized conditions went smoothly giving trans acid 
136 as the major product (Scheme	  48).101,102,103 
Scheme	  48	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Scheme	  49 
 
 According to the literature,104 substituted cyclopropane lithium halocarbenoids 
138 favor conformation 138a rather than 138b, wherein lithium locates syn to the 
aromatic system (Scheme	  49). It is believed that the lithiated intermediate 138a is more 
thermodynamically stable than cyclopropane 138b, due to the fact that the bulky bromine 
atom and large phenyl ring are located on the opposite sides of the cyclopropane. 
Carboxylation of dibromocyclopropanes 135a-e with a methyl substituent on the ring 
resulted in selective formation of acids 136a-e which is consisted with the proposed 
mechanism. When the size of the smaller substituent was increased from methyl to ethyl, 
carboxylation of cyclopropane 136f with gave a mixture of diastereomers 136f and 137f 
(dr 8:1). Surprisingly, reaction of naphthyl substituted dibromocyclorpopane 135g also 
resulted in the formation of a mixture of diastereomers (dr 6:1) and the acid 136g was 
obtained only in 42% yield. This effect can be attributed to higher activation energies of 
carboxylation of lithium halocarbenoids 138a with a bulky substituent, thus carbon 
dioxide can also react with sterically more accessible intermediate 138b. 
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 Having substantial amounts of racemic acids 136, we attempted to resolve them 
into individual enantiomers via diastereomeric salt formation. The salt forming 
conditions were found by screening of different resolving agents and solvent 
combinations for the acid rac-136a (). To our delight, both enantiomers of 136a can be 
obtained with cinchonine (CN) and with its pseudoenantiomer cinchonidine (CD) (Scheme	  
50). Treatment of rac-136a with stoichiometric amounts with cinchonine in boiling 
acetone and subsequent cooling resulted in the formation of diastereomeric salt 136aCN. 
Isolation of the salt by simple suction filtration, followed by acid-base extraction gave 
(+)-136a in 98% ee. The remaining filtrate was concentrated in vacuum, remaining 
pseudoracemic acid 136a was recovered and treated with cinchonidine under the same 
conditions giving salt 136aCD which is then converted into (-)-136a in highly 
enantiopure form (91% ee). Enantiomeric excess of acids 136 was determined by chiral 
GC or HPLC analysis of corresponding esters (See experimental part). The absolute 
stereochemistry of (-)-136a the obtained acids was determined by a single-crystal X-ray 
analysis of the corresponding chiral salt 136aCD (Figure	  3). 
Scheme	  50 
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Figure	  3	  ORTEP	  drawing	  of	  136aCD	  showing	  50%	  probability	  amplitude	  displacement	  ellipsoids.	  
  
	  
 We were unable to obtain X-ray quality crystals of the opposite diastereomeric 
salt 136aCN. In order to confirm the absolute stereochemistry of the other enantiomer 
(+)-136a, corresponding diethylamide (+)-132ac was subjected to X-ray analysis (Figure	  
4). 
Figure	  4	  Synthesis	  and	  ORTEP	  drawing	  of	  (+)-­‐132a	  showing	  50%	  probability	  amplitude	  displacement	  
ellipsoids. 
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Table	  2	  
Entry Acid Resolving 
agent 
%ee Entry Acid Resolving 
agent 
%ee 
1 (+)-136b CN >99 10 (-)-136b CD >99 
2 (+)-136c CN 92 11 (-)-136c CD 52 
3 (+)-136d CN >99 12 (-)-136d CD >99 
4 (+)-136e CN >99 13 (-)-136e CD >99 
5 (+)-136f CN >99 14 (-)-136f CD >99 
6 (+)-136g CN >99 15 (-)-136g CD 54 
CN – cinchonine, CD – cinchonidine  
 Having optimized the resolution conditions, we moved on to other cyclopropyl 
acids 136b-g (Table	   2). To our delight, resolution with cinchonine and chinchonidine 
proved to be highly efficient for most of the cyclorpopyl acids. Generally, enantiopure 
acids (>99% ee) were obtained after a single crystallization with a chiral base. However, 
acid (+)-136c was obtained with 92%ee, as for (-)-136c and (-)-136g the enantiomeric 
excess was about 50%. An X-ray analysis of chiral ammonium salt  (-)-136bCD 
indicated the same absolute configuration as (-)-136bCD (Figure	   5). The absolute 
configuration of acids 136c-g was assigned by analogy. Enantiopure acids were used to 
prepare corresponding chiral amides for the formal nucleophilic substitution reaction. 
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Figure	  5	  ORTEP	  drawing	  of	  136bCD	  showing	  50%	  probability	  amplitude	  displacement	  ellipsoids. 
 
 3.2. Optimization of the Reaction Conditions 
 We began by testing a model reaction of bromocyclopropane 132aa using benzyl 
alcohol 140a as a pronucleophile, using the standard reaction conditions employed 
previously for the addition of alkoxides.105 This reaction provided cyclopropyl ether 
134aaa as a major diastereomer (dr = 14:1), albeit in only 49% yield (Table	  3, entry 1). 
The stereoselectivity of the addition followed the predicted pattern: the in situ generated 
cyclopropene underwent addition of the nucleophile from the least hindered face, while 
the subsequent thermodynamically driven epimerization at the α-carbon of the amide set 
the third stereocenter. The minor stereoisomer 139aaa was isolated, and its relative 
configuration was established by NMR experiments. It was thus confirmed that the 
observed diastereoselectivity is a result of the facial differentiation at the nucleophilic 
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attack step, whereas the last stereocenter is set with perfect diastereoselectivity via a 
thermodynamically driven epimerization, which occurs very rapidly in the presence of  
Table	  3	  
	  
	  
no.	   base	   T,	  °C	   solvent	   18-­‐c-­‐6,	  %	   yield,	  %b	   drc	  
1	   t-­‐BuOK	   60	   THF	   10	   49	   14:1	  
2	   t-­‐BuOK	   80	   THF	   10	   62	   11:1	  
3	   t-­‐BuOK	   90	   THF	   10	   61	   8:1	  
4	   KOH	   80	   THF	   10	   37e	   22:1	  
5	   KOHd	   80	   THF	   10	   37e	   19:1	  
6	   t-­‐BuOK	   80	   Toluene	   10	   28	   2:1	  
7	   t-­‐BuOK	   80	   DCM	   10	   -­‐	   -­‐	  
8	   t-­‐BuOK	   80	   DMA	   10	   59	   27:1	  
9	   t-­‐BuOK	   80	   NMP	   10	   76	   32:1	  
10	   t-­‐BuOK	   80	   CH3CN	   10	   35	   19:1	  
11	   t-­‐BuOK	   80	   DMSO	   10	   71	   36:1	  
12	   t-­‐BuOK	   40	   DMSO	   10	   80	   46:1	  
13	   t-­‐BuOK	   25	   DMSO	   10	   20e	   50:1	  
aOptimization reactions performed in 0.03 mmol scale. bGC yields of major diastereomer 
134aaa. cdr (134aaa:139aaa) was determined by GC of crude reaction mixtures. 
dReaction time – 1 week. eIncomplete conversion.  
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t-BuOK. Increasing the temperature to 80 °C allowed for an improved yield of 134aaa, 
however, at the expense of diastereoselectivity (entry 2). A further temperature increase 
caused notable deterioration of the diastereomeric ratio with no yield improvement (entry 
3). Performing the reaction with a weaker base, KOH, did not proceed to completion, 
even after prolonged stirring at higher temperatures, despite providing excellent 
diastereoselectivities. Poor conversions achieved with KOH were attributed to the fact 
that dehydrohalogenation of 132aa requires higher effective basicity of the medium as 
compared to β-bromocyclopropylcarboxamides, in which deprotonation occurs at the 
more acidic α-carbon. Other alkaline bases such as lithium, sodium, magnesium 
hydroxides, and tert-butoxides gave no reaction. Solvent screening revealed that polar, 
aprotic solvents, such as DMSO and NMP, were superior media for this transformation 
(entries 9 and 11). Accordingly, DMSO was chosen as the medium due to being a safer 
alternative.106 A quick temperature optimization in DMSO showed that the best yield and 
dr’s are achieved at 40°C (entry 12). 
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 3.3. Formal Substitution Using Homochiral Substrate 
 To showcase the efficient transfer of the chiral information from the starting 
material to the product, homochiral bromocyclopropane 132ba derived from (1R,2S)-1-
bromo-2-methyl-2-(p-tolyl)cyclopropane-1-carboxylic acid (-)-136b was cleanly 
converted into benzyl cyclopropyl ether 134baa in excellent isolated yield and 
diastereoselectivity (Scheme	  51). The retention of configuration of the quaternary carbon 
throughout the reaction was confirmed by an X-ray analysis of the product 134bab 
(Figure	   6	   ORTEP	   drawing	   of	   134bab	   showing	   50%	   probability	   amplitude	   displacement	  
ellipsoids.). 
Scheme	  51	  
	  
Figure	  6	  ORTEP	  drawing	  of	  134bab	  showing	  50%	  probability	  amplitude	  displacement	  ellipsoids.	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 3.4. Oxygen-based Nucleophiles 
 Having optimized the reaction conditions, we moved on to examine the scope of 
this reaction. Screening a series of alcohols against a few 
bromocyclopropylcarboxamides 132 revealed that the sterics of the nucleophiles had a 
significant effect on their reactivity. Thus, all primary alcohols, including those bearing 
functional groups, reacted smoothly under optimized conditions (Scheme	   52). A brief 
survey of substituents on the carboxamide group showed that tertiary and bulky 
secondary amides are compatible with optimized conditions. Reaction in DMSO 
consistently allowed for high diastereoselectivities, although in a few cases provided 
lower yields due to partial loss of product upon extraction. The reaction with a secondary 
alcohol proceeded much more sluggishly in DMSO and led to substantial decomposition; 
however, a reasonable yield of 134aag was obtained under alternative conditions in THF 
at higher temperatures. Attempts to add phenols were not successful. Interestingly, 
addition of tert-butyl alcohol to cyclopropene did not give expected cyclopropyl ether 
134aah even at higher temperatures (80°C in DMSO), instead a carboxamide 141aa was 
observed in 66% yield (Scheme	  53).  
 We believe that a bulky tert-butyl alohol adds to cyclopropene 132aa at higher 
temperature giving the desired cyclorpopane 134aah (Scheme	  53). However, under basic 
conditions cyclopropyl ether 134aah  decomposes giving isoprene 142a and an aldehyde 
142b. The later one is attacked by a tert-butoxide forming intermediate 142d which then 
gives tert-butyl formate 142f and enolate 142g. Upon protonation of 142g a final product 
N-(tert-butyl)-3-phenylbutanamide 141aa is formed. This reaction occurs with a loss of 
chirality and does not have much value for the synthetic community. Similar compounds 
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can be obtained in enantiopure form by simple amidation of corresponding carboxylic 
acids107 or via stereoselective additions of organometallic species to α,β-enamides108. 
Scheme	  52 
Reactions performed on 0.2 mmol scale; isolated yields are listed. Values of dr are measured by 
GC or NMR analysis of crude reaction mixtures. a Reaction performed in THF, 80°C, 12 h. 
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Scheme	  53 
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 3.5. Nitrogen-based Nucleophiles 
 To access β-ACC derivatives through this methodology, we tested a series of 
different amines as N-pronucleophiles; however, our initial attempts to induce addition 
primary and secondary amines, as well as carboxamides and sulfonamides, were 
unsuccessful.  We were pleased to find that azoles underwent facile addition to provide 
substituted hetarylcyclopropanes 143 under previously optimized conditions (Scheme	  54). 
Reaction in the presence of pyrrole afforded the corresponding tetrasubstituted 
cyclopropanes 143aaa and 143baa in high yields and excellent diastereoselectivities. We 
were happy to find that such problematic nucleophiles such as indoles, known for their 
susceptibility to Friedel-Crafts alkylation, dimerization, and polymerization,109 afforded 
good isolated yields of the corresponding adducts. Substituted indoles and 7-azaindole 
proceeded cleanly to afford the corresponding cyclopropanes. Similarly, pyrazole was 
engaged in a very efficient transformation with cyclopropylbromides 132aa and 132ba, 
providing good yields of N-cyclopropylpyrazoles 143aae and 143bae, respectively, 
although longer reaction times were reaquired and the diastereoselectivities were slightly 
lower. More acidic azoles uncluding imidazoles, benzimidazoles and triazoles did not 
participate in the title reaction. 
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Scheme	  54 
 
Reactions performed on 0.2 mmol scale; isolated yields are listed. Values of dr are measured by 
GC or NMR analysis of crude reaction mixtures. a Reaction time is 72 h. 
 Anilines were also tested in this reaction and to our delight N-methylaniline 123a 
reacted with 132aa giving a stable donor-acceptor cyclopropane 144aa in 55% and dr 
3:1. p-Flouro-N-methylaniline 123f can be utilized in the described reaction providing 
with a tetrasubstituted cyclopropane 144ab with similar diastereoselectivity and yield. It 
was found that increased steric hindrance at the N- termini of the pronucleophile had a 
significant effect on the reaction course. Thus, aniline bearing an ethyl substituent greatly 
increased the reaction’s efficacy; the diastereoselectivity was much higher for 144ac.  
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Scheme	  55	  
	  
While substrate with secondary alkyl group at the N-terminus did not undergo the 
addition at all (144ad). 
 These cyclopropane adducts 144 do not undergo a ring-opening reaction which is 
observe on disubstituted cyclopropanes 126 (Scheme	   40, Chapter 2). Tetrasubstituted 
cyclopropanes 144 proved to be stable even without the presence of the aromatic system 
with electron-withdrawing groups. The unusual stability of 144 is caused by 
stereoelectronic factors (Scheme	  56). In order for the ring-opening reaction to occur, the 
tetrasubstituted cyclopropane 144 has to be in a conformation 144A with a nitrogen lone 
pair positioned anti-periplanar to the C1-C3 bond of the cyclopropane. Due to the steric 
interactions of alkyl substituent on the nitrogen and a methyl group on the cyclopropane 
ring, conformation 144A is highly disfavored, thus cyclopropane 144 exists in a more 
stable conformation 144B.  
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Scheme	  56 
 
3.6. Effects of the Substituents on the Cyclopropane 
 The sensitivity of the reaction to sterics can be further seen by comparing the 
reactivity of bromocyclopropanes 132aa and 132fa, possessing a methyl and an ethyl 
group, respectively, at the β-quaternary center (Scheme	   57). In spite of providing the 
same isolated yield as 134aaa, homologue 134faa reacted very sluggishly at 40°C and 
required higher temperature to achieve full conversion, which led to a lower, although 
still respectable, diastereoselectivity. Reaction of 132fa with pyrrole followed the same 
trend: the diastereoselectivity and the rate of the reaction were significantly lower. The 
carboxamides 132ga possessing a larger naphthyl substituent also participated in a dual-
control substitution reaction with known oxygen- and nitrogen-based nucleophiles. As 
expected such modification of the substrate gave superb diastereselectivities in the title 
reaction (Scheme	  58). 
H
N
Ph
H3C
EWG
H
CH3
Ph
H
NPh
EWG
H
CH3
Ph
CH3
144A 144B
N
R
N CON(Et)2
Ph
R
Ph
N
O
144
145
Undergoes ring-opening Stable conformer
	   87	  
Scheme	  57	  
a Reaction stirred at 40°C for 12 h, then at 80°C for 30 minutes.	  
Scheme	  58	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3.7. Intramolecular formal nucleophilic substitution 
 We envisioned the intramolecular mode of the dual-control reaction would serve 
as a convenient probe for stretching the limits of the challenging nucleophilic endo-trig 
medium ring closures and provide a useful tool for the construction of novel types of 
medium-sized heterocycles. The intramolecular reaction could allow access to several 
important classes of compounds including medium and large cyclopropyl-fused 
heterocycles. Besides biologically active bicyclic compounds discussed in Chapter 1 
(Scheme	  1) it is important to mention cyclopropyl-fused macrocycle MK-5172 discovered 
at Merck which has the potential to be the cornerstone of an all-oral treatment for 
hepatitis C virus (Figure	  7).110  
Figure	  7 
  
 Generation of cyclopropene species 146 from bromocyclopropane 145 bearing a 
pronucleophilic moiety tethered through the carboxamide would enable an endo-trig 
cyclization, leading to bicyclic scaffolds 147 (Scheme	   59). It was indicated that the 
lengths of the tether plays a crucial role in the cyclization process. Bromocyclopropanes 
145b with a three carbon atom tether underwent highly efficient 8-endo-trig cyclization 
affording the corresponding oxazacanone 147b in excellent yield. 9-Membered cycle  
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Scheme	  59 
Reactions stirred at 40°C for 12 h, C = 0.04M  
147c was obtained in lower yield from a very flexible substrate 147c, possessing no 
additional stereoselectivity-inducing elements in the tether. Bromocyclopropanes 145e 
and 145f bearing gem-dialkyl substituents on the tether gave corresponding 8-membered 
heterocycles 147e and 147f albeit in 31-37% yield. Due to Thorpe-Ingold effect the 
geometry of the tether is changed and the nucleophilic oxygen atom is delivered at a 
different angle, resulting in lower yield compared to 147b. It should also be mentioned 
that cyclization did not require high dilutions and afforded consistently high yields in 
preparatively convenient concentration ranges. 
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Scheme	  60 
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 8-Endo-trig cyclization of 145 produced cis-fused heterocycles 147 exclusively as 
equilibration to the trans-fused diastereomers 147B is unfavored unlike in the 
corresponding intermolecular nucleophilic additions to similar substrates (Scheme	  60). A 
series of oxazacanones 147 were obtained in good to excellent yields. It was found that 
increasing the size of the substituent on the nitrogen has a positive effect on the efficacy 
of the reaction. Bromocyclopropanes 145l and 145n bearing a methyl group on 
carboxamide function gave bicyclic moieties 147l and 147n in lower yield. It is believed 
that upon the formation of cyclopropene 146, the nucleophilic alkoxide anion is 
coordinated to potassium ion, which may also coordinate to the oxygen of the amide 
(Scheme	   61). Such preorganization places the nucleophilic center far from the reactive 
double bond. By placement of a bulky substituent (e.g. benzyl group) on the amide, 
reactive conformer 146B is more favored, due to restricted coordination of potassium and 
carbonyl oxygen. 
Scheme	  61	  
	  
 All oxazacanones were prepared from enantiopure starting material and isolated 
as single diastereomers, A high level of selectivity was also observed on a 
bromocyclopropane 145k with an ethyl substituent on the cyclopropane ring. Heterocycle 
147m was prepared on a smaller scale compared to other oxazacanones 147 and the 
N
R
O
OK
N
R
O
O
non-reactive reactive
146A 146B
	   92	  
isolated yield was only 49%. We were also delighted to obtain benzooxazocinone 147o 
from corresponding substrate 145o under optimized conditions (Scheme	  62).  
Scheme	  62 
  
3.8. Future Directions 
 One of the possible future directions of the presented research would be a 
development of an alternative “dual-control” reaction utilizing a combination of directing 
and thermodynamic controls. In order to perform a diastereoselective addition in this 
manner a substrate possessing a suitable directing group should be designed (Scheme	  63). 
This new type of “dual-control” reaction could potentially be performed in an 
intramolecular fashion. Placement of a nucleophile on the amide function would result in  
endo-trig cyclization (eq.1). An exo-trig cyclization may be invoked with a nucleophilic 
moiety tethered to a substrate via the directing group. 
Scheme	  63	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Scheme	  64	  
	  
	  
	  
3.9. Conclusions 
 In conclusion, a “dual-control” strategy was successfully employed for a highly 
diastereoselective inter- and intramolecular addition of nucleophilic species to in situ 
generated cyclopropenes. This reaction afforded tetrasubstituted donor-acceptor 
cyclopropanes with all three asymmetric carbons in the strained ring. The chiral integrity 
of the starting material is translated to the product via a sequential installation of two 
stereogenic centers efficiently controlled by steric and thermodynamic effects. 	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3.10. Experimental 
3.10.1. Synthesis of the Starting Materials 
 
1,2-dimethyl-4-(prop-1-en-2-yl)benzene (134с): A solution of 
potassium tert-butoxide (7.71 g, 68.7 mmol, 0.955 equiv.) in dry THF (75 
mL) was added drop wise to a stirred suspension of methyltriphenylphosphonium 
bromide (41.16 g, 115.2 mmol, 1.6 equiv.) in dry THF (175 mL) at 0 ºC.  The resulting 
yellow mixture was stirred for one hour at 0 ºC and then a solution of 3’,4’-
dimethylacetophenone (10.7 g, 10.7 mL, 72.0 mmol, 1.0 equiv.) in THF was added drop 
wise and stirred overnight.  The mixture was then quenched with saturated aqueous 
NH4Cl and partitioned between water (25 mL) and diethyl ether (3 x 75 mL).  Combined 
ethereal phases were washed with brine, dried with MgSO4, filtered, and concentrated.  
The residue was purified by short column chromatography using silica gel and a hexane 
mobile phase to afford 1,2-dimethyl-4-(prop-1-en-2-yl)benzene as a clear oil in 82% 
yield (8.6 g, 59 mmol). 1H NMR (500MHz, CDCl3): δ 7.18−7.01 (m, 3H), 5.25 (s, 1H), 
4.94 (s, 1H), 2.20 (s, 3H), 2.18 (s, 3H), 2.06 (s, 3H); 13C (126 MHz, CDCl3): δ 143.4, 
139.0, 136.4, 136.0, 129.6 (-), 126.9 (-), 123.1 (-), 111.6 (+), 22.0 (-), 20.1 (-), 19.6 (-); 
FTIR (KBr, cm-1): 3084, 3020, 2970, 2941, 2918, 2887, 2862, 1630, 1566, 1504, 1450, 
1371, 1020, 995, 881, 822, 733; HRMS (TOF ES): Found 153.1253, calculated for 
C11H14Li (M+Li) 153.1256 (2.0 ppm). 
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 (2,2-dibromo-1methylcyclopropyl)-1,2-dimethylbenzene (135с): 
(Typical Procedure): 1,2-dimethyl-4-(prop-1-en-2-yl)benzene 134с 
(17.48 g, 119.5 mmol, 1.0 equiv.) without further purification was mixed 
with bromoform (45.24 g, 15.65 mL, 179.0 mmol, 1.5 equiv.), tetradecyltrimethyl-
ammonium bromide (TDTAB) (750 mg, 2.23 mmol, 0.019 equiv.), and dichloromethane 
(200 mL).  The mixture was vigorously stirred and 50% aqueous solution of sodium 
hydroxide (12 g NaOH, 12 mL H2O) was added drop wise.  The mixture was stirred 
(900-1100 rpm) overnight at 30−35 ºC.  When GC analysis indicated full conversion of 
the olefin, the mixture was quenched with water (300 mL) and extracted with 
dichloromethane (3 x 50 mL).  Combined organic phases were washed with brine, dried 
with MgSO4, filtered, and concentrated.  The residue was purified by flash column 
chromatography on silica gel with hexanes as the mobile phase to afford (2,2-dibromo-
1methylcyclopropyl)-1,2-dimethylbenzene as a light yellow oil in 78% yield (29.72 g, 
93.25 mmol). 1H NMR (400MHz, CDCl3): δ 7.18–7.01 (m, 3H), 2.29 (s, 3H), 2.27 (s, 
3H), 2.15 (d, J = 7.5 Hz, 1H), 1.76 (d, J = 7.5 Hz, 1H), 1.71 (s, 3H); 13C (126 MHz, 
CDCl3): δ 139.9, 136.7, 135.7, 129.8 (+), 129.7 (+), 125.9 (+), 37.4 (-), 35.6, 33.8, 28.0 
(+), 20.0 (+), 19.7 (+); FTIR (KBr, cm-1): 2980, 2966, 2924, 2864, 2359, 1504, 1447, 
1427, 1062, 1022, 822, 692; HRMS (TOF ES): Found 314.9389, calculated for C12H13Br2 
(M-H) 314.9384 (1.6 ppm). 
 (2,2-dibromo-1-methylcyclopropyl)-4-ethylbenzene (135d): 
Compound was obtained via typical procedure using 1-ethyl-4-(prop-1-en-
2-yl)benzene 134d (18.68 g, 127.7 mmol, 1.0 equiv.) mixed with 
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bromoform ( 48.52 g, 16.79 mL, 192.0 mmol, 1.5 equiv.), tetradecyltrimethyl-ammonium 
bromide (TDTAB) (750 mg, 2.23 mmol, 0.017 equiv.), and dichloromethane (200 mL).  
Sodium hydroxide (13 g, 319 mmol, 2.5 equiv.) in 13 mL of water was added drop wise.  
(2,2-dibromo-1-methylcyclopropyl)-4-ethylbenzene was obtained as a clear oil in 77% 
yield (31.1 g, 97.9 mmol). 1H NMR (400MHz, CDCl3): δ 7.25 – 7.18 (m, 4H), 2.66 (q, J 
= 7.6 Hz, 2H), 2.15 (d, J = 7.5 Hz, 1H), 1.77 (d, J = 7.5 Hz, 1H), 1.71 (s, 3H), 1.26 (t, J = 
7.6 Hz, 3H); 13C (126 MHz, CDCl3): 143.3, 139.7, 128.5 (+, 2C), 128.0 (+, 2C), 37.3, 
35.6, 33.8 (-), 28.6 (-), 27.9 (+), 15.5 (+); FTIR (KBr, cm-1): 3022, 2962, 2928, 2893, 
2870, 1512, 1445, 1427, 1377, 1082, 1063, 1051, 1018, 831, 692, 573; HRMS (TOF ES): 
Found 314.9386, calculated for C12H13Br2 (M-H) 314.9384 (0.6 ppm).  
3.10.2. Synthesis of Racemic Bromoarylylcyclopropanecarboxylic Acids 
 (1R*,2S*)-1-bromo-2-methyl-2-phenylcyclopropanecarboxylic acid (136a):  
(Typical procedure): Oven-dried 500 mL two-necked flask was 
charged under nitrogen atmosphere with solution of (2,2-dibromo-1-
methylcyclopropyl)benzene 135a (20.3 g, 70.0 mmol, 1.0 equiv) in 200 mL 
of anhydrous THF. The solution was cooled to -78 oC and n-BuLi (2.5 M in hexanes, 
26.5 mL, 66.5 mmol, 0.95 equiv) was added dropwise through an addition funnel over 
the course of 15 minutes. After the addition was complete, the reaction mixture was 
wormed to -61 oC and stirred for 20 minutes. The cold solution was then cannulated into 
1 L flask containing freshly condensed CO2. The reaction mixture was stirred for 2 hours 
under constant flow of dry CO2 gas, while allowed to warm to room temperature.  The 
mixture was partitioned between 140 mL of water and 100 mL of CHCl3 and acidified 
with 210 mL of 4N HCl. The aqueous layer was extracted with CHCl3 (3 x 40 mL). The 
CO2H
Br
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combined organic phases were then back-extracted with saturated NaHCO3 (3 x 40 mL).  
The combined aqueous extracts were washed with 20 mL CHCl3, acidified to pH < 1, and 
extracted with CHCl3 (3 x 40 mL). The combined organic phases were dried with 
anhydrous MgSO4 and concentrated in vacuum to yield 15.3 g (60.0 mmol, 90.2%) of 1-
bromo-2-methyl-2-phenylcyclopropanecarboxylic acid as a colorless crystalline solid, 
mp: 90-92 oC. 1H NMR (400 MHz, CDCl3) δ 7.33–7.14 (m, 5H), 2.46 (d, J = 6.4 Hz, 
1H), 1.74 (s, 3H), 1.41 (d, J = 6.4 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 173.1, 140.2, 
128.6 (+, 2C), 128.0 (+, 2C), 127.4 (+), 39.4, 37.2, 28.724 (-), 27.8 (+); FT IR (KBr, cm-
1): 3384, 2923, 1445, 1238, 1213, 1150, 1109, 1061, 1028, 968, 932, 874, 800, 766, 700, 
604, 559, 532; HRMS (TOF ES): found 247.0305, calculated for C11H13NBrOLi (M+Li) 
247.0310 (2.0 ppm).  
 (1R*,2S*)-1-bromo-2-methyl-2-(p-tolyl)cyclopropanecarboxylic acid (136b):  
This compound was obtained according to a typical procedure 
employing 2.5 M n-BuLi (26.5 mL, 66.5 mmol) and 1-(2,2-dibromo-1-
methylcyclopropyl)-4-methylbenzene 135b (21.28 g, 70 mmol) as a 
starting material. Acid-base extraction yielded 13.37 g (49.7 mmol, 75%) 
of 136b as a colorless solid, mp: 114.2-114.9 oC. 1H NMR (500 MHz, CDCl3) δ 7.07 (td, 
J = 8.5, 3.3 Hz, 4H), 2.44 (d, J = 6.4 Hz, 1H), 2.31 (s, 3H), 1.71 (s, 3H), 1.37 (d, J = 6.4 
Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 172.1, 137.2, 137.0, 129.3 (+, 2C), 127.9 (+, 
2C), 39.5, 36.8, 28.7 (-), 27.8 (+), 21.3 (+); FT IR (KBr, cm-1): 3022, 2984, 2964, 2923, 
1699, 1419, 1296, 1278, 1246, 818; HRMS (TOF ES): found 267.0015, calculated for 
C12H12NBrO2 (M-H) 247.0021 (2.2 ppm). 
CO2H
Br
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 (1R*,2S*)-1-bromo-2-(3,4-dimethylphenyl)-2-methylcyclopro-
panecarboxylic acid (136c): 
A solution of (2,2-dibromo-1methylcyclopropyl)-1,2-
dimethylbenzene 135c (23.7 g, 74.5 mmol, 1.0 equiv.) in dry THF (200 mL) 
was added to a 500 ml oven dried two neck flask under nitrogen atmosphere.  The 
solution was cooled to -78 ºC and 2.5 M n-BuLi (4.54 g, 28.3 ml, 70.8 mmol, 0.950 
equiv.) was added drop wise with an addition funnel over the course of 15 minutes.  
Immediately following the addition of n-BuLi, the reaction mixture was warmed to -61 
ºC and stirred for 20 minutes.  The mixture was then cannulated into a 1 L three neck 
flask containing freshly condensed carbon dioxide and allowed to warm to room 
temperature with moderate stirring while under a constant flow of dry CO2 gas.  The 
mixture was quenched with 140 mL of water and then added to 100 mL of chloroform.  
The mixture was acidified with 210 mL of 4N HCl.  The aqueous layer was extracted 
with chloroform (3 x 40 mL).  Combined organic phases were then extracted with 
saturated sodium bicarbonate (3 x 40 mL). The remaining aqueous solution was washed 
with 20 mL chloroform.  The combined aqueous phases were then acidified to pH<1 and 
extracted with chloroform (3 x 40 mL).  The combined organic layers were dried with 
MgSO4, filtered, and concentrated to afford the product as light yellow crystals in 71% 
yield (14.2 g, 50.1 mmol). Mp: 127−129 ºC; 1H NMR (500MHz, CDCl3): δ 7.05–6.86 
(m, 3H), 2.42 (d, J = 6.3 Hz, 1H), 2.21 (s, 3H), 2.20 (s, 3H), 1.70 (s, 3H), 1.36 (d, J = 6.3 
Hz, 1H); 13C (126 MHz, CDCl3): δ 174.0, 137.5, 136.7, 135.6, 129.8 (+), 129.1 (+), 125.2 
(+), 39.6, 36.9, 28.8 (-), 28.0 (+), 19.8 (+), 19.6 (+); FTIR (KBr, cm-1): 3084, 3015, 2982, 
2968, 2924, 2885, 2866, 2652, 1699, 1445, 1418, 1302, 1281, 1250, 1221, 1061, 878, 
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820, 696; HRMS (TOF ES): Found 281.0179, calculated for C13H14BrO2 (M-H) 281.0177 
(0.7 ppm). 
 (1R*,2S*)-1-bromo-2-(4-ethylphenyl)-2-methylcyclopropane-
carboxylic acid (136d): 
Compound was obtained via typical procedure using 1-(2,2-
dibromo-1-methylcyclopropyl)-4-ethylbenzene 135d (22.4 g, 70.4 mmol, 1.0 equiv.) in 
THF (200 mL) and 2.5 M n-BuLi (4.28 g, 26.8 mL, 66.9 mmol, 0.95 equiv.).  (1R*,2S*)-
bromo-2-(4-ethylphenyl)-2-methylcyclopropanecarboxylic acid was obtained as light 
brown crystals in 46% yield (8.57 g, 30.3 mmol). MP: 109-111 ºC; 1H NMR (500MHz, 
CDCl3): δ 7.15–7.03 (m, 4H), 2.61 (q, J = 7.6 Hz, 2H), 2.44 (d, J = 6.4 Hz, 1H), 1.71 (s, 
3H), 1.37 (d, J = 6.4 Hz, 1H), 1.22 (t, J = 7.6 Hz, 3H); 13C (126 MHz, CDCl3): δ 173.7, 
143.3, 137.3, 128.0 (+, 2C), 127.9 (+, 2C), 39.5, 37.0, 28.8 (-), 28.6 (-), 27.8 (+), 15.6 
(+); FTIR (KBr, cm-1): 3090, 3049, 3022, 2964, 2928, 2895, 2872, 1701, 1516, 1421, 
1377, 1298, 1286, 1250, 1119, 1080, 1063, 1045, 941, 885, 862, 833, 696, 569; HRMS 
(TOF ES): Found 283.0328, calculated for C13H16BrO2 (M+H) 283.0334 (2.1 ppm). 
 (1R*,2S*)-1-bromo-2-methyl-2-(m-tolyl)cyclopropanecarboxylic acid (136e):  
Compound was obtained via typical procedure using 1-(2,2-
dibromo-1-methylcyclopropyl)-3-methylbenzene 135e (23.9 g, 78.5 mmol, 
1.0 equiv.) in THF (200 mL) and 2.5 M n-BuLi (4.78 g, 29.9 mL, 74.7 
mmol, 0.95 equiv.).  (1R*, 2S*)-1-bromo-2-methyl-2-(m-tolyl)cyclopropanecarboxylic 
acid was obtained as a yellow oil in 76% yield (15.2 g, 56.4 mmol). 1H NMR (400MHz, 
CDCl3): δ 7.18–6.93 (m, 4H), 2.44 (d, J = 6.3 Hz, 1H), 2.30 (s, 3H), 1.71 (s, 3H), 1.38 (d, 
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J = 6.4 Hz, 1H); 13C (126 MHz, CDCl3): δ 172.7, 140.1, 138.2, 128.7 (+), 128.5 (+), 
128.2 (+), 125.0 (+), 39.5, 37.1, 28.8 (-), 27.9 (+), 21.5 (+); FTIR (KBr, cm-1): 3400, 
3364, 3225, 3180, 3101, 3020, 2984, 2964, 2926, 2864, 1699, 1418, 1379, 1298, 1248, 
1200, 1049, 947, 876, 787, 706, 671; HRMS (TOF ES): Found 269.0184, calculated for 
C12H14BrO2 (M+H) 269.0177 (2.6 ppm). 
 (1R*,2S*)-1-bromo-2-ethyl-2-phenylcyclopropanecarboxylic acid (136f): 
 This compound was obtained according to a typical procedure 
employing 2.5 M n-BuLi (21.3 mL, 53.3 mmol) and  (2,2-dibromo-1-
ethylcyclopropyl)benzene 135f (17.07 g, 56.15 mmol) as a starting 
material. Acid-base extraction yielded 10.87 g (42.5 mmol, 76%) of a diastereomeric 
mixture of acids (8:1). Major diastereomer can be obtained in pure form by 
recrystallization from ethyl acetate as a colorless solid, mp: 124.3−125.1 oC. 
Diastereomeric mixture (2:1) isolated from the mother liquor was used for preparation of 
carboxamide 3e.  1H NMR (500 MHz, CDCl3) δ 7.25–7.12 (m, 5H), 2.35 (dd, J = 6.3, 1.5 
Hz, 1H), 2.08 (ddd, J = 13.9, 7.4, 1.4 Hz, 1H), 1.89 (dq, J = 14.8, 7.4 Hz, 1H), 1.34 (d, J 
= 6.3 Hz, 1H), 0.84 (t, J = 7.4 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 172.6, 138.1, 
129.0 (+, 2C), 128.4 (+, 2C), 127.4 (+), 42.0, 39.9, 33.6 (-), 27.7 (-), 11.2 (+); FT IR 
(KBr, cm-1): 3084, 3058, 3026, 2972, 2873, 1699, 1417, 1298, 1286, 1238, 1099, 1066, 
879, 754, 700; HRMS (TOF ES): found 275.0254, calculated for C12H13BrO2Li (M+Li) 
275.0259 (1.8 ppm). 
 
CO2H
Br
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 (1R*, 2S*)-1-bromo-2-methyl-2(naphthalene-2-yl)cyclopro-
panecarboxylic acid (136g): 
Compound was obtained via typical procedure using 2-(2,2-
dibromo-1-methylcyclopropyl)naphthalene 135g (23.8 g, 70.0 mmol, 1.0 equiv.) in THF 
(200 mL) and 2.5 M  n-BuLi (4.26 g, 26.6 mL, 66.5 mmol, 0.95 equiv.).  (1R*, 2S*)-1-
bromo-2-methyl-2(naphthalene-2-yl)cyclopropanecarboxylic acid was obtained as dark 
brown highly viscous oil in 45% yield (9.06 g, 29.7 mmol). 1H NMR (500MHz, CDCl3): 
δ 7.80–7.13 (m, 7H), 2.46 (d, J = 6.4 Hz, 1H), 1.70 (s, 3H), 1.38 (d, J = 6.4 Hz, 1H); 13C 
(126 MHz, CDCl3): δ 172.6, 137.7, 133.4, 132.6, 128.4 (+), 127.9 (+), 127.8 (+), 126.9 
(+), 126.3 (+), 126.1 (+), 126.0 (+), 39.5, 37.3, 29.0 (-), 27.9 (+); FTIR (KBr, cm-1): 
3053, 2359, 2341, 1697, 1420, 1292, 1231, 1061, 856, 818, 748, 681, 444, 424, 411; 
HRMS (TOF ES): Found 303.0027, calculated for C15H12BrO2 (M-H) 303.0021 (2.0 
ppm). 
 
3.10.3. Resolution of Bromoarylylcyclopropanecarboxylic Acids 
 
(1S,2R)-1-bromo-2-methyl-2-phenylcyclopropanecarboxylic 
acid ((+)-136a):Typical Procedure:  (1R*, 2S*)-1-bromo-2-methyl-2-
phenylcyclopropanecarboxylic acid 136a (13.50 g, 52.92 mmol, 1.0 
equiv.) and cinchonine (15.85 g, 53.84 mmol, 1.0 equiv.) were dissolved in a minimum 
amount of acetone (~300 mL) with stirring and heating. The solution was stirred for 20 
minutes and then filtered while hot into an insulated Erlenmeyer flask. The flask was 
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capped and the mixture was allowed to cool to room temperature over two hours. The 
capped flask was then placed in the freezer and left overnight.  Recovered crystals ([α]D = 
+109.1°, c 0.502 CH2Cl2) were isolated by suction filtration and dissolved in ethyl acetate 
(100 mL). The organic phase was added to water and acidified to pH of 2 using 6N 
hydrochloric acid. The product was extracted using ethyl acetate (3 X 50 mL), dried, 
filtered, and concentrated. (1S,2R)-1-bromo-2-methyl-2-phenylcyclopropanecarboxylic 
acid was obtained as a light yellow oil in 62% yield (4.20 g, 16.5 mmol 98% ee). Spectral 
properties of this material were identical to those reported above for racemic acid; [α]D 
(28.5ºC, 589 nm, 1 dm): +56.5° (c 0.2 CH2Cl2). 
 (1R,2S)-1-bromo-2-methyl-2-phenylcyclopropanecarboxylic 
acid ((-)-136a): Typical Procedure:  (1R*, 2S*)-1-bromo-2-methyl-2-
phenylcyclopropanecarboxylic acid 136a (13.5 g, 52.9 mmol, 1.0 equiv.) 
and cinchonidine (11.2 g, 38.0 mmol, 0.72 equiv.) were dissolved in a minimum amount 
of acetone (~300 mL) with stirring and heating. The solution was stirred for 20 minutes 
and then filtered while hot into an insulated Erlenmeyer flask. The flask was capped and 
the mixture was allowed to cool to room temperature over two hours. The capped flask 
was then placed in the freezer and left overnight.  Recovered crystals ([α]D = -102.2°, c 
0.360 CH2Cl2) were isolated by suction filtration and dissolved in ethyl acetate (100 mL). 
The organic phase was added to water and acidified to pH of 2 using 6N hydrochloric 
acid. The product was extracted using ethyl acetate (3 X 50 mL), dried, filtered, and 
concentrated. (1S,2R)-1-bromo-2-methyl-2-phenylcyclopropanecarboxylic acid was 
obtained as a light yellow oil in 53% yield (3.8 g, 14.1 mmol, 91% ee). Spectral 
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properties of this material were identical to those reported above for racemic acid; [α] D 
(28.5ºC, 589 nm, 1 dm): - 49.4°, (c 0.172 CH2Cl2). 
(1S,2R)-1-bromo-2-methyl-2-(p-tolyl)cyclopropanecarboxylic 
acid ((+)-136b):  
Compound was obtained via typical procedure using racemic 
(1R*, 2S*)-1-bromo-2-methyl-2-(p-tolyl)cyclopropanecarboxylic acid 136b (5.25 g, 19.5 
mmol, 1.0 equiv.), cinchonine (5.75 g, 19.5 mmol, 1.0 equiv.), and acetone (~300 mL). 
Recovered crystals ([α] D = +103.9°, c 0.640 CH2Cl2) were dissolved in ethyl acetate (100 
mL). (1S,2R)-1-bromo-2-methyl-2-(p-tolyl)cyclopropanecarboxylic acid was recovered 
as a light yellow oil in 50% yield (1.3 g, 4.8 mmol, >99% ee). Spectral properties of this 
material were identical to those reported above for racemic acid; [α] D (28.5ºC, 589 nm, 1 
dm): +66.0°, (c 0.106 CH2Cl2). 
 (1R,2S)-1-bromo-2-methyl-2-(p-tolyl)cyclopropanecarboxylic 
acid ((-)-136b):  
Compound was obtained via typical procedure using racemic 1-
bromo-2-methyl-2-(p-tolyl)cyclopropanecarboxylic acid 136b (5.254 g, 19.52 mmol, 1.0 
equiv.), cinchonidine (5.747 g, 19.52 mmol, 1.0 equiv.) and acetone (~300 mL). 
Recovered crystals ([α]D = -139.3°, c 0.600 CH2Cl2) were dissolved in ethyl acetate (100 
mL). (1R,2S)-1-bromo-2-methyl-2-(p-tolyl)cyclopropanecarboxylic acid was obtained as 
a cream colored solid in 34% yield (0.879 g, 3.27 mmol, >99% ee). Spectral properties of 
this material were identical to those reported above for racemic acid; [α]D (28.5ºC, 589 
nm, 1 dm): -61.0°, (c 0.100 CH2Cl2). 
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(1S,2R)-1-bromo-2-(3,4-dimethylphenyl)-2-
methylcyclopropanecarboxylic acid ((+)-136c):   
Compound was obtained via typical procedure using racemic 
(1R*,2S*)-1-bromo-2-(3,4-dimethylphenyl)-2-methylcyclopropanecarboxylic acid 136c 
(5.00 g, 17.7 mmol, 1.0 equiv.), cinchonine (5.00 g, 16.9 mmol, 0.96 equiv.), and acetone 
(~300 mL). Recovered crystals ([α]D = +94.1°, c 0.408 CH2Cl2) were dissolved in ethyl 
acetate (100 mL). (1S,2R)-1-bromo-2-(3,4-dimethylphenyl)-2-
methylcyclopropanecarboxylic acid was obtained as a light yellow oil in 34% yield (0.85 
mg, 3.0 mmol, 92% ee). Spectral properties of this material were identical to those 
reported above for racemic acid; [α]D (28.5ºC, 589 nm, 1 dm): +54.7°, (c 0.172 CH2Cl2). 
(1R,2S)-1-bromo-2-(3,4-dimethylphenyl)-2-methylcyclopropane 
carboxylic acid ((-)-136c): Compound was obtained via typical procedure 
using racemic (1R*,2S*)-1-bromo-2-(3,4-dimethylphenyl)-2-
methylcyclopropanecarboxylic acid 136c (5.00 g, 17.7 mmol, 1.0 equiv.), cinchonidine 
(3.05 g, 10.2 mmol, 0.58 equiv.), and acetone (200 mL). Recovered crystals ([α]D = 
+67.4°, c 0.328 CH2Cl2)  ([α]= 67.4, c=0.328) were dissolved in ethyl acetate (100 mL). 
(1R,2S)-1-bromo-2-(3,4-dimethylphenyl)-2-methylcyclopropanecarboxylic acid was 
recovered as a a light yellow oil in 66% yield (1.65 g, 5.83 mmol, 52% ee). Spectral 
properties of this material were identical to those reported above for racemic acid; [α]D 
(28.5ºC, 589 nm, 1 dm): -31.6°, (c 0.190 CH2Cl2). 
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(1S,2R)-1-bromo-2-(4-ethylphenyl)-2-methylcyclopropane 
carboxylic acid  ((+)-136d):     
Compound was obtained via typical procedure using racemic 
(1R*,2S*)-1-bromo-2-(4-ethylphenyl)-2-methylcyclopropanecarboxylic acid 136d  (5.01 
g, 17.7 mmol, 1.0 equiv.), cinchonine (2.5 g, 8.5 mmol, 0.48 equiv.), and acetone (~300 
mL). Recovered crystals ([α]D = +109.4°, c 0.170 CH2Cl2) were dissolved in ethyl acetate 
(~75 mL). (1R,2S)-1-bromo-2-(4-ethylphenyl)-2-methylcyclopropanecarboxylic acid was 
recovered as a yellowish brown solid in 33% yield (0.82 g, 2.9 mmol, >99% ee). MP: 
72.8-74.8 ºC. Spectral properties of this material were identical to those reported above 
for racemic acid; [α]D (28.5ºC, 589 nm, 1 dm): +69.8°, (c 0.116 CH2Cl2). 
 
(1R,2S)-1-bromo-2-(4-ethylphenyl)-2-methylcyclopropane 
carboxylic acid ((-)-136d):      
Compound was obtained via typical procedure using racemic 
(1R*,2S*)-1-bromo-2-(4-ethylphenyl)-2-methylcyclopropanecarboxylic acid 136d  (5.01 
g, 17.7 mmol, 1.0 equiv.), cinchonidine (2.5 g, 8.5 mmol, 0.44 equiv.), and acetone (~300 
mL). Recovered crystals ([α]D = -70.2°, c 0.124 CH2Cl2) were dissolved in ethyl acetate 
(~75 mL). (1R,2S)-1-bromo-2-(4-ethylphenyl)-2-methylcyclopropanecarboxylic acid was 
recovered as a yellowish-brown solid in 35% yield (0.87 g, 3.1 mmol, >99% ee). MP: 
71.0-73.2ºC. Spectral properties of this material were identical to those reported above 
for racemic acid; [α]D (28.5ºC, 589 nm, 1 dm): -55.4°, (c 0.130 CH2Cl2). 
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(1S,2R)-1-bromo-2-methyl-2-(m-tolyl)cyclopropane 
carboxylic acid ((+)-136e):      
Compound was obtained via typical procedure using racemic 
(1R*,2S*)-1-bromo-2-methyl-2-(m-tolyl)cyclopropanecarboxylic acid 136e (4.78 g, 17.6 
mmol, 1.0 equiv.), cinchonine (5.17 g, 17.6 mmol, 1.0 equiv.), and acetone (~300 mL). 
Recovered crystals ([α]D = +113.9°, c 0.418 CH2Cl2) were dissolved in ethyl acetate (100 
mL). (1S,2R)-1-bromo-2-methyl-2-(m-tolyl)cyclopropanecarboxylic acid was obtained as 
cream colored crystals in 23% yield (0.55 g, 2.0 mmol >99% ee). MP: 92.0-93.4 ºC. 
Spectral properties of this material were identical to those reported above for racemic 
acid; [α]D (28.5ºC, 589 nm, 1 dm): +77.5°, (c 0.102 CH2Cl2). 
 
(1R,2S)-1-bromo-2-methyl-2-(m-tolyl)cyclopropanecarboxylic 
acid ((-)-136e):      
Compound was obtained via typical procedure using racemic 
(1R*,2S*)-1-bromo-2-methyl-2-(m-tolyl)cyclopropanecarboxylic acid 136e (4.78 g, 17.6 
mmol, 1.0 equiv), cinchonidine (2.59 g, 8.79 mmol, 0.5 equiv.), and acetone (~200 mL). 
Recovered crystals  ([α]D = -93.5°, c 0.184 CH2Cl2) were dissolved in ethyl acetate (75 
mL). (1R,2S)-1-bromo-2-methyl-2-(m-tolyl)cyclopropanecarboxylic acid was obtained as 
a grey oil in 11.4% yield (0.27 g, 1.0 mmol, >99% ee). Spectral properties of this material 
were identical to those reported above for racemic acid; [α]D (28.5ºC, 589 nm, 1 dm): -
74.6°, (c 0.114 CH2Cl2). 
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(1S,2R)-1-bromo-2-ethyl-2-phenylcyclopropanecarboxylic 
acid ((+)-136f):    
Compound was obtained via typical procedure using racemic 
(1R*, 2S*)-1-bromo-2-ethyl-2-phenylcyclopropanecarboxylic acid 136f (5.39 g, 20.0 
mmol, 1.0 equiv.), cinchonine (5.89 g, 20.0 mmol, 1.0 equiv.), and acetone (~300 mL). 
Recovered crystals ([α]D = +93.5°, c 0.306 CH2Cl2) were dissolved in ethyl acetate (100 
mL). (1S,2R)-1-bromo-2-ethyl-2-phenylcyclopropanecarboxylic acid was recovered as a 
cream colored solid in 57% yield (1.53 g, 5.68 mmol >99% ee). MP: 75-76.5 ºC. Spectral 
properties of this material were identical to those reported above for racemic acid; [α]D 
(28.5ºC, 589 nm, 1 dm): +69.5°, (c 0.118 CH2Cl2).  
 
 (1R,2S)-1-bromo-2-ethyl-2-phenylcyclopropanecarboxylic 
acid ((-)-136f):     
Compound was prepared according typical procedure using 
racemic 1-bromo-2-ethyl-2-phenylcyclopropanecarboxylic acid 136f (5.39 g, 20.0 mmol, 
1.0 equiv.), cinchonidine (5.89 g, 20.0 mmol, 1.0 equiv.), acetone (~300 mL). Recovered 
crystals ([α]D = -74.7°, c 0.418 CH2Cl2) were dissolved in ethyl acetate (100 mL). 
(1R,2S)-1-bromo-2-ethyl-2-phenylcyclopropanecarboxylic acid was recovered as a cream 
colored solid in 40% yield (1.06 g, 3.94 mmol, >99% ee). MP: 72.5-73.4 ºC. Spectral 
properties of this material were identical to those reported above for racemic acid; [α]D 
(28.5ºC, 589 nm, 1 dm): -43.1°, (c 0.144 CH2Cl2).  
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(1S,2R)-1-bromo-2-methyl-2-(naphthalen-2-yl)cyclopro-
panecarboxylic acid ((+)-136g):      
Compound was obtained via typical procedure using racemic 
(1R*, 2S*)-1-bromo-2-methyl-2(naphthalene-2-yl)cyclopropanecarboxylic acid 136g 
(4.68 g, 14.6 mmol, 1.0 equiv.), cinchonine (4.30g, 14.6 mmol, 1.0 equiv.), and acetone 
(~300 mL). Recovered crystals ([α]D = +112.0°, c 0.382 CH2Cl2)  were dissolved in ethyl 
acetate (100 mL). (1S,2R)-1-bromo-2-methyl-2-(naphthalen-2-yl)cyclopropanecarboxylic 
acid was recovered as a dark brown solid in 51% yield (1.19 g, 3.72 mmol,* 99% ee). 
MP: 121.5-123.5 ºC. Spectral properties of this material were identical to those reported 
above for racemic acid; [α]D (28.5ºC, 589 nm, 1 dm): +108.2°, (c 0.122 CH2Cl2).  
(1R,2S)-1-bromo-2-methyl-2-(naphthalen-2-yl)cyclopro-
panecarboxylic acid ((+)-136g):       
Compound was obtained via typical procedure using racemic (1R*, 
2S*)-1-bromo-2-methyl-2(naphthalene-2-yl)cyclopropanecarboxylic acid 136g (4.68 g, 
14.6 mmol, 1.0 equiv.), cinchonidine (4.30 g, 14.6 mmol, 1.0 equiv.), acetone (~300 mL). 
Recovered crystals ([α]D = -96.1°, c 0.382 CH2Cl2) were dissolved in ethyl acetate (100 
mL). (1R*, 2S*)-1-bromo-2-methyl-2(naphthalene-2-yl)cyclopropanecarboxylic acid was 
recovered as a dark brown oil in 73% yield (1.7 g, 5.3 mmol, 54% ee). Spectral properties 
of this material were identical to those reported above for racemic acid; [α]D (28.5ºC, 589 
nm, 1 dm): -57.4°, (c 0.162 CH2Cl2).  
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3.10.4. Synthesis of Bromoarylylcyclopropanecarboxylic Acid Methyl Esters 
 
(1R*,2S*)-methyl 1-bromo-2-methyl-2-phenylcyclopro-
panecarboxylate 136aE 
Typical Procedure: (1R,2S)-1-bromo-2-methyl-2-
phenylcyclopropanecarboxylic acid 136a (255 mg, 0.947 mmol, 1.0 equiv.), potassium 
carbonate (276 mg, 2.00 mmol, 2.0 equiv.), and methyl iodide (280 mg, 123 µL, 1.97 
mmol, 2.0 equiv.) were combined in dimethyl formamide (10 mL) and stirred vigorously 
for 12 hours. The mixture was quenched with water (5 mL) and then partitioned between 
water and dichloromethane. The product was extracted using CH2Cl2 (3 X 10 mL), dried 
(MgSO4), filtered, and concentrated. Recovered material was purified by silica gel 
chromatography to afford the title compound as a light yellow oil in 71% yield (181 mg, 
0.672 mmol). Rf= 0.22 (hexanes/ethyl acetate 50:1). 1H NMR (500MHz, CDCl3): δ 7.56–
7.01 (m, 5H), 3.34 (s, 3H), 2.55 (d, J = 6.4 Hz, 1H), 1.75 (s, 3H), 1.40 (d, J = 6.5 Hz, 
1H); 13C (126 MHz, CDCl3): δ 168.5, 140.7, 128.5 (+, 2C), 128.1 (+, 2C), 127.2 (+), 52.9 
(+), 40.4, 35.9, 27.9 (-), 27.5 (+); FTIR (KBr, cm-1): 3026, 2986, 2951, 1732, 1603, 1497, 
1434, 1379, 1325, 1298, 1285, 1234, 1115, 1094, 1061, 1026, 982, 876, 775, 758, 721, 
700, 559, 542; HRMS (TOF ES): Found 269.0177, calculated for C12H14BrO2 (M+H) 
269.0177 (0.0 ppm).  
GC Rt (Column: J&W Scientific Cyclodex-B 30 meter 0.250 mm bore column, 
120.0ºC iso, N2 30.0 mL/min, H2 40 mL/min, Air 400 mL/min): (+) 49.72, (-) 50.57 min. 
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(1S,2R)-methyl 1-bromo-2-methyl-2-phenylcyclopro-
panecarboxylate (+)-136aE: 
Compound was obtained via typical procedure using (1S,2R)-1-
bromo-2-methyl-2-phenylcyclopropanecarboxylic acid (+)-136a (50 mg, 0.20 mmol, 1.0 
equiv.), potassium carbonate (55 mg, 0.40 mmol, 2.0 equiv.), methyl iodide (56.8 mg, 
24.9 µL, 0.400 mmol, 2.0 equiv.) and DMF (5 mL). (1S,2R)-methyl 1-bromo-2-methyl-
2-phenylcyclopropanecarboxylate was obtained as a light yellow oil in 70% yield (37.7 
mg, 0.140 mmol). Spectral properties of this material were identical to those reported 
above for racemic ester; [α]D (28.5ºC, 589 nm, 1 dm): +34.6°, (c 0.220 CH2Cl2). 
GC Rt (Column: J&W Scientific Cyclodex-B 30 meter 0.250 mm bore column, 
120.0ºC iso, N2 30.0 mL/min, H2 40 mL/min, Air 400 mL/min): 49.72 min. 
 
 (1R,2S)-methyl 1-bromo-2-methyl-2-phenylcyclopro-
panecarboxylate (-)-136aE: 
Compound was obtained via typical procedure using (1R,2S)- 1-
bromo-2-methyl-2-phenylcyclopropanecarboxylic acid (-)-136a (50 mg, 0.19 mmol, 1.0 
equiv.), potassium carbonate (51.4 mg, 0.372 mmol, 2.0 equiv.), methyl iodide (52.8 mg, 
23.2 µL, 0.372 mmol, 2.0 equiv.), and DMF (5 mL). (1R,2S)-methyl 1-bromo-2-methyl-
2-phenylcyclopropanecarboxylate was obtained as a light yellow oil in 71% yield (36.3 
mg, 0.135 mmol). Spectral properties of this material were identical to those reported 
above for racemic ester; [α]D (28.5ºC, 589 nm, 1 dm): -32.3°, (c 0.820 CH2Cl2). 
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GC Rt (Column: J&W Scientific Cyclodex-B 30 meter 0.250 mm bore column, 
120.0ºC iso, N2 30.0 mL/min, H2 40 mL/min, Air 400 mL/min): 50.57 min. 
(1R*,2S*)-methyl 1-bromo-2-methyl-2-(p-tolyl)cyclopropane-
carboxylate 136bE:: 
Compound was obtained via typical procedure using (1R*,2S*)-1-
bromo-2-methyl-2-(p-tolyl)cyclopropanecarboxylic acid 136b (300 mg, 1.11 mmol, 1.0 
equiv.), potassium carbonate (307 mg, 2.22 mmol, 2.0 equiv.), and methyl iodide (315 
mg, 138 µL, 2.22 mmol, 2.0 equiv.) and dimethyl formamide (10 mL). (1R*,2S*)-methyl 
1-bromo-2-methyl-2-(p-tolyl)cyclopropanecarboxylate was obtained as a light yellow oil 
in 80% yield (251 mg, 0.888 mmol). Rf: 0.22 (hexanes/ethyl acetate 50:1). 1H NMR 
(500MHz, CDCl3): δ 7.14–7.04 (m, 4H), 3.36 (s, 3H), 2.50 (d, J = 6.4 Hz, 1H), 2.30 (s, 
3H), 1.71 (s, 3H), 1.35 (d, J = 6.4 Hz, 1H); 13C (126 MHz, CDCl3): δ 168.6, 137.6, 136.8, 
129.2 (+, 2C), 127.9 (+, 2C), 53.0 (+), 40.3, 35.6, 27.9 (-), 27.5 (+), 21.2 (+); FTIR (KBr, 
cm-1): 2984, 2951, 2926, 1732, 1516, 1435, 1377, 1325, 1300, 1281, 1232, 1113, 1094, 
1063, 1047, 820, 719, 557; HRMS (TOF ES): Found 283.0335, calculated for 
C13H16BrO2 (M+H) 283.0334, 0.4 ppm.  
GC Rt (Column: J&W Scientific Cyclodex-B 30 meter 0.250 mm bore column, 
131ºC iso, N2 30.0 mL/min, H2 40 mL/min, Air 400 mL/min): (+) 45.097, (-) 45.636 min. 
(1S,2R)-methyl 1-bromo-2-methyl-2-(p-tolyl)cyclopropane-
carboxylate (+)-136bE: 
Compound was obtained via typical procedure using (1S,2R)- 1-
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bromo-2-methyl-2-(p-tolyl)cyclopropanecarboxylic acid (+)-136b (54 mg, 0.20 mmol, 
1.0 equiv.), potassium carbonate (55 mg, 0.40 mmol, 2.0 equiv.), methyl iodide (56.5 mg, 
24.8 µL, 0.400 mmol, 2.0 equiv.) and DMF (5 mL). (1S,2R)-methyl 1-bromo-2-methyl-
2-(p-tolyl)cyclopropanecarboxylate was obtained as light yellow oil in 80% yield (44 mg, 
0.16 mmol). Spectral properties of this material were identical to those reported above for 
racemic ester; [α]D (28.5ºC, 589 nm, 1 dm): +42.6°, (c 0.620 CH2Cl2). 
GC Rt (Column: J&W Scientific Cyclodex-B 30 meter 0.250 mm bore column, 
131.0ºC iso, N2 30.0 mL/min, H2 40 mL/min, Air 400 mL/min): (+) 45.08 min. 
(1R,2S)-methyl 1-bromo-2-methyl-2-(p-tolyl)cyclopropane-
carboxylate (-)-136bE: 
Typical Procedure: (1R,2S)-1-bromo-2-methyl-2-(p-
tolyl)cyclopropanecarboxylic acid (-)-136b  (300 mg, 1.11 mmol, 1.0 equiv.), potassium 
carbonate (306 mg, 2.22 mmol, 2.0 equiv.), and methyl iodide (315 mg, 138 µL, 2.22 
mmol, 2.0 equiv.) were combined in dimethyl formamide (10 mL) and stirred vigorously 
for 12 hours. The mixture was quenched with water (5 mL) and then partitioned between 
water and dichloromethane. The product was extracted using DCM (3 X 10 mL), dried 
(MgSO4), filtered, and concentrated. Recovered material was purified by silica gel 
chromatography to afford the title compound as a light yellow oil in 80% yield (251 mg, 
0.888 mmol). Spectral properties of this material were identical to those reported above 
for racemic ester; [α]D (28.5ºC, 589 nm, 1 dm): -38.3°, (c 0.300 CH2Cl2). 
GC Rt (Column: J&W Scientific Cyclodex-B 30 meter 0.250 mm bore column, 
131.0ºC iso, N2 30.0 mL/min, H2 40 mL/min, Air 400 mL/min): 45.619 min.  
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(1R*, 2S*)-methyl 1-bromo-2-(3,4-dimethylphenyl)-2-methyl-
cyclopropanecarboxylate 136сE: 
Compound was obtained via typical procedure using racemic 
(1R*,2S*)-1-bromo-2-(3,4-dimethylphenyl)-2-methylcyclopropanecarboxylic acid 136с 
(50 mg, 0.18 mmol, 1.0 equiv.), potassium carbonate (48.8 mg, 0.353 mmol, 2.0 equiv.), 
methyl iodide (50.0 mg, 22.0 µL, 0.353 mmol, 2.0 equiv.), and DMF (5 mL).  (1R*, 
2S*)-methyl 1-bromo-2-(3,4-dimethylphenyl)-2-methylcyclopropanecarboxylate was 
obtained as a light yellow oil in 85% yield (45.5 mg, 0.15 mmol). Rf= 0.22 
(hexanes/ethyl acetate 50:1). 1H NMR (500MHz, CDCl3): δ 7.08–6.90 (m, 3H), 3.38 (s, 
3H), 2.48 (d, J = 6.4 Hz, 1H), 2.22 (s, 3H), 2.21 (s, 3H), 1.71 (s, 3H), 1.34 (d, J = 6.3 Hz, 
1H); 13C (126 MHz, CDCl3):  δ 168.6, 138.1, 136.6, 135.5, 129.7 (+), 129.2 (+), 125.4 
(+), 53.0 (+), 40.3, 35.6, 27.9 (-), 27.6 (+), 19.9 (+), 19.6 (+); FTIR (KBr, cm-1): 2982, 
2949, 2924, 1732, 1506, 1435, 1377, 1306, 1283, 1236, 1221, 1095, 1063, 874, 822, 717, 
600; HRMS (TOF ES): Found 296.0412, Calculated for C14H17BrO2 (M+) 296.0412 (0.0 
ppm). HPLC Rt (Column: CHIRALCEL OD-H (250 mm x 4.6 mm), 0.5% iPrOH/hexane, 
flow = 0.7 mL/min, UV 254 nm): (+) 8.92 min, (-) 9.86 min. 
(1S,2R)-methyl 1-bromo-2-(3,4-dimethylphenyl)-2-methyl 
cyclopropanecarboxylate (+)-136сE: 
Compound was obtained via typical procedure using (1S,2R)-
1-bromo-2-(3,4-dimethylphenyl)-2-methylcyclopropanecarboxylic acid (+)-136с (50.0 
mg, 0.177 mmol, 1.0 equiv.), potassium carbonate (48.9 mg, 0.354 mmol, 2.0 equiv.), 
methyl iodide (50.2 mg, 21.9 µL, 0.354 mmol, 2.0 equiv.), and DMF (5 mL). (1S,2R)-
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methyl 1-bromo-2-(3,4-dimethylphenyl)-2-methylcyclopropanecarboxylate was obtained 
as a light yellow oil in 85% yield (45 mg, 0.15 mmol). Spectral properties of this material 
were identical to those reported above for racemic ester; [α]D (28.5ºC, 589 nm, 1 dm): 
+35.4°, (c 0.820 CH2Cl2). HPLC Rt (Column: CHIRALCEL OD-H (250 mm x 4.6 mm), 
0.5% iPrOH/hexane, flow = 0.7 mL/min, UV 254 nm): (+) 8.92 min 
 (1R,2S)-methyl 1-bromo-2-(3,4-dimethylphenyl)-2-methyl 
cyclopropanecarboxylate (-)-136сE: 
Compound was obtained via typical procedure using (1R,2S)-1-
bromo-2-(3,4-dimethylphenyl)-2-methylcyclopropanecarboxylic acid (-)-136с (50.0 mg, 
0.186 mmol, 1.0 equiv.), potassium carbonate (51.5 mg, 0.372 mmol, 2.0 equiv.), methyl 
iodide (52.8 mg, 23.2 µL, 0.372 mmol, 2.0 equiv.) and DMF (5 mL). (1R,2S)-methyl 1-
bromo-2-(3,4-dimethylphenyl)-2-methylcyclopropanecarboxylate was obtained as  a light 
yellow oil in 85% yield (47 mg, 0.16 mmol). Spectral properties of this material were 
identical to those reported above for racemic ester; [α]D (28.5ºC, 589 nm, 1 dm): -20.4°, 
(c 0.940 CH2Cl2). HPLC Rt (Column: CHIRALCEL OD-H (250 mm x 4.6 mm), 0.5% 
iPrOH/hexane, flow = 0.7 mL/min, UV 254 nm): (-) 9.86 min. 
 
(1R*,2S*)-methyl 1-bromo-2-(4-ethylphenyl)-2-methylcyclo-
propanecarboxylate 136сdE: 
Compound was obtained via typical procedure using racemic 
(1R*,2S*)-1-bromo-2-(4-ethylphenyl)-2-methylcyclopropanecarboxylic acid 136d (50 
mg, 0.18 mmol, 1.0 equiv.), potassium carbonate (48.8 mg, 0.352 mmol, 2.0 equiv.) 
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methyl iodide (50 mg, 21.9 µL, 0.352 mmol, 2.0 equiv.), and DMF (5ml).  (1R*,2S*)-
methyl 1-bromo-2-(4-ethylphenyl)-2-methylcyclopropanecarboxylate was obtained as a 
light yellow oil in 73% yield (39 mg, 0.13 mmol). Rf= 0.22 (hexanes/ethyl acetate 50:1). 
1H NMR (500MHz, CDCl3): δ 7.16–7.07 (m, 4H), 3.33 (s, 3H), 2.60 (q, J = 7.6 Hz, 2H), 
2.50 (d, J = 6.5 Hz, 1H), 1.71 (s, 3H), 1.35 (d, J = 6.4 Hz, 1H), 1.20 (t, J = 7.6 Hz, 3H); 
13C (126 MHz, CDCl3): δ 168.6, 143.2, 137.8, 128.0 (+, 2C), 127.9 (+, 2C), 52.9 (+), 
40.4, 35.5, 28.6 (-), 27.8 (-), 27.5 (+), 15.6 (+); FTIR (KBr, cm-1): 3022, 2962, 2978, 
2872, 1732, 1514, 1435, 1377, 1327, 1300, 1286, 1232, 1113, 1094, 1063, 1045, 982, 
833, 716, 571; HRMS (TOF ES): Found 295.0334, calculated for C14H16BrO2 (M-H) 
295.0334, 0.0 ppm. 
GC Rt (Column: J&W Scientific Cyclodex-B 30 meter 0.250 mm bore column, 
130.5ºC iso, N2 30.0 mL/min, H2 40 mL/min, Air 400 mL/min): (+) 71.878, (-) 72.685 
min. 
(1S,2R)-methyl 1-bromo-2-(4-ethylphenyl)-2-methylcyclo-
propanecarboxylate (+)-136сE:  
Compound was obtained via typical procedure using 
(1S.2R)- 1-bromo-2-(4-ethylphenyl)-2-methylcyclopropanecarboxylic acid (+)-136с 
(50.0 mg, 0.176 mmol, 1.0 equiv.), potassium carbonate (48.6 mg, 0.352 mmol, 2.0 
equiv.), methyl iodide (49.9 mg, 21.9 µL, 0.352 mmol, 2.0 equiv.) and DMF (5 mL). 
(1S,2R)-methyl 1-bromo-2-(4-ethylphenyl)-2-methylcyclopropanecarboxylate was 
obtained as a light yellow oil in 73% yield (38.0 mg, 0.128 mmol). Spectral properties of 
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this material were identical to those reported above for racemic ester; [α]D (28.5ºC, 589 
nm, 1 dm): +42.6°, (c 0.660 CH2Cl2). 
GC Rt (Column: J&W Scientific Cyclodex-B 30 meter 0.250 mm bore column, 
130.5ºC iso, N2 30.0 mL/min, H2 40 mL/min, Air 400 mL/min): 71.878 min. 
(1R,2S)-methyl 1-bromo-2-(4-ethylphenyl)-2-
methylcyclopropanecarboxylate (-)-136dE: 
Compound was obtained via typical procedure using (1R,2S)- 1-
bromo-2-(4-ethylphenyl)-2-methylcyclopropanecarboxylic acid (-)-136d (50.0 mg, 0.176 
mmol, 1.0 equiv.), potassium carbonate (48.6 mg, 0.352 mmol, 2.0 equiv.), methyl iodide 
(49.9 mg, 21.9 µL, 0.352 mmol, 2.0 equiv.), DMF (5 mL). (1R,2S)-methyl 1-bromo-2-(4-
ethylphenyl)-2-methylcyclopropanecarboxylate was obtained as a light yellow oil in 40% 
yield (38.5 mg, 0.128 mmol).  Spectral properties of this material were identical to those 
reported above for racemic ester; [α]D (28.5ºC, 589 nm, 1 dm): -40.3°, (c 0.340 CH2Cl2). 
GC Rt (Colum: J&W Scientific Cyclodex-B 30 meter 0.250 mm bore column, 
130.5ºC iso, N2 30.0 mL/min, H2 40 mL/min, Air 400 mL/min): 72.685 min. 
 
(1R*,2S*)-methyl 1-bromo-2-methyl-2-(m-tolyl)cyclopropane-
carboxylate 136eE: 
Compound was obtained via typical procedure using racemic 
(1R*,2S*)-1-bromo-2-methyl-2-(m-tolyl)cyclopropanecarboxylic acid 136e (50 mg, 0.19 
mmol, 1.0 equiv.), potassium carbonate (51.4 mg, 0.372 mmol, 2.0 equiv.), methyl iodide 
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(52.8 mg, 23.2 µL, 0.372 mmol, 2.0 equiv.), and DMF (5 mL).  (1R*,2S*)-methyl 1-
bromo-2-methyl-2-(m-tolyl)cyclopropanecarboxylate was obtained as a light yellow oil 
in 65% Yield (35 mg, 0.12 mmol). Rf=0.22 (hexanes/ethyl acetate 50:1). 1H NMR 
(500MHz, CDCl3): δ 7.19–6.98 (m, 4H), 3.34 (s, 3H), 2.50 (d, J = 6.4 Hz, 1H), 2.31 (s, 
3H), 1.71 (s, 3H), 1.36 (d, J = 6.4 Hz, 1H); 13C (126 MHz, CDCl3): δ 168.6, 140.7, 138.1, 
128.8 (+), 128.4 (+), 128.0 (+), 125.1 (+), 52.9 (+), 40.4, 35.9, 28.0 (-), 27.6 (+), 21.5 (+); 
FTIR (KBr, cm-1): 2984, 2951, 2926, 1732, 1607, 1489, 1435, 1377, 1329, 1302, 1279, 
1242, 1200, 1117, 1094, 1063, 872, 789, 706; HRMS (TOF ES): Found 282.0248, 
calculated for C13H15BrO2 (M+) 282.0255 (2.5 ppm).  
GC Rt (Column: J&W Scientific Cyclodex-B 30 meter 0.250 mm bore column, 
125.0ºC iso, N2 30.0 mL/min, H2 40 mL/min, Air 400 mL/min): (+) 52.905, (-) 53.985 
min. 
(1S,2R)-methyl 1-bromo-2-methyl-2-(m-tolyl)cyclopro-
panecarboxylate (+)-136eE: 
Compound was obtained via typical procedure using (1S,2R)-
1-bromo-2-methyl-2-(m-tolyl)cyclopropanecarboxylic acid (+)-136e (50.0 mg, 0.186 
mmol, 1.0 equiv.), potassium carbonate (51.5 mg, 0.372 mmol, 2.0 equiv.), methyl iodide 
(52.5 mg, 23.2 µL, 0.372 mmol, 2.0 equiv.), and DMF (5 mL). (1S,2R)-methyl 1-bromo-
2-methyl-2-(m-tolyl)cyclopropanecarboxylate was obtained as a light yellow oil in 65% 
yield (34 mg, 0.12 mmol). Spectral properties of this material were identical to those 
reported above for racemic ester; [α]D (28.5ºC, 589 nm, 1 dm): +23.3°, (c 0.820 CH2Cl2). 
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GC Rt (Column: J&W Scientific Cyclodex-B 30 meter 0.250 mm bore column, 
125.0ºC iso, N2 30.0 mL/min, H2 40 mL/min, Air 400 mL/min): 52.905 min. 
 
(1R,2S)-methyl 1-bromo-2-methyl-2-(m-tolyl)cyclopro-
panecarboxylate (-)-136eE: 
Compound was obtained via typical procedure using (1R,2S)- 1-
bromo-2-methyl-2-(m-tolyl)cyclopropanecarboxylic acid (-)-136e (50.0 mg, 0.186 mmol, 
1.0 equiv.), potassium carbonate (51.5 mg, 0.372 mmol, 2.0 equiv.), methyl iodide (52.5 
mg, 23.2 µL, 0.372 mmol, 2.0 equiv.), and DMF (5 mL). (1R,2S)-methyl 1-bromo-2-
methyl-2-(m-tolyl)cyclopropanecarboxylate was obtained as a light yellow oil in 65% 
yield (34 mg, 0.12 mmol). Spectral properties of this material were identical to those 
reported above for racemic ester; [α]D (28.5ºC, 589 nm, 1 dm): -30.2°, (c 0.420 CH2Cl2). 
GC Rt (Column: J&W Scientific Cyclodex-B 30 meter 0.250 mm bore column, 
125.0ºC iso, N2 30.0 mL/min, H2 40 mL/min, Air 400 mL/min): 53.985 min. 
 
(1R*,2S*)-methyl 1-bromo-2-ethyl-2-phenylcyclopro-
panecarboxylate 136fE: 
Compound was obtained using racemic (1R*,2S*)-1-bromo-2-
(4-ethylphenyl)-2-methylcyclopropanecarboxylic acid 136f (100 mg, 0.372 mmol, 1.0 
equiv.), potassium carbonate (103 mg, 0.744 mmol, 2.0 equiv), methyl iodide (106 mg, 
46.4 µL, 0.745 mmol, 2.0 equiv.) and DMF (5 mL).  (1R*,2S*)-methyl 1-bromo-2-ethyl-
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2-phenylcyclopropanecarboxylate was obtained as a light yellow oil in 91% yield (95.7 
mg, 0.338 mmol). Rf=0.22 (hexanes/ethyl acetate 50:1). 1H NMR (500MHz, CDCl3): δ 
7.33–7.17 (m, 5H), 3.34 (s, 3H), 2.45 (d, J = 6.4, 1H), 2.11 (dtd, J = 14.6, 7.3, 1.5 Hz, 
1H), 1.92 (dq, J = 13.7, 7.4 Hz, 1H), 1.35 (d, J = 6.3 Hz, 1H), 0.89 (t, J = 7.4 Hz, 3H); 
13C (126 MHz, CDCl3): δ 168.6, 138.7, 129.1 (+, 2C), 128.3 (+, 2C), 127.3 (+), 52.9 (+), 
40.9, 40.9, 33.4 (-), 26.9 (-), 11.2 (+); FTIR (KBr, cm-1): 3026, 2970, 2951, 2934, 1732, 
1495, 1435, 1377, 1300, 1286, 1225, 1118, 1090, 1067, 989, 881, 795, 756, 721, 702, 
592; HRMS (TOF ES): Found 282.0257, calculated for C13H15BrO2 (M+) 282.0255 (0.7 
ppm). 
GC Rt (Column: J&W Scientific Cyclodex-B 30 meter 0.250 mm bore column, 
134.1ºC iso, N2 30.0 mL/min, H2 40 mL/min, Air 400 mL/min): (+) 34.635, (-) 34.967 
min. 
 
(1S,2R)-methyl 1-bromo-2-ethyl-2-phenylcyclopropane-
carboxylate (+)-136fE: 
Compound was obtained via typical procedure using (1S,2R)-1-
bromo-2-ethyl-2-phenylcyclopropanecarboxylic acid (+)-136f (50 mg, 0.19 mmol, 1.0 
equiv.), potassium carbonate (51.4 mg, 0.372 mmol, 2.0 equiv.), methyl iodide (52.8 mg, 
23.2 µL, 0.372 mmol, 2.0 equiv.) and DMF (5 mL). (1S,2R)-methyl 1-bromo-2-ethyl-2-
phenylcyclopropanecarboxylate was obtained as a light yellow oil in 90% yield (48.4 mg, 
0.171 mmol). Spectral properties of this material were identical to those reported above 
for racemic ester; [α]D (28.5ºC, 589 nm, 1 dm): +19.3°, (c 0.244 CH2Cl2). 
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GC Rt (Column: J&W Scientific Cyclodex-B 30 meter 0.250 mm bore column, 
134.1ºC iso, N2 30.0 mL/min, H2 40 mL/min, Air 400 mL/min): 34.635 min. 
 
(1R,2S)-methyl 1-bromo-2-ethyl-2-phenylcyclopropane-
carboxylate (-)-136fE: 
Compound was obtained via typical procedure using (1R,2S)- 1-
bromo-2-ethyl-2-phenylcyclopropanecarboxylic acid (-)-136f (50.0 mg, 0.186 mmol, 1.0 
equiv.), potassium carbonate (51.4 mg, 0.371 mmol, 2.0 equiv.), methyl iodide (52.6 mg, 
23.2 µL, 0.371 mmol, 2.0 equiv.), and DMF (5 mL). (1R,2S)-methyl 1-bromo-2-ethyl-2-
phenylcyclopropanecarboxylate was obtained as a light yellow oil in 91% yield (49 mg, 
0.17 mmol). Spectral properties of this material were identical to those reported above for 
racemic ester; [α]D (28.5ºC, 589 nm, 1 dm): -30.9°, (c 0.800 CH2Cl2). 
HPLC Rt (Column: J&W Scientific Cyclodex-B 30 meter 0.250 mm bore column, 
134.1ºC iso, N2 30.0 mL/min, H2 40 mL/min, Air 400 mL/min): 34.967 min. 
 
(1R*,2S*)-methyl 1-bromo-2-methyl-2-(naphthalen-2-
yl)cyclopropanecarboxylate 136gE: 
Compound was obtained via typical procedure using racemic 
(1R*,2S*)-1-bromo-2-methyl-2(naphthalene-2-yl)cyclopropanecarboxylic acid 136g (50 
mg, 0.16 mmol, 1.0 equiv.), potassium carbonate (45.3 mg, 0.328 mmol, 2.0 equiv.), 
methyl iodide (46.5 mg, 20.4 µL, 0.328 mmol, 2.0 equiv.), and DMF (5 mL).  (1R*,2S*)-
	   121	  
methyl 1-bromo-2-methyl-2-(naphthalen-2-yl)cyclopropanecarboxylate was obtained as a 
light brown oil in 71% yield (38 mg, 0.12 mmol). Rf=0.22 (hexanes/ethyl acetate 50:1). 
1H NMR (500MHz, CDCl3): δ 7.94–7.33 (m, 7H), 3.26 (s, 3H), 2.66 (d, J = 6.5 Hz, 1H), 
1.81 (s, 3H), 1.47 (d, J = 6.5 Hz, 1H); 13C (126 MHz, CDCl3): 168.5, 138.2, 133.4, 132.6, 
128.3 (+), 127.9 (+), 127.8 (+), 126.9 (+), 126.3 (+), 126.1 (+), 126.0 (+), 53.0 (+), 40.4, 
36.1, 28.1 (-), 27.5 (+); FTIR (KBr, cm-1): 2984, 2949, 1734, 1435, 1325, 1294, 1271, 
1246, 1227, 1196, 1134, 1101, 1063, 982, 955, 895, 858, 820, 746, 717; HRMS (TOF 
ES): Found 319.0331, calculated for C16H16BrO2 (M+H) 319.0334 (0.9 ppm). 
HPLC Rt (Column: CHIRALCEL OD-H (250 mm x 4.6 mm), 0.5% 
iPrOH/hexane, flow = 0.7 mL/min, UV 254 nm): (+) 16.39 min, (-) 18.42 min. 
 
 (1S,2R)-methyl 1-bromo-2-methyl-2-(naphthalen-2yl) 
cyclopropanecarboxylate (+)-136gE: 
Compound was obtained via typical procedure using (1S,2R)-1-bromo-2-methyl-
2-(naphthalen-2-yl)cyclopropanecarboxylic acid (+)-136g (50 mg, 0.16 mmol, 1.0 
equiv.), potassium carbonate (45.3 mg, .328 mmol, 2.0 equiv.), methyl iodide (46.6 mg, 
0.328 mmol, 2.0 equiv.), and DMF (5 mL). (1S,2R)-methyl 1-bromo-2-methyl-2-
(naphthalen-2-yl)cyclopropanecarboxylate was obtained as a light brown oil in 75% yield 
(38 mg, 0.12 mmol). Spectral properties of this material were identical to those reported 
above for racemic ester; [α]D (28.5ºC, 589 nm, 1 dm): +90.0°, (c 0.600 CH2Cl2). 
HPLC Rt (Column: CHIRALCEL OD-H (250 mm x 4.6 mm), 0.5% 
iPrOH/hexane, flow = 0.7 mL/min, UV 254 nm): (+) 16.39 min 
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 (1R,2S)-methyl 1-bromo-2-methyl-2-(naphthalen-2-
yl)cyclopropanecarboxylate (-)-136gE: 
Compound was obtained via typical procedure using (1R,2S)- 1-
bromo-2-methyl-2-(naphthalen-2-yl)cyclopropanecarboxylic acid (-)-136g (50.0 mg, 
0.164 mmol, 1.0 equiv.), potassium carbonate (45.3 mg, 0.328 mmol, 2.0 equiv.), methyl 
iodide (46.5 mg, 40.8 µL, 0.328 mmol, 2.0 equiv.), and DMF (5 mL). (1R,2S)-methyl 1-
bromo-2-methyl-2-(naphthalen-2-yl)cyclopropanecarboxylate was obtained as a light 
yellow oil in 73% yield (38 mg, 0.12 mmol). Spectral properties of this material were 
identical to those reported above for racemic ester; [α]D (28.5ºC, 589 nm, 1 dm): -39.8°, 
(c 0.560 CH2Cl2). 
HPLC Rt (Column: CHIRALCEL OD-H (250 mm x 4.6 mm), 0.5% 
iPrOH/hexane, flow = 0.7 mL/min, UV 254 nm): (-) 18.42 min. 
3.10.5. Synthesis of Bromoarylcyclopropanecarboxamides 
	  
(1R*,2S*)-1-bromo-N-(tert-butyl)-2-methyl-2- phenylcyclo-
propanecarboxamide (132aa): 
Typical procedure: A flame dried 100 mL round-bottom flask 
equipped with a drying tube and magnetic stir bar was charged with 1-bromo-2-methyl-2-
phenylcyclopropanecarboxylic acid (136a) (1.28 g, 5.00 mmol, 1.00 equiv), DMF (10 
drops) and 40 mL of CH2Cl2. The mixture was then treated with oxalyl chloride (0.65 
mL, 7.5 mmol, 1.5 equiv) at 0 ̊C, stirred for 15 min, then warmed to room temperature 
and additionally stirred for 2 hours. The solvent was then removed in vacuum and the 
Br
O
HN
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crude acyl chloride was dissolved in 20 mL of dry THF, followed by the addition of a 
solution of tert-butyl amine (1.57 ml, 15.0 mmol, 3.00 equiv) in 20 mL of THF. The 
reaction mixture was stirred overnight. After the reaction was complete, the solvent was 
removed in vacuum and the resulting residue was partitioned between 25 mL of EtOAc 
and 25 mL of water.  The organic phase was separated; the aqueous layer was extracted 
with EtOAc (2 x 50 mL). The combined organic phases were dried (MgSO4) and 
concentrated. The residue was purified by chromatography on silica gel to afford the 
titled compound, 1.21 g, 3.90 mmol yield 78% bromocyclopropyl amide (136a) as a 
white solid, mp: 71−73 oC, Rf  0.30 (hexanes/EtOAc 6:1). Analytically pure product can 
be also obtained by recrystallization of a crude product in cyclohexane. 1H NMR (500 
MHz, CDCl3) δ 7.67−6.96 (m, 5H), 6.22 (br. s, 1H), 2.58 (d, J = 6.4 Hz, 1H), 1.71 (s, 
3H), 1.24 (d, J = 6.3 Hz, 1H), 1.09 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 165.3, 140.5, 
128.3 (+, 2C), 128.1 (+, 2C), 126.9 (+), 51.6, 45.1, 34.8, 28.4 (+, 3C), 27.9 (+), 26.3 (-); 
FT IR (KBr, cm-1): 3423, 3346, 1678, 1664, 1514, 1223, 771, 750, 692; HRMS (TOF 
ES): found 310.0807, calculated for C15H21BrNO (M+H) 310.0813 (1.9 ppm). 
 
 (1R*,2S*)-N-benzyl-1-bromo-2-methyl-2-phenylcyclopro- 
panecarboxamide (132ab):  
This compound was obtained according to a typical procedure 
employing 1-bromo-2-methyl-2-phenylcyclopropanecarboxylic acid (136a) (1.28 g, 5.00  
mmol, 1.00 equiv), oxalyl chloride (0.65 mL, 7.5 mmol, 1.5 equiv) and benzyl amine 
(1.64 mL, 15.0 mmol, 3.0 equiv). Chromatographic purification afforded title compound 
Br
O
HN
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as a white solid, mp: 91−93 oC, Rf 0.36 (hexanes/EtOAc 6:1). Yield 1.29 g (3.75 mmol, 
75%). 1H NMR (500 MHz, CDCl3) δ 7.37−7.12 (m, 8H), 7.07−6.97 (m, 2H), 6.74 (br. s, 
1H), 4.21 (ddd, J = 20.1, 14.8, 5.9 Hz, 2H), 2.70 (d, J = 6.3 Hz, 1H), 1.71 (s, 3H), 1.34 
(d, J = 6.3 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 166.5, 140.4, 138.0, 128.7 (+, 2C), 
128.4 (+, 2C), 128.0 (+, 2C), 127.9 (+, 2C), 127.6 (+), 127.1 (+), 44.6 (-), 44.5, 35.5, 28.1 
(+), 27.1 (-); FT IR (KBr, cm-1): 3331, 3060, 2930, 1651, 1602, 1518, 1495, 
1445,1425,1296, 1284, 1250, 1059, 773, 750, 737, 696; HRMS (TOF ES): found 
361.0916, calculated for C18H22BrN2O (M+NH4) 361.0915 (0.3 ppm). 
 ((1R*,2S*)-1-bromo-2-methyl-2-phenylcyclopropyl) 
(pyrrolidin-1-yl)methanone (132ac):  
This compound was obtained according to a typical procedure 
employing 1-bromo-2-methyl-2-phenylcyclopropanecarboxylic acid (136a) (1.28 g, 5.00  
mmol, 1.00 equiv), oxalyl chloride (0.65 mL, 7.5 mmol, 1.5 equiv) and pyrrolidine (1.23 
mL, 15.0 mmol, 3.00 equiv). Chromatographic purification afforded title compound as a 
white solid, mp: 78−81 oC, Rf 0.20 (hexanes/EtOAc 6:1). Yield 970 mg (3.15 mmol, 
63%). 1H NMR (500 MHz, CDCl3) δ 7.31−7.15 (m, 5H), 3.44−3.32 (m, 1H), 3.24 (ddd, J 
= 12.1, 8.4, 3.7 Hz, 1H), 3.05 (ddd, J = 10.7, 7.4, 3.2 Hz, 1H), 2.79 (dt, J = 12.1, 8.2 Hz, 
1H), 2.62 (d, J = 7.4 Hz, 1H), 1.84 (s, 3H), 1.68 (dddd, J = 13.3, 10.0, 6.6, 3.5 Hz, 2H), 
1.63−1.51 (m, 1H), 1.50−1.40 (m, 1H), 1.35 (d, J = 7.4 Hz, 2H), 1.02 (dtt, J = 11.9, 9.6, 
7.1 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 164.7, 138.3, 128.2 (+, 2C), 127.0 (+), 126.3 
(+, 2C), 47.6 (-), 46.0 (-), 43.7, 30.5, 27.0 (-), 25.8 (-), 24.4 (+), 23.8 (-); FT IR (KBr, cm-
1): 2970, 2951, 2874, 1639, 1499, 1429, 1340, 1194, 1061, 1030, 874, 766, 696, 663, 600, 
Br
O
N
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544; HRMS (TOF ES): found 308.0650, calculated for C15H19BrNOLi (M+H) 308.0646 
(1.3 ppm). 
 (1R*,2S*)-1-bromo-N-(tert-butyl)-2-methyl-2-(p-tolyl) 
cyclopropanecarboxamide (132ba):  
This compound was obtained according to a typical procedure 
employing 1-bromo-2-methyl-2-(p-tolyl)cyclopropane carboxylic acid (136b) (1.08 g, 
4.00  mmol, 1.00 equiv), oxalyl chloride (0.52 mL, 6.0 mmol, 1.5 equiv) and tert-butyl 
amine (1.2 mL, 12 mmol, 3.0 equiv). Chromatographic purification afforded title 
compound as a white solid, mp: 83.5−84.7 oC, Rf 0.30 (hexanes/EtOAc 6:1). Yield 1.07 g 
(3.30 mmol, 83%). 1H NMR (500 MHz, CDCl3) δ 7.18−6.89 (m, 4H), 6.22 (br. s, 1H), 
2.54 (d, J = 6.3 Hz, 1H), 2.28 (s, 3H), 1.69 (s, 3H), 1.22 (d, J = 6.3 Hz, 1H), 1.11 (s, 9H); 
13C NMR (126 MHz, CDCl3) δ 165.4, 137.5, 136.5, 129.0 (+, 2C), 127.9 (+, 2C), 51.6, 
45.2, 34.6, 28.4 (+, 3C), 28.0 (+), 26.4 (-), 21.2 (+); FT IR (KBr, cm-1): 3425, 2964, 
1682, 1516, 1454, 1392, 1363, 1296, 1280, 1256, 1223, 1078, 1061, 1042, 818, 719; 
HRMS (TOF ES):  found 322.0806, calculated for C16H21BrNO (M-H) 322.0807 (0.3 
ppm).  
 (1R*,2S*)-1-bromo-N-(tert-butyl)-2-ethyl-2-phenylcyclo- 
propane carboxamide (132fa): 
 This compound was obtained according to a typical procedure 
employing a mixture of 1-bromo-2-ethyl-2-phenylcyclopropanecarboxylic acids (136f) 
(1.35 g, 5.00 mmol, 1.00 equiv) (dr 2:1), oxalyl chloride (0.65 mL, 7.5 mmol, 1.5 equiv) 
and tert-butyl amine (1.58 mL, 15.0 mmol, 3.00 equiv). Chromatographic purification 
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afforded title compound as a white solid, mp: 49.1-50.4 oC, Rf 0.32 (hexanes/EtOAc 6:1). 
Yield a 2:1 mixture of the title compound 1.57 g (4.84 mmol, 97%) as a white solid. 
Major isomer: 1H NMR (500 MHz, CDCl3) δ 7.25−7.11 (m, 5H), 6.26 (br. s, 1H), 2.49 
(dd, J = 6.2, 1.7 Hz, 1H), 2.11 (ddd, J = 13.8, 7.3, 1.7 Hz, 1H), 1.84 (dd, J = 13.8, 7.4 Hz, 
1H), 1.19 (d, J = 6.2 Hz, 1H), 1.10 (s, 9H), 0.85 (t, J = 7.4 Hz, 3H); 13C NMR (126 MHz, 
CDCl3) δ 165.3, 138.4, 129.0 (+, 2C), 128.0 (+, 2C), 126.9 (+), 51.6, 45.7, 40.1, 33.9 (-), 
28.4 (+, 3C), 25.2 (-), 11.4 (+); Minor isomer: 1H NMR (500 MHz, CDCl3) δ 7.47−7.27 
(m, 5H), 6.31 (s, 1H), 2.07 (d, J = 6.5 Hz, 1H), 1.93−1.87 (m, 1H), 1.60 (dd, J = 13.7, 7.4 
Hz, 1H), 1.55 (dd, J = 6.4, 1.3 Hz, 1H), 1.41 (s, 9H), 0.77 (t, J = 7.3 Hz, 3H); 13C NMR 
(126 MHz, CDCl3) δ 166.8, 141.4, 129.8 (+, 2C), 128.1 (+, 2C), 127.2 (+), 52.0, 42.9, 
41.1, 40.1, 33.9, 28.7 (+, 3C), 27.3 (-), 24.7 (-), 11.6 (+); FT IR (KBr, cm-1): 3423, 3350, 
3059, 2966, 2931, 2873, 2359, 2351, 1772, 1734, 1716, 1682, 1653, 1603, 1514, 1452, 
1448, 1419, 1392, 1285, 1253, 1221, 1155, 1141, 1121, 1096, 1066, 1045, 1028, 985, 
970, 905, 875, 860, 840, 818, 795, 750, 720, 700, 683, 656, 620; HRMS (TOF ES): found 
323.0882, calculated for C16H22BrNO (M+) 323.0885 (0.9 ppm). 
3.10.5. Synthesis of Homochiral Bromoarylcyclopropanecarboxamides 
 (1R,2S)-1-bromo-N-(tert-butyl)-2-methyl-2-(p-
tolyl)cyclopropane-1-carboxamide (-)-132ba:  
As described above for the analogous reaction of the racemate, a 
similar experiment that started with (1R,2S)-1-bromo-2-methyl-2-(p-
tolyl)cyclopropane-1-carboxylic acid (-)-136b gave the title compound as yellow oil. 
Spectral properties of this material were identical to those reported above for racemic 
amide; [α]D= –21.3° (c 0.50, CH2Cl2). 
Br
O
HN
	   127	  
(1R,2S)-1-bromo-N-(tert-butyl)-2-methyl-2-(naphthalen-2-
yl)cyclopropane-1-carboxamide (-)-132ga: 
 This compound was obtained according to a typical procedure  
employing a (1R,2S)-1-bromo-2-methyl-2-(naphthalen-2-yl)cyclopro-
pane-1-carboxylic acid (-)-136g (0.608 g, 2.00 mmol, 1.00 equiv), oxalyl chloride (0.26 
mL, 3.0 mmol, 1.5 equiv) and tert-butyl amine (0.63 mL, 6.0 mmol, 3.00 equiv). 
Chromatographic purification afforded title compound as a white solid, mp: 88.1-89.6 oC, 
Rf 0.32 (hexanes/EtOAc 20:1). Yield  0.427 g (1.2 mmol, 60%). 1H NMR (500 MHz, 
CDCl3) δ 7.82−7.68 (m, 3H), 7.65 (d, J = 1.2 Hz, 1H), 7.46−7.39 (m, 2H), 7.35 (dd, J = 
8.5, 1.8 Hz, 1H), 6.32 (br., s, 1H), 2.69 (d, J = 6.3 Hz, 1H), 1.78 (s, 3H), 1.34 (d, J = 6.3 
Hz, 1H), 1.03 (s, 9H).  ;13C NMR (126 MHz, CDCl3) δ 165.3, 138.2, 133.3, 132.5, 128.0 
(+), 127.8 (+), 127.7 (+), 126.8 (+), 126.3 (+), 126.1 (+), 125.7 (+), 51.6, 45.2, 35.1, 28.4 
(+, 3C), 28.1 (+), 26.6 (-); FT IR (KBr, cm-1): 3421, 3053, 2964, 2925, 1678, 1599, 
1512, 1454, 1392, 1363, 1290, 1221, 1134, 1063, 958, 893, 856, 815, 750; HRMS (TOF 
ES): found 359.0883, calculated for C19H22BrNO (M+) 359.0885 (0.6 ppm). [α]D= –
41.87° (c 0.418, CH2Cl2).  
(1S,2R)-1-bromo-N,N-diethyl-2-methyl-2-phenylcyclo-
propane-1-carboxamide (+)-132ac:  
This compound was obtained according to a typical procedure  
employing a (1S,2R)-1-bromo-2-methyl-2-phenylcyclopropane-1-
carboxylic acid   (+)-136a (0.510 g, 2.00 mmol, 1.00 equiv), oxalyl chloride (0.26 mL, 
3.0 mmol, 1.5 equiv) and diethyl amine (0.823 mL, 6.0 mmol, 3.00 equiv). 
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Chromatographic purification afforded title compound as a light yellow solid, mp: 74.3–
76.2 oC, Rf 0.34 (hexanes/EtOAc 10:1). Yield  0.537 g (1.7 mmol, 87%) 1H NMR (500 
MHz, CDCl3) δ 7.43–7.04 (m, 5H), 3.48 (dt, J = 14.2, 7.1 Hz, 1H), 3.37 (dq, J = 14.2, 7.1 
Hz, 1H), 2.71 (dq, J = 14.0, 7.1 Hz, 1H), 2.65 (d, J = 7.3 Hz, 1H), 2.58 (dq, J = 14.0, 7.0 
Hz, 1H), 1.85 (s, 3H), 1.33 (d, J = 7.3 Hz, 1H), 1.00 (t, J = 7.1 Hz, 3H), 0.47 (t, J = 7.1 
Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 165.8, 138.1, 128.1 (+), 127.0 (+), 126.7 (+), 
42.4, 42.0 (-), 38.3 (-), 31.0, 26.9 (-), 24.3 (+), 12.6 (+), 11.1 (+); FT IR (KBr, cm-1): 
2977, 2933, 1643, 1639, 1498, 1456, 1433, 1380, 1282, 1219, 1064, 719, 696, 582; 
HRMS (TOF ES): found 309.0724, calculated for C15H20BrNO (M+) 309.0728 (1.3 
ppm). [α]D= +17.01° (c 0.194, CH2Cl2).  
(1R,2S)-1-bromo-N,N,2-trimethyl-2-phenylcyclopropane-1-
carboxamide (+)-132ad: 
This compound was obtained according to a typical procedure  
employing a (1R,2S)-1-bromo-2-methyl-2-phenylcyclopropane-1-carboxylic acid (5b*)  
(0.510 g, 2.00 mmol, 1.00 equiv), oxalyl chloride (0.26 mL, 3.0 mmol, 1.5 equiv) and 40 
wt. % aq. solution oddimethyl amine (0.753 mL, 6.0 mmol, 3.00 equiv). 
Chromatographic purification afforded title compound as a white solid, mp: 81.7-83.3 oC, 
Rf 0.34 (hexanes/EtOAc 10:1). Yield  0.466 g (1.65 mmol, 83%) 1H NMR (500 MHz, 
CDCl3) δ 7.43–7.10 (m, 5H), 2.65 (s, 3H), 2.57 (d, J = 7.4 Hz, 1H), 2.56 (s, 3H) 1.85 (s, 
3H), 1.37 (d, J = 7.4 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 166.5, 138.2, 128.1 (+, 2C), 
127.1 (+, 2C), 126.3, 42.6, 38.5 (+), 35.3 (+), 30.8, 27.0 (-), 24.1 (+); FT IR (KBr, cm-1): 
2927, 1647, 1558, 1496, 1396, 1272, 1176, 1082, 1058, 1029, 954, 763, 696, 680, 669, 
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650; HRMS (TOF ES): found 281.0415, calculated for C13H16BrNO (M+) 281.0415 (0.0 
ppm). [α]D= +13.3° (c 0.098, CH2Cl2).  
3.10.6. Formal Nucleophilic Substitution of Bromocyclopropanes  
3.10.7. Diastereoselective reaction employing racemic substrates 
	  
 (1R*,2R*,3S*)-3-(benzyloxy)-N-(tert-butyl)-2-methyl-2-
phenylcyclopropanecarboxamide (134aaa): 
Procedure A: An oven‐dried 10 mL Weaton vial was 
charged with 18-crown‐6 (5.3 mg, 20 µmol, 10 mol%), t-BuOK (134 mg, 1.20 mmol, 
6.00 equiv), benzyl alcohol (62 µL, 0.60 mmol, 3.0 equiv) and anhydrous THF (10.0 
mL). The mixture was stirred at room temperature for 1 minute and bromocyclopropane 
132aa (62 mg, 0.20 mmol, 1.0 equiv) was added in a single portion. The reaction mixture 
was stirred overnight at 80 oC, then solvent was removed in vacuo, and the residue was 
partitioned between 15 mL of water and 15 mL of ethyl acetate, aqueous layer was 
extracted with ethyl acetate (3 x 15 mL). Combined organic extracts were washed with 
brine and dried over MgSO4, filtered and evaporated. Flash column chromatography on 
Silica gel afforded the title compound as a white solid, mp 133.6–134.9 oC, Rf 0.30 
(hexane‐EtOAc 6:1), yield 33 mg (0.1 mmol, 49%), dr 11:1.  
Procedure B: An oven‐dried 10 mL Weaton vial was charged with 18‐
crown‐6 (5.3 mg, 20 µmol, 10 mol%), t-BuOK (134 mg, 1.20 mmol, 6.00 equiv), 
benzyl alcohol (62 µL, 0.6 mmol, 3.0 equiv) and anhydrous DMSO (5.0 mL). The 
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mixture was stirred at room temperature for 1 minute and bromocyclopropane 132aa (62 
mg, 0.2 mmol, 1.0 equiv) was added in a single portion. The reaction mixture was stirred 
overnight at 40 oC, and then the reaction mixture was poured into a separatory funnel and 
was partitioned between 10 mL of water and 100 mL of ethyl acetate. Organic layers 
were washed with water (3 x 10 mL) and brine (10 mL). Organic extract was dried over 
MgSO4, filtered and evaporated. Flash column chromatography on Silica gel afforded the 
title compound as a white solid, identical to the one described in Procedure A. Yield 46 
mg (0.136 mmol 68%), dr 46:1.  
1H NMR (500 MHz, CDCl3) δ 7.87–6.54 (m, 10H), 4.99 (br. s, 1H), 4.70 (d, J = 
2.5 Hz, 2H), 4.14 (d, J = 3.3 Hz, 1H), 1.68 (d, J = 3.4 Hz, 1H), 1.56 (s, 3H), 1.14 (s, 9H); 
13C NMR (126 MHz, CDCl3) δ 167.8, 141.3, 137.7, 128.7 (+, 2C), 128.6 (+, 2C), 128.5 
(+, 2C), 128.3 (+, 2C), 128.1 (+), 127.0 (+), 73.5 (-), 66.4 (+), 51.2, 37.3, 37.2 (+), 28.8 
(+, 3C), 22.0 (+); FT IR (KBr, cm-1): 3315, 2966, 2927, 1643, 1541, 1497, 1454, 1390, 
1375, 1363, 1274, 1226, 1205, 1143, 1103, 1068, 1041, 1026, 983, 752, 739, 698; HRMS 
(TOF ES): found 360.1941, calculated for C22H27NO2Na (M+Na) 360.1939 (0.6 ppm). 
   (1S*,2R*,3R*)-3-(benzyloxy)-N-(tert-butyl)-2-methyl-2-
phenylcyclopropanecarboxamide (139aaa):  
was obtained a minor product by cromatographic separation 
of diastereomeric mixture obtained in reaction with benzyl alcohol (Procedure A).  The 
compound was isolated as a white solid, Rf 0.27 (hexane‐EtOAc 6:1).  Yeild 1.5 mg 
(4.4 µmol, 2%).  1H NMR (400 MHz, CDCl3) δ 7.43–7.19 (m, 8H), 7.11 (dd, J = 7.4, 2.0 
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Hz, 2H), 5.36 (br. s, 1H), 4.58–4.32 (m, 2H), 3.84 (d, J = 3.5 Hz, 1H), 1.95 (d, J = 3.5 
Hz, 1H), 1.47 (s, 3H), 1.35 (s, 9H). 
 
 (1R*,2R*,3S*)-N-(tert-butyl)-3-methoxy-2-methyl-2-phenyl-
cyclopropanecarboxamide (134aaf):  
This compound was obtained according to a typical procedure A 
from bromocyclopropane 132aa employing methanol (24 µL, 0.6 mmol, 3.0 equiv) as 
pronucleophile. The subsequent chromatographic purification afforded 47 mg (0.18 
mmol, 90%) of the title compound as a white solid, mp: 163 oC, Rf 0.31 (hexanes-EtOAc 
6:1), dr 15:1. Alternatively, this compound can be obtained according to procedure B 
with a 31 mg (0.12 mmol, 60%) yield, dr 37:1. 1H NMR (400 MHz, CDCl3) δ 7.56–6.97 
(m, 5H), 5.07 (s, 1H), 4.01 (d, J = 3.3 Hz, 1H), 3.51 (s, 3H), 1.65 (d, J = 3.3 Hz, 1H), 
1.51 (s, 3H), 1.15 (s, 9H); 13C NMR (126 MHz, CDCl3) 167.9, 141.4, 128.7 (+, 2C), 
128.5 (+, 2C), 126.9 (+), 67.9 (+), 58.8 (+), 51.2, 37.3, 36.8 (+), 28.8 (+, 3C), 21.6 (+); 
FT IR (KBr, cm-1): 3323, 3063, 2971, 2958, 2925, 2868,1640, 1547, 1271, 1134, 988; 
HRMS (TOF ES): found 262.1804, calculated for C16H24NO2 (M+H) 262.1807 (1.1 
ppm).  
 
 (1R*,2R*,3S*)-N-(tert-butyl)-3-ethoxy-2-methyl-2-phenyl-
cyclopropanecarboxamide (134aae): 
 This compound was obtained according to procedure A from 
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bromocyclopropane 132aa employing ethanol (35 µL, 0.6 mmol, 3.0 equiv) as 
pronucleophile. The subsequent chromatographic purification afforded 49 mg (0.18 
mmol, 89%) of the title compound as a white solid, mp: 147.0–147.5 oC, Rf 0.31 
(hexanes/ EtOAc 6:1), dr 7:1. Alternatively, this compound can be obtained according to 
procedure B with a 37 mg (0.134 mmol, 67%) yield, dr 36:1. 1H NMR (400 MHz, 
CDCl3) δ 7.24 (tdd, J = 8.5, 7.7, 1.6 Hz, 5H), 5.06 (s, 1H), 4.05 (d, J = 3.4 Hz, 1H), 3.71 
(q, J = 7.0 Hz, 2H), 1.65 (d, J = 3.4 Hz, 1H), 1.51 (s, 3H), 1.29 (t, J = 7.0 Hz, 3H), 1.15 
(s, 9H); 13C NMR (126 MHz, CDCl3) δ 168.0, 141.5, 128.7 (+, 2C), 128.5 (+, 2C), 126.9 
(+), 66.8 (-), 66.3 (+), 51.2, 37.2, 37.0 (+), 28.8, 21.8, 15.3; FT IR (KBr, cm-1): 3323, 
3063, 2971, 2959, 2926, 2869, 1640, 1548, 1442, 1271, 1134, 988; HRMS (TOF ES): 
found 274.1809, calculated for C17H24NO2 (M-H) 274.1807 (0.7 ppm). 
 (1R*,2R*,3S*)-N-(tert-butyl)-2-methyl-2-phenyl-3-
propoxycyclo propanecarboxamide (134aad): 
 This compound was obtained according to procedure A from 
bromocyclopropane 132aa employing n-propanol (45 µL, 0.6 mmol, 3.0 equiv) as 
pronucleophile. The subsequent chromatographic purification afforded 46 mg (0.16 
mmol, 80%) of the title compound as a white solid, mp: 132.5–133.0 oC, Rf 0.28 
(hexanes/EtOAc 6:1), dr 9:1. Alternatively, this compound can be obtained according to 
procedure B with a 38 mg (0.13 mmol, 66%) yield, dr 42:1. 1H NMR (500 MHz, CDCl3) 
δ 7.35–7.12 (m, 5H), 5.08 (br. s, 1H), 4.04 (d, J = 3.3 Hz, 1H), 3.60 (dt, J = 8.9, 4.5 Hz, 
2H), 1.68 (dd, J = 13.1, 5.9 Hz, 2H), 1.66 (d, J = 3.2 Hz, 1H), 1.51 (s, 3H), 1.15 (s, 9H), 
0.97 (t, J = 7.4 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 168.0, 141.5, 128.8 (+, 2C), 
128.5 (+, 2C), 126.9 (+), 73.1 (-), 66.4 (+), 51.2, 37.3, 37.1 (+), 28.8 (+, 3C), 23.1 (-), 
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21.8 (+), 10.9 (+); FT IR (KBr, cm-1): 3307, 2962, 2929, 1643, 1545, 1456, 1389, 1275, 
1227, 1158, 763, 699; HRMS (TOF ES): found 312.1938, calculated for C18H27NO2Na 
(M+Na) 312.1939 (0.3 ppm). 
 (1R*,2R*,3S*)-N-(tert-butyl)-2-methyl-3-((4-
methylbenzyl)oxy)-2-phenylcyclopropanecarboxamide 
(134aaj): This compound was obtained according to a typical 
procedure B from bromocyclopropane 132aa employing 4-
methylbenzyl alcohol (73 mg, 0.60 mmol, 3.0 equiv) as pronucleophile. The subsequent 
chromatographic purification afforded 56 mg (0.16 mmol, 79%) of the title compound as 
a white solid, mp: 148.2–148.9 oC, Rf 0.31 (hexanes/EtOAc 6:1), dr 48:1. 1H NMR (500 
MHz, CDCl3) δ 7.42–7.07 (m, 9H), 4.97 (br. s, 1H), 4.65 (d, J = 1.4 Hz, 2H), 4.11 (d, J = 
3.4 Hz, 1H), 2.36 (s, 3H), 1.66 (d, J = 3.4 Hz, 1H), 1.55 (s, 3H), 1.14 (s, 9H); 13C NMR 
(126 MHz, CDCl3) δ 167.9, 141.4, 137.8, 134.6, 129.3 (+, 2C), 128.7 (+, 2C), 128.5 (+, 
2C), 128.4 (+, 2C), 126.9 (+), 73.4 (-), 66.3 (+), 51.1, 37.3, 37.2 (+), 28.8 (+, 3C), 22.0 
(+), 21.4 (+); FT IR (KBr, cm-1): 3325, 3196, 3057, 2970, 2960, 2923, 2738, 1643, 1545, 
1363, 1276, 1226, 1144, 1103, 1068, 1024, 808, 761, 700; HRMS (TOF ES): found 
351.2201, calculated for C23H29NO2 (M+) 351.2198 (0.9 ppm). 
 
 (1R*,2R*,3S*)-N-(tert-butyl)-3-(2-methoxyethoxy)-2-methyl-2-
phenylcyclopropanecarboxamide (134aac):  
This compound was obtained according to procedure B 
from bromocyclopropane 132aa employing 2-methoxyethanol (47 µL, 0.60 mmol, 3.0 
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equiv) as pronucleophile. The subsequent chromatographic purification afforded 48 mg 
(0.16 mmol, 79%) of the title compound as a white solid, mp: 122.2–123.5 oC, Rf 0.30 
(hexanes/EtOAc 2:1), dr >50:1. 1H NMR (500 MHz, CDCl3) δ 7.32 – 7.13 (m, 5H), 5.08 
(br. s, 1H), 4.12 (d, J = 3.3 Hz, 1H), 3.87 – 3.74 (m, 2H), 3.66 – 3.56 (m, 2H), 3.41 (s, 
3H), 1.69 (d, J = 3.3 Hz, 1H), 1.52 (s, 3H), 1.14 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 
167.9, 141.4, 128.7 (+, 2C), 128.5 (+, 2C), 126.9 (+), 71.8 (-), 70.5 (-), 66.8 (+), 59.2 (+), 
51.1, 37.4, 37.0 (+), 28.8 (+, 3C), 21.8 (+); FT IR (KBr, cm-1): 3317, 2962, 2926, 2872, 
2359, 1643, 1547, 1497, 1446, 1391, 1363, 1275, 1226, 1199, 1153, 1126, 1105, 1087, 
1070, 1026, 883, 759, 700; HRMS (TOF ES): found 305.1985, calculated for C18H27NO3 
(M+) 305.1991 (2.0 ppm). 
 
 (1R*,2R*,3S*)-3-(allyloxy)-N-(tert-butyl)-2-methyl-2-
phenylcyclo propanecarboxamide (134aab): 
 This compound was obtained according to procedure B from 
bromocyclopropane 132aa employing allyl alcohol (41 µL, 0.6 mmol, 3.0 equiv) as 
pronucleophile. The subsequent chromatographic purification afforded 53 mg (0.18 
mmol, 92%) of the title compound as a white solid, mp: 120.9–122.2 oC, Rf 0.22 
(hexanes/EtOAc 5:1), dr >50:1. 1H NMR (500 MHz, CDCl3) δ 7.32–7.14 (m, 5H), 6.00 
(ddt, J = 17.1, 10.4, 5.7 Hz, 1H), 5.37 (dd, J = 17.2, 1.6 Hz, 1H), 5.24 (dd, J = 10.4, 1.6 
Hz, 1H), 5.04 (br. s, 1H), 4.22–4.14 (m, 2H), 4.10 (d, J = 3.3 Hz, 1H), 1.68 (d, J = 3.3 
Hz, 1H), 1.53 (s, 3H), 1.14 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 167.9, 141.4, 134.3 
(+), 128.7 (+, 2C), 128.6 (+, 2C), 127.0 (+), 117.8 (-), 72.3 (-), 66.2 (+), 51.2, 37.3, 37.1 
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(+), 28.8 (+, 3C), 21.9 (+); FT IR (KBr, cm-1): 3304, 2964, 2926, 2868, 1731, 1643, 1545, 
1454, 1361, 1275, 1226, 1147, 985, 926, 764, 700; HRMS (TOF ES): found 286.1804, 
calculated for C18H24NO2 (M-H) 286.1807 (1.0 ppm). 
 
 (1R*,2R*,3S*)-N-(tert-butyl)-3-isopropoxy-2-methyl-2-
phenylcyclo propanecarboxamide (134aag):  
This compound was obtained according to procedure A from 
bromocyclopropane 132aa employing isopropanol (45 µL, 0.6 mmol, 3.0 equiv) as 
pronucleophile. The subsequent chromatographic purification afforded 35 mg (0.12 
mmol, 60%) of the title compound as a white solid, mp: 147.8–148.8 oC, Rf 0.32 
(hexanes/EtOAc 6:1), dr 10:1. 1H NMR (500 MHz, CDCl3) δ 7.35–7.13 (m, 5H), 5.07 
(br. s, 1H), 4.12 (d, J = 3.4 Hz, 1H), 3.85 (dt, J = 12.3, 6.2 Hz, 1H), 1.65 (d, J = 3.4 Hz, 
1H), 1.52 (s, 3H), 1.29 (dd, J = 7.5, 6.2 Hz, 6H), 1.16 (s, 9H); 13C NMR (126 MHz, 
CDCl3) δ 168.1, 141.6, 128.7 (+, 2C), 128.5 (+, 2C), 126.9 (+), 72.8 (+), 64.5 (+), 51.2, 
37.3, 37.2 (+), 28.8 (+, 3C), 22.5 (+), 22.3 (+), 22.0 (+); FT IR (KBr, cm-1): 3254, 3193, 
3064, 2970, 2877, 1639, 1550, 1494, 1448, 1434, 1363, 1284, 1275, 1226, 1178, 1139, 
698; HRMS (TOF ES): found 288.1964, calculated for C18H26NO2 (M-H) 288.1964 (0.0 
ppm). 
 (1R*,2R*,3S*)-N-benzyl-3-methoxy-2-methyl-2-phenylcy-
clopropane carboxamide (134abf): 
 This compound was obtained according to a typical procedure A from 69 mg of 
bromocyclopropane 132ab employing methanol (24 µL, 0.60 mmol, 3.0 equiv) as 
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pronucleophile. The subsequent chromatographic purification afforded 48 mg (0.13 
mmol, 63%) of the title compound as a yellow solid, 96.2–98.1 oC, Rf 0.32 
(hexanes/EtOAc 5:1), dr 13:1. 1H NMR (500 MHz, CDCl3) δ 7.52–7.15 (m, 8H), 7.08 
(dd, J = 7.7, 1.5 Hz, 2H), 5.58 (br. s, 1H), 4.27 (ddd, J = 68.8, 14.6, 5.5 Hz, 2H), 4.13 (d, 
J = 3.3 Hz, 1H), 3.52 (s, 3H), 1.75 (d, J = 3.3 Hz, 1H), 1.52 (s, 3H); 13C NMR (126 MHz, 
CDCl3) δ 168.7, 141.1, 138.5, 128.7 (+, 2C), 128.7 (+, 2C), 128.6 (+, 2C), 128.1 (+, 2C), 
127.6 (+), 127.1 (+), 68.2 (+), 58.8 (+), 43.8 (-), 37.9, 36.2 (+), 21.7 (+); FT IR (KBr, cm-
1): 3300,3061, 3026, 2957, 2871, 1726, 1643, 1602, 1547, 1497, 1417, 1377, 1348, 1267, 
1205, 1192, 1134, 1072, 1028, 1013, 760, 752, 698, 651; HRMS (TOF ES): found 
295.1579, calculated for C19H21NO2 (M+) 295.1572 (2.4 ppm). 
 ((1R*,2R*,3S*)-3-ethoxy-2-methyl-2-phenylcyclopropyl) 
(pyrrolidin-1-yl)methanone (132ace): 
 This compound was obtained according to procedure B from 62 
mg of bromocyclopropane 132ac employing ethanol (35 µL, 0.60 mmol, 3.0 equiv) as 
pronucleophile. The subsequent chromatographic purification afforded 40 mg (0.15 
mmol, 73%) of the title compound as a colorless oil, Rf 0.25 (hexanes/EtOAc 1:1), dr 
48:1. 1H NMR (500 MHz, CDCl3) δ 7.37 – 7.06 (m, 5H), 4.29 (d, J = 3.4 Hz, 1H), 3.73–
3.68 (m, 2H), 3.45 (br., 4H), 1.93 (d, J = 3.4 Hz, 1H), 1.89 (br., 4H), 1.58 (s, 3H), 1.29 (t, 
J = 7.0 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 167.3, 141.6, 128.5 (+, 2C), 128.2 (+, 
2C), 126.7 (+), 66.7 (-), 66.2 (+), 46.3 (-, 2C, br.), 37.3, 35.6 (+), 25.4 (-, 2C, br.), 21.3 
(+), 15.4 (+); FT IR (KBr, cm-1): 3024, 2974,2927, 2871, 1733, 1679, 1637, 1494, 1445, 
1408, 1386, 1360, 1350, 1319, 1267, 1246, 1226, 1180, 1153, 1123, 1105, 1062, 1042, 
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1022, 881, 763, 700; HRMS (TOF ES): found 273.1727, calculated for C17H23NO2 (M+) 
273.1729 (0.7 ppm). 
 
 (1R*,2R*,3S*)-N-(tert-butyl)-2-methyl-2-phenyl-3-(1H-
pyrrol-1-yl)cyclopropanecarboxamide (143aaa):  
This compound was obtained according to procedure A from 
bromocyclopropane 132aa employing pyrrole (42 µL, 0.6 mmol, 3.0 equiv) as 
pronucleophile. The subsequent chromatographic purification afforded 16.5 mg (0.056 
mmol, 28%) of the title compound as a white solid, mp: 198.4–199.0 oC, Rf 0.28 
(hexanes/EtOAc 5:1), dr 19:1. Alternatively, this compound can be obtained according to 
procedure B with a 41 mg (0.14 mmol, 69%) yield, dr 44:1. 1H NMR (500 MHz, CDCl3) 
δ 7.27–7.15 (m, 5H), 6.70 (t, J = 2.1 Hz, 2H), 6.11 (t, J = 2.1 Hz, 2H), 5.25 (br. s, 1H), 
4.26 (d, J = 4.2 Hz, 1H), 2.12 (d, J = 4.2 Hz, 1H), 1.20 (s, 3H), 1.13 (s, 9H); 13C NMR 
(126 MHz, CDCl3) δ 166.7, 140.7, 128.7 (+, 2C), 128.6 (+, 2C), 127.4 (+), 121.6 (+, 2C), 
108.7 (+, 2C), 51.6, 44.9 (+), 37.4, 36.7 (+), 28.8 (+, 9C), 22.9 (+); FT IR (KBr, cm-1): 
3302, 2966, 2928, 1647, 1548, 1265, 725, 700; HRMS (TOF ES): found 295.1804, 
calculated for C19H23N2O (M-H) 295.1810 (2.0 ppm). 
 (1R*,2R*,3S*)-N-(tert-butyl)-3-(1H-indol-1-yl)-2-
methyl-2-phenylcyclopropanecarboxamide (143aac): 
 This compound was obtained according to procedure B 
from bromocyclopropane 132aa employing indole (70 mg, 0.6 mmol, 3.0 equiv) as 
pronucleophile. The subsequent chromatographic purification afforded 54 mg (0.16 
Ph
N
O
HN
Ph
N
O
HN
	   138	  
mmol, 78%) of the title compound as a white solid, mp: 179.7–180.6 oC, Rf 0.33 
(hexanes/EtOAc 5:1), dr >50:1. 1H NMR (500 MHz, CDCl3) δ 7.65 (d, J = 7.8 Hz, 1H), 
7.60 (dd, J = 8.2, 0.7 Hz, 1H), 7.51 (dd, J = 8.2, 1.1 Hz, 2H), 7.40 (t, J = 7.7 Hz, 2H), 
7.31 (dt, J = 9.1, 4.3 Hz, 1H), 7.28–7.23 (m, 1H), 7.19 – 7.09 (m, 2H), 6.54 (dd, J = 3.2, 
0.6 Hz, 1H), 5.35 (br. s, 1H), 4.44 (d, J = 4.2 Hz, 1H), 2.32 (d, J = 4.2 Hz, 1H), 1.33 (s, 
3H), 1.21 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 166.6, 140.5, 137.5, 129.1, 128.9 (+, 
2C), 128.6 (+, 2C), 128.2 (+), 127.5 (+), 122.2 (+), 121.2 (+), 120.1 (+), 110.6 (+), 102.0 
(+), 51.6, 42.4 (+), 37.3, 37.0 (+), 28.8 (+, 3C), 22.7 (+). FT IR (KBr, cm-1): 3312, 2968, 
1647, 1544, 1512, 1479, 1462, 1446, 1363, 1311, 1267, 1224, 1199, 1089, 763, 740, 700; 
HRMS (TOF ES): found 345.1960, calculated for C23H25N2O (M-H) 345.1967 (2.0 ppm). 
 
 (1R*,2R*,3S*)-N-(tert-butyl)-3-(2-methoxyethoxy)-2-
methyl-2-(p-tolyl)cyclopropanecarboxamide (134bac):  
This compound was obtained according to procedure B from 
65 mg of bromocyclopropane 132ba employing 2-methoxyethanol (47 µL, 0.60 mmol, 
3.0 equiv) as pronucleophile. The subsequent chromatographic purification afforded 58 
mg (0.18 mmol, 91%) of the title compound as a white solid, mp: 119.3–120.0 oC, Rf 
0.25 (hexanes/EtOAc 2:1), dr 25:1. 1H NMR (500 MHz, CDCl3) δ 7.13 (d, J = 8.1 Hz, 
2H), 7.08 (d, J = 7.9 Hz, 2H), 4.08 (d, J = 3.1 Hz, 1H), 3.88–3.70 (m, 2H), 3.61 (t, J = 4.1 
Hz, 2H), 3.41 (s, 3H), 2.29 (s, 3H), 1.67 (d, J = 3.1 Hz, 1H), 1.50 (s, 3H), 1.15 (s, 9H); 
13C NMR (126 MHz, CDCl3) δ 168.1, 138.3, 136.4, 129.3 (+, 2C), 128.6 (+, 2C), 71.8 (-
), 70.4 (-), 67.0 (+), 59.2 (+), 51.2, 37.2, 36.9 (+), 28.8 (+, 3C), 21.9 (+), 21.2 (+); FT IR 
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(KBr, cm-1): 3321, 2964, 2924, 2871, 1645, 1541, 1517, 1454, 1390, 1364, 1275, 1226, 
1200, 1151, 1126, 1099, 1084, 1043, 817; HRMS (TOF ES): found 342.2047, calculated 
for C19H29NO3Na (M+Na) 342.2045 (0.6 ppm).  
  
 (1R*,2R*,3S*)-3-(benzyloxy)-N-(tert-butyl)-2-ethyl-2-
phenylcyclo propanecarboxamide (134caa):  
This compound was obtained according to the following 
protocol: An oven‐dried 10 mL Weaton vial was charged with 18‐crown‐6 (12 mg, 45 
µmol, 10 mol %), t-BuOK (304 mg, 2.7 mmol, 6.0 equiv), benzyl alcohol (140 µL, 1.35 
mmol, 3.0 equiv) and anhydrous DMSO (10.0 mL). The mixture was stirred at room 
temperature for 1 minute and bromocyclopropane 132fa (148 mg, 0.45 mmol, 1.0 equiv) 
was added in a single portion. The reaction mixture was stirred overnight at 40 oC, GC 
analysis showed incomplete conversion (70% based on starting material) and dr 15:1, 
after heating at 80 oC for 30 minutes the reaction was complete. Flash column 
chromatography on Silica gel afforded the title compound as a white solid, mp: 117.7–
118.5 oC , Rf 0.31 (hexane‐EtOAc 6:1),. Yield 105 mg (0.31 mmol, 68%), dr 14:1. 1H 
NMR (500 MHz, CDCl3) δ 7.53–7.03 (m, 10H), 4.95 (br. s, 1H), 4.76–4.61 (m, 2H), 4.10 
(d, J = 3.3 Hz, 1H), 1.98 (dq, J = 14.8, 7.4 Hz, 1H), 1.77 (dq, J = 14.4, 7.3 Hz, 1H), 1.66 
(d, J = 3.3 Hz, 1H), 1.16 (s, 9H), 0.89 (t, J = 7.4 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 
168.2, 139.2, 137.8, 129.8 (+, 2C), 128.6 (+, 2C), 128.3 (+, 2C), 128.1 (+, 2C), 127.9 (+), 
127.0 (+), 73.4 (-), 67.2 (+), 51.1, 43.1, 36.3 (+), 28.8 (+, 3C), 28.4 (-), 11.6 (+); FT IR 
(KBr, cm-1): 3411, 3321, 3200, 2966, 2931, 2874, 1726, 1643, 1603, 1541, 1497, 1454, 
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1388, 1377, 1364, 1329, 1267, 1227, 1196, 1178, 1143, 1109, 1070, 1043, 1027, 1001, 
959, 910, 856, 794, 752, 734, 700, 661, 617, 598; HRMS (TOF ES): found 374.2091, 
calculated for C23H29NO2 (M+Na) 374.2096 (1.3 ppm). 
 
 (1R*,2R*,3S*)-N-(tert-butyl)-2-ethyl-2-phenyl-3-(1H-
pyrrol-1-yl)cyclopropane-1-carboxamide (143faa):  
This compound was obtained according to procedure B from 
65 mg of bromocyclopropane 132fa employing pyrrole (42 µL, 0.60 mmol, 3.0 equiv) as 
pronucleophile. The reaction mixture was stirred overnight at 40 oC, GC analysis showed 
incomplete conversion (75% based on starting material) and dr 17:1, after heating at 80 
oC for 30 minutes the reaction was complete. The subsequent chromatographic 
purification afforded 35 mg (0.114 mmol, 57%) of the title compound as a white solid, 
mp: 177.5–120.0 oC, Rf 0.29 (hexanes/EtOAc 6:1), dr 14:1. 1H NMR (500 MHz, CDCl3) 
δ 7.44–7.07 (m, 5H), 6.72 (t, J = 2.1 Hz, 2H), 6.12 (t, J = 2.1 Hz, 2H), 5.28 (br. s, 1H), 
4.25 (d, J = 4.3 Hz, 1H), 2.12 (d, J = 4.3 Hz, 1H), 1.45–1.32 (m, 2H), 1.16 (s, 9H), 0.71 
(t, J = 7.4 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 166.9, 138.6, 129.7 (+, 2C), 128.4 (+, 
2C), 127.4 (+), 121.7 (+, 2C), 108.6 (+, 2C), 51.6, 46.3 (+), 43.0, 35.1 (+), 28.8 (+, 3C), 
28.5 (-), 11.3 (+); FT IR (KBr, cm-1): 3317, 3060, 2968, 2931, 1647, 1545, 1492, 1446, 
1263, 1224, 721, 698; HRMS (TOF ES): found 309.1968, calculated for C20H25N2ONa 
(M-H) 342.2045 (0.6 ppm).  
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(1R*,2R*,3S*)-N-(tert-butyl)-2-methyl-2-phenyl-3-(1H-
pyrazol-1-yl)cyclopropane-1-carboxamide (143aae): 
 This compound was obtained according to procedure B 
from 62 mg of bromocyclopropane 132aa, pyrazole  (41 mg, 0.60 mmol, 3.0 equiv) as 
pronucleophile. The subsequent chromatographic purification afforded 50 mg (0.168 
mmol, 84%) of the title compound as a white solid, mp: 191.0–192.5 oC, Rf 0.4 
(CH2Cl2/MeOH 20:1), dr 14:1. 1H NMR (500 MHz, CDCl3) δ 7.52 (d, J = 2.2 Hz, 1H), 
7.48 (d, J = 1.7 Hz, 1H), 7.34–7.22 (m, 4H), 7.21–7.12 (m, 1H), 6.26 (t, J = 2.1 Hz, 1H), 
5.47 (br. s, 1H), 4.49 (d, J = 4.1 Hz, 1H), 2.49 (d, J = 4.1 Hz, 1H), 1.16 (s, 9H), 1.15 (s, 
3H); 13C NMR (126 MHz, CDCl3) δ 166.34, 140.58, 139.52 (+), 130.61 (+), 128.67 (+, 
2C), 128.59 (+, 2C), 127.35 (+), 106.25 (+), 51.64, 47.02 (+), 37.76, 35.86 (+), 28.82 (+, 
3C), 22.55 (+); FT IR (KBr, cm-1): 3305, 2966, 1650, 1544, 1515, 1446, 1392, 1361, 
1271, 1226, 1097, 979, 858, 754, 700, 653; HRMS (TOF ES): found 298.1923, calculated 
for C18H24N3O (M+H) 298.1919 (1.3 ppm).  
3.10.8. Diastereoselective reaction employing homochiral substrates 
 (1R,2R,3S)-3-(benzyloxy)-N-(tert-butyl)-2-methyl-2-(p-
tolyl)cyclo propanecarboxamide (134baa)*:  
This compound was obtained according to a procedure B 
from 130 mg of bromocyclopropane (-)-132ba employing benzyl alcohol (124 µL, 1.20 
mmol, 3.00 equiv) as pronucleophiles. The subsequent chromatographic purification 
afforded 129 mg (0.367 mmol, 92%) of the title compound as a white solid, mp: 139.8–
140.6 oC, Rf 0.33 (hexanes/EtOAc 6:1), dr 44:1. [α]D= –24.5° (c 1.10, CH2Cl2). 1H NMR 
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(500 MHz, CDCl3) δ 7.54–7.17 (m, 5H), 7.10 (q, J = 8.1 Hz, 4H), 5.03 (br. s, 1H), 4.87–
4.53 (m, 2H), 4.12 (d, J = 3.3 Hz, 1H), 2.30 (s, 3H), 1.66 (d, J = 3.3 Hz, 1H), 1.54 (s, 
3H), 1.16 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 168.0, 138.3, 137.7, 136.4, 129.3 (+, 
2C), 128.6 (+, 2C), 128.5 (+, 2C), 128.3 (+, 2C), 128.0 (+), 73.5 (-), 66.6 (+), 51.1, 37.1 
(+), 28.8 (+, 3C), 22.1 (+), 21.2 (+); FT IR (KBr, cm-1):  3308, 3063, 3030, 2966, 2926, 
2864, 1643, 1543, 1516, 1454, 1431, 1375, 1364, 1346, 1277,  1226, 1204, 1144, 1099, 
987, 817, 750, 734, 698; HRMS (TOF ES): found 374.2098, calculated for C23H29NO2 
(M+Na) 374.2096 (0.5 ppm). 
(1R,2R,3S)-N-(tert-butyl)-2-methyl-3-(1H-pyrazol-1-yl)-
2-(p-tolyl)cyclopropane-1-carboxamide (143bae):  
This compound was obtained according to a procedure B 
from 65 mg of bromocyclopropane (-)-132ba employing pyrazole (41 mg, 0.60 mmol, 
3.00 equiv) as pronucleophiles. The subsequent chromatographic purification afforded 47 
mg (0.158 mmol, 79%) of the title compound as a white solid, mp: 147.9–148.5 oC, Rf 
0.35 (CH2Cl2/MeOH 20:1), dr 15:1. [α]D= +40.57° (c 0.35, CH2Cl2). 1H NMR (500 MHz, 
CDCl3) δ  7.51 (d, J = 2.1 Hz, 1H), 7.47 (d, J = 1.2 Hz, 1H), 7.17 (d, J = 7.9 Hz, 2H), 
7.05 (d, J = 7.9 Hz, 2H), 6.25 (t, J = 1.9 Hz, 1H), 5.69 (br. s, 1H), 4.46 (d, J = 4.0 Hz, 
1H), 2.61–2.45 (m, 1H), 2.24 (s, 3H), 1.16 (s, 9H), 1.12 (s, 3H); 13C NMR (126 MHz, 
CDCl3) δ 166.5, 139.4 (+), 137.6, 136.8, 130.6 (+), 129.4 (+, 2C), 128.4 (+, 2C), 106.2 
(+), 51.6, 47.1 (+), 37.4, 35.8 (+), 28.8 (+, 3C), 22.7 (+), 21.3 (+); FT IR (KBr, cm-1): 
3306, 2964, 2925, 1649, 1544, 1452, 1392, 1274, 1224, 1089, 1047, 820, 752, 615; 
HRMS (TOF ES): found 312.2081, calculated for C19H26N3O (M+H) 312.2076 (1.6 
ppm). 
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(1R,2R,3S)-3-(allyloxy)-N-(tert-butyl)-2-methyl-2-(p-
tolyl)cyclopropane-1-carboxamide (134bab): 
This compound was obtained according to a procedure B from 
65 mg of bromocyclopropane (-)-132ba employing allyl alcohol (41 µL, 
0.60 mmol, 3.00 equiv) as pronucleophile. The subsequent chromatographic purification 
afforded 42 mg (0.146 mmol, 73%) of the title compound as a white solid, mp: 120.6–
122.7 oC, Rf 0.38 (hexanes/EtOAc 5:1), dr 50:1. [α]D= -21.8° (c 0.16, CH2Cl2). 1H NMR 
(500 MHz, CDCl3) δ 7.12 (d, J = 8.1 Hz, 2H), 7.08 (d, J = 7.9 Hz, 2H), 5.99 (ddt, J = 
16.2, 10.5, 5.7 Hz, 1H), 5.36 (dd, J = 17.2, 1.6 Hz, 1H), 5.24 (dd, J = 10.4, 1.4 Hz, 1H), 
5.08 (br. s, 1H), 4.27–4.10 (m, 2H), 4.07 (d, J = 3.3 Hz, 1H), 2.29 (s, 3H), 1.65 (d, J = 3.3 
Hz, 1H), 1.50 (s, 3H), 1.16 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 168.1, 138.3, 136.4, 
134.3 (+), 129.3 (+, 2C), 128.5 (+, 2C), 117.7 (-), 72.3 (-), 66.4 (+), 51.1, 37.0 (+), 37.0, 
28.8 (+, 3C), 22.0 (+), 21.2 (+); FT IR (KBr, cm-1): 3301, 2966, 2923, 1643, 1546, 1515, 
1454, 1226, 1145, 985, 925, 817; HRMS (TOF ES): found 300.1967, calculated for 
C19H26NO2 (M-H) 300.1964 (1.0 ppm). 
(1R,2R,3S)-N-(tert-butyl)-2-methyl-3-(1H-pyrrol-1-yl)-2-
(p-tolyl)cyclopropane-1-carboxamide (143baa): 
This compound was obtained according to a procedure B 
from 65 mg of bromocyclopropane (-)-132ba  employing pyrrole  
(42 µL, 0.60 mmol, 3.00 equiv) as pronucleophile. The subsequent chromatographic 
purification afforded 52 mg (0.168 mmol, 84%) of the title compound as a white solid, 
mp: 208.0–210.1 oC, Rf 0.31 (hexanes/EtOAc 6:1), dr 1:0. [α]D= +46.48° (c 0.142, 
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CH2Cl2). 1H NMR (500 MHz, CDCl3) δ 7.22 (d, J = 8.0 Hz, 2H), 7.14 (d, J = 7.9 Hz, 
2H), 6.77 (t, J = 2.1 Hz, 2H), 6.19 (t, J = 2.1 Hz, 2H), 5.35 (br. s, 1H), 4.31 (d, J = 4.2 
Hz, 1H), 2.32 (s, 3H), 2.17 (d, J = 4.2 Hz, 1H), 1.26 (s, 3H), 1.22 (s, 9H); 13C NMR (126 
MHz, CDCl3) δ 166.9, 137.7, 137.0, 129.5 (+, 2C), 128.4 (+, 2C), 121.6 (+, 2C), 108.6 
(+, 2C), 51.6, 45.0 (+), 37.1, 36.7 (+), 28.8 (+, 3C), 23.1 (+), 21.3 (+); FT IR (KBr, cm-1): 
3319, 2966, 2925, 1645, 1546, 1539, 1492, 1454, 1361, 1265, 1224, 1093, 1066, 981, 
817, 721, 700; HRMS (TOF ES): found 309.1974, calculated for C20H25N2O (M-H) 
309.1967 (2.3 ppm). 
 
 (1R,2R,3S)-N-(tert-butyl)-2-methyl-2-(naphthalen-2-yl)-
3-(1H-pyrrol-1-yl)cyclopropane-1-carboxamide (143gaa): 
This compound was obtained according to a procedure B 
from 72 mg of bromocyclopropane (-)-132ga employing pyrrole  
(42 µL, 0.60 mmol, 3.00 equiv) as pronucleophile. The subsequent chromatographic 
purification afforded 52 mg (0.149 mmol, 75%) of the title compound as a white solid, 
mp: 181.4–183.2 oC, Rf 0.23 (hexanes/EtOAc 6:1), dr 81:1. [α]D= +15.63° (c 0.096 
CH2Cl2). 1H NMR (500 MHz, CDCl3) δ  8.01–7.67 (m, 4H), 7.57–7.35 (m, 3H), 6.85 (t, J 
= 2.1 Hz, 2H), 6.23 (t, J = 2.1 Hz, 2H), 5.44 (br., s, 1H), 4.46 (d, J = 4.1 Hz, 1H), 2.28 (d, 
J = 4.2 Hz, 1H), 1.36 (s, H), 1.19 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 166.7, 138.3, 
133.6, 132.7, 128.5 (+), 127.8 (+), 127.8 (+), 127.3 (+), 126.7 (+), 126.3 (+), 126.0 (+), 
121.7 (+, 2C), 108.7 (+, 2C), 51.7, 45.2 (+), 37.7, 36.8 (+), 28.8 (+, 3C), 23.0 (+); FT IR 
(KBr, cm-1): 3305, 2968, 1650, 1548, 1492, 1454, 1392, 1265, 1224, 1132, 1091, 1064, 
N
O
HN
	   145	  
981, 854, 817, 721, 680, 657; HRMS (TOF ES): found 346.2047, calculated for 
C23H26N2O (M+) 346.2045 (0.6 ppm). 
 
(1R,2R,3S)-3-(allyloxy)-N-(tert-butyl)-2-methyl-2-
(naphthalen-2-yl)cyclopropane-1-carboxamide (134gab): 
This compound was obtained according to a procedure B from 
72 mg of bromocyclopropane (-)-132ga employing allyl alcohol (41 
µL, 0.60 mmol, 3.00 equiv) as pronucleophile. The subsequent chromatographic 
purification afforded 58 mg (0.172 mmol, 88%) of the title compound as a white solid, 
mp: 122.2–125.1 oC, Rf 0.26 (hexanes/EtOAc 4:1), dr 1:0. [α]D= -7.87° (c 0.178, 
CH2Cl2). 1H NMR (500 MHz, CDCl3) δ 7.85–7.72 (m, 3H), 7.69 (s, 1H), 7.50–7.36 (m, 
2H), 7.35 (dd, J = 8.4, 1.7 Hz, 1H), 6.04 (ddt, J = 22.1, 10.5, 5.7 Hz, 1H), 5.41 (dd, J = 
17.2, 1.6 Hz, 1H), 5.27 (dd, J = 10.4, 1.4 Hz, 1H), 5.17 (br. s, 1H), 4.34–4.05 (m, 2H), 
4.22 (d, J = 3.3 Hz, 1H), 1.75 (d, J = 3.3 Hz, 1H), 1.59 (s, 3H), 1.13 (s, 9H); 13C NMR 
(126 MHz, CDCl3) δ 167.9, 139.0, 134.3 (+), 133.6, 132.6, 128.2 (+), 127.8 (+), 127.8 
(+), 127.3 (+), 127.0 (+), 126.1 (+), 125.7 (+), 117.8 (-), 72.4 (-), 66.5 (+), 51.2, 37.5 , 
37.1 (+), 28.8 (+, 3C), 22.0 (+); FT IR (KBr, cm-1): 3319, 2966, 2925, 1643, 1542, 1454, 
1361, 1269, 1226, 1147, 1128, 1087, 1062, 1041, 985, 923, 856, 817, 744, 667; HRMS 
(TOF ES): found 338.2119, calculated for C22H28NO2 (M+H) 338.2120 (0.3 ppm). 
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 (1R,2R,3S)-N-(tert-butyl)-3-(2-methoxyethoxy)-2-
methyl-2-(naphthalen-2-yl)cyclopropane-1-carboxamide 
(134gab): 
This compound was obtained according to a procedure B 
from 65 mg of bromocyclopropane (-)-132ga  employing 2-methoxyethanol (47 µL, 0.60 
mmol, 3.00 equiv) as pronucleophile. The subsequent chromatographic purification 
afforded 54 mg (0.151 mmol, 76%) of the title compound as a white solid, mp: 143.2–
144.2 oC, Rf 0.245 (hexanes/EtOAc 2:1), dr 1:0. [α]D= -6.1° (c 0.214, CH2Cl2). 1H NMR 
(500 MHz, CDCl3) δ 7.86–7.65 (m, 4H), 7.54–7.32 (m, 3H), 5.19 (br. s, 1H), 4.23 (d, J = 
3.3 Hz, 1H), 3.96–3.77 (m, 2H), 3.73–3.60 (m, 2H), 3.44 (s, 3H), 2.17 (s, 3H), 1.76 (d, J 
= 3.3 Hz, 1H), 1.12 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 167.9, 139.0, 133.6, 132.6, 
128.2 (+), 127.8 (+), 127.3 (+), 127.0 (+), 126.0 (+), 125.7 (+), 71.9 (-), 70.5 (-), 67.0 (+), 
59.3 (+), 51.2, 37.6, 37.0  (+), 31.1 (+), 28.8 (+, 3C), 21.9 (+); FT IR (KBr, cm-1): 3323, 
2966, 2871, 1645, 1541, 1454, 1390, 1363, 1269, 1226, 1151, 1124, 956, 856, 817, 742, 
667; HRMS (TOF ES): found 356.2225, calculated for C22H30NO3 (M+H) 356.2226 (0.3 
ppm). 
 
(1S,2S,3R)-N,N-diethyl-2-methyl-2-phenyl-3-(1H-
pyrrolo[2,3-b]pyridin-1-yl)cyclopropane-1-carboxamide 
(143abd): 
This compound was obtained according to a procedure B 
from 62 mg of bromocyclopropane (+)-132ac employing 7-azaindole (71 mg, 0.60 mmol, 
O
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3.00 equiv) as pronucleophile. The subsequent chromatographic purification afforded 34 
mg (0.102 mmol, 50%) of the title compound as a white solid, mp: 113.2–114.0 oC, Rf 
0.42 (hexanes/EtOAc 2:1), dr 20:1. [α]D= -5.2° (c 0.669, CH2Cl2). 1H NMR (500 MHz, 
CDCl3) δ 8.38 (dd, J = 4.7, 1.5 Hz, 1H), 7.90 (dd, J = 7.8, 1.5 Hz, 1H), 7.65–7.51 (m, 
2H), 7.34 (t, J = 7.7 Hz, 2H), 7.25 (d, J = 7.5 Hz, 1H), 7.22 (d, J = 3.6 Hz, 1H), 7.08 (dd, 
J = 7.8, 4.7 Hz, 1H), 6.47 (d, J = 3.5 Hz, 1H), 4.72 (d, J = 4.3 Hz, 1H), 3.85 (dq, J = 14.4, 
7.1 Hz, 1H), 3.78–3.62 (m, 1H), 3.43 (dq, J = 14.3, 7.1 Hz, 1H), 2.97 (dq, J = 14.0, 7.0 
Hz, 1H), 2.73 (d, J = 4.3 Hz, 1H), 1.40 (t, J = 7.1 Hz, 3H), 1.26 (s, 3H), 0.97 (t, J = 7.1 
Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 166.9, 149.4, 143.6 (+), 141.13, 128.9 (+, 2C), 
128.6 (+), 128.6 (+, 2C), 128.3 (+), 127.1 (+), 120.9, 116.3, 100.00, 42.7 (+), 42.1 (-), 
40.4 (-), 37.5, 33.3 (+), 22.6 (+), 14.9 (+), 12.8 (+);  FT IR (KBr, cm-1): 2972, 2929, 
1733, 1637, 1479, 1460, 1448, 1433, 1377, 1265, 1220, 1143, 1097, 1070, 652, 846, 196, 
775, 763, 723, 702, 624, 598; HRMS (TOF ES): found 348.2076, calculated for 
C22H26N3O (M+H) 348.2076 (0.0 ppm). 
  
(1S,2S,3R)-N,N-diethyl-2-methyl-3-(3-methyl-1H-
indol-1-yl)-2-phenylcyclopropane-1-carboxamide (143abc):  
This compound was obtained according to a procedure B 
from 62 mg of bromocyclopropane (+)-132ac  employing skatole (79 mg, 0.60 mmol, 
3.00 equiv) as pronucleophile. The subsequent chromatographic purification afforded 50 
mg (0.137 mmol, 69%) of the title compound as a white solid, mp: 116.2–117.5 oC, Rf 
0.21 (hexanes/EtOAc 5:1), dr 32:1. [α]D= -64.0° (c 0.05, CH2Cl2). 1H NMR (500 MHz, 
O
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CDCl3) δ 7.58 (d, J = 7.8 Hz, 1H), 7.48 (d, J = 8.1 Hz, 1H), 7.41 (d, J = 7.8 Hz, 2H), 7.35 
(t, J = 7.7 Hz, 2H), 7.27 (d, J = 6.0 Hz, 1H), 7.24–7.20 (m, 1H), 7.14 (dd, J = 11.0, 3.9 
Hz, 1H), 6.92 (s, 1H), 4.63 (d, J = 4.2 Hz, 1H), 3.76 (td, J = 14.3, 7.0 Hz, 1H), 3.66 (td, J 
= 13.9, 7.0 Hz, 1H), 3.34 (dq, J = 14.3, 7.0 Hz, 1H), 2.93 (dq, J = 13.9, 7.0 Hz, 1H), 2.55 
(d, J = 4.2 Hz, 1H), 2.34 (s, 3H), 1.42 (s, 3H), 1.32 (t, J = 7.1 Hz, 3H), 0.86 (t, J = 7.1 Hz, 
3H); 13C NMR (126 MHz, CDCl3) δ 166.5, 140.3, 137.9, 129.4, 128.7 (+, 2C), 128.1 (+, 
2C), 127.2 (+), 125.7 (+), 122.0 (+), 119.3 (+), 119.2 (+), 111.1 , 110.5 (+), 42.3 (+), 41.9 
(-), 40.2 (-), 37.0, 35.9 (+), 22.1 (+), 15.9 (+), 12.7 (+), 9.8 (+); FT IR (KBr, cm-1): 2972, 
2927, 1639, 1465, 1379, 1309, 1263, 1230, 1143, 759, 740, 698; HRMS (TOF ES): found 
360.2200, calculated for C24H28N2O (M+) 360.2202 (0.6 ppm). 
 
(1S,2S,3R)-N,N-diethyl-3-(ethyl(phenyl)amino)-2-
methyl-2-phenylcyclopropane-1-carboxamide (144ac): 
This compound was obtained according to a procedure B 
from 62 mg of bromocyclopropane (+)-132ac  employing N-ethylaniline (75 µL, 0.60 
mmol, 3.00 equiv) as pronucleophile. The subsequent chromatographic purification 
afforded 42 mg (0.128 mmol, 64%) of the title compound as yellow oil, Rf 0.31 
(hexanes/EtOAc 5:1), dr 13:1. [α]D= +11.6° (c 0.16, CH2Cl2). 1H NMR (500 MHz, 
CDCl3) δ 7.51 – 7.14 (m, 7H), 7.01–6.89 (m, 2H), 6.76 (t, J = 7.3 Hz, 1H), 3.84 (d, J = 
4.6 Hz, 1H), 3.70–3.42 (m, 4H), 3.14 (dq, J = 14.3, 7.1 Hz, 1H), 2.84 (dq, J = 13.9, 7.0 
Hz, 1H), 1.95 (d, J = 4.6 Hz, 1H), 1.60 (s, 3H), 1.21 (t, J = 7.0 Hz, 3H), 1.14 (t, J = 7.1 
Hz, 3H), 0.76 (t, J = 7.1 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 167.3, 149.2, 141.0, 
O
NN
	   149	  
129.2 (+, 2C), 128.4 (+, 2C), 127.6 (+, 2C), 126.7 (+, 2C), 118.0 (+), 115.7 (+), 46.3 (+), 
46.2 (-), 41.5 (-), 39.7 (-) , 36.9 (+), 14.5 (+), 12.5 (+), 11.2 (+); FT IR (KBr, cm-1): 3085, 
2972, 2358, 1637, 1598, 1498, 1458, 1444, 1434, 1377, 1259, 1143, 1080, 831, 752, 696, 
613; HRMS (TOF ES): found 350.2358, calculated for C23H30N2O (M-H) 350.2358 (0.0 
ppm). 
 
 (1S,2S,3R)-N,N-diethyl-3-(ethyl(phenyl)amino)-2-
methyl-2-(naphthalen-2-yl)cyclopropane-1-carboxamide 
(144gc): This compound was obtained according to a procedure 
B from 72 mg of bromocyclopropane (-)-132ga employing N-
ethylaniline (75 µL, 0.60 mmol, 3.00 equiv) as pronucleophile. 
The subsequent chromatographic purification afforded 30 mg (0.136 mmol, 68%) of the 
title compound as a white solid, Rf 0.31 (hexanes/EtOAc 6:1), dr 1:0. [α]D= +10.81° (c 
0.074, CH2Cl2). 1H NMR (500 MHz, CDCl3) δ 7.97–7.66 (m, 4H), 7.55–7.39 (m, 3H), 
7.27–7.19 (m, 2H), 7.06–6.93 (m, 2H), 6.80 (t, J = 7.3 Hz, 1H), 5.18 (br. s, 1H), 3.71 (d, 
J = 4.4 Hz, 1H), 3.77–3.64 (m, 1H), 3.61–3.48 (m, 1H), 1.73 (d, J = 4.4 Hz, 1H), 1.61 (s, 
3H), 1.25 (t, J = 7.0 Hz, 3H), 1.10 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 167.8, 149.2, 
139.2, 133.6, 132.5, 129.2 (+, 2C), 128.3 (+), 127.9 (+), 127.8 (+), 126.9 (+), 126.8 (+), 
126.2 (+), 125.8 (+), 118.3 (+), 116.0 (+), 51.3, 46.8 (+), 46.4 (-), 39.2 (+), 39.0, 28.8 (+, 
3C), 21.9 (+), 11.2 (+); FT IR (KBr, cm-1): 2968, 2358, 1645, 1595, 1531, 1498, 1454, 
1366, 1255, 1188, 817, 742, 692; HRMS (TOF ES): found 399.2438, calculated for 
C27H31N2O (M-H) 399.2436 (1.0 ppm). 
O
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 (1S,2S,3R)-N,N-diethyl-2-methyl-3-
(methyl(phenyl)amino)-2-phenylcyclopropane-1-carboxamide 
(144aa): 
This compound was obtained according to a procedure B from 
62 mg of bromocyclopropane (+)-132ac employing N-methylaniline (65 µL, 0.60 mmol, 
3.00 equiv) as pronucleophile. The subsequent chromatographic purification afforded 36 
mg (0.11 mmol, 55%) of the title compound as yellow oil, Rf 0.22 (hexanes/EtOAc 5:1), 
dr 3:1. [α]D= +33.1° (c 0.366, CH2Cl2). 1H NMR (500 MHz, CDCl3) δ 7.43–7.12 (m, 
7H), 6.95 (d, J = 7.9 Hz, 2H), 6.79 (d, J = 7.3 Hz, 3H), 3.78 (d, J = 4.4 Hz, 1H), 3.68–
3.55 (m, 2H), 3.19 (dd, J = 14.7, 7.2 Hz, 1H), 3.11 (s, 3H), 2.94–2.79 (m, 1H), 1.97 (d, J 
= 4.4 Hz, 1H), 1.62 (s, 3H), 1.17 (t, J = 7.1 Hz, 3H), 0.79 (t, J = 7.1 Hz, 3H); 13C NMR 
(126 MHz, CDCl3) δ 167.2, 151.0, 141.0, 129.2 (+, 2C), 128.5 (+, 2C), 127.8 (+, 2C), 
126.8 (+), 118.1, 114.8 (+, 2C), 48.5 (+), 41.6 (-), 40.4 (+), 39.8 (-), 38.3, 36.9 (+), 21.0 
(+), 14.6 (+), 12.6 (+);  FT IR (KBr, cm-1): 2972, 2929, 1639, 1598, 1500, 1479, 1444, 
1433, 1379, 1305, 1220, 1143, 1116, 1029, 950, 904, 698, 611; HRMS (TOF ES): found 
337.2281, calculated for C22H29N2O (M+H) 3370.2280 (0.3 ppm). 
 (1S,2S,3R)-N,N-diethyl-3-((4-fluorophenyl) 
(methyl)amino)-2-methyl-2-phenylcyclopropane-1-carboxamide 
(144ab): 
This compound was obtained according to a procedure B 
from 62 mg of bromocyclopropane (+)-132ac employing 4-fluoro-
O
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N-methylaniline (72 µL, 0.60 mmol, 3.00 equiv) as pronucleophile. The subsequent 
chromatographic purification afforded 42 mg (0.118 mmol, 59%) of the title compound 
as a yellow oil, Rf 0.25 (hexanes/EtOAc 4:1), dr 3:1. [α]D= +35.4° (c 0.362, CH2Cl2). 1H 
NMR (500 MHz, CDCl3) δ 7.35–7.27 (m, 4H), 7.21 (ddd, J = 5.0, 4.5, 1.9 Hz, 1H), 7.00 
– 6.84 (m, 4H), 3.71 (d, J = 4.4 Hz, 1H), 3.67–3.55 (m, 2H), 3.18 (dd, J = 14.7, 7.2 Hz, 
1H), 3.08 (s, 3H), 2.85 (dd, J = 13.6, 7.0 Hz, 1H), 1.91 (d, J = 4.4 Hz, 1H), 1.62 (s, 3H), 
1.16 (t, J = 7.2 Hz, 3H), 0.79 (t, J = 7.1 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 167.1, 
157.2, 155.3, 147.5, 147.5, 140.8, 128.4 (+, 2C), 127.6 (+, 2C), 126.7 (+), 116.0 (+), 
116.0 (+), 115.5 (+), 115.3 (+), 48.8 (+), 41.5 (-), 39.7 (-), 36.8(+), 20.8 (+), 14.4 (+), 
12.5 (+);  FT IR (KBr, cm-1): 2974, 2873, 1635, 1510, 1479, 1458, 1446, 1379, 1263, 
1224, 1143, 1022, 825, 763, 698; HRMS (TOF ES): found 353.2028, calculated for 
C22H26FN2O (M-H) 353.2029 (0.3 ppm). 
3.10.9. Approach to Medium-Sized Rings via endo-trig Cyclization 
 
 (1R,8R,9S)-6-(furan-2-ylmethyl)-9-methyl-9-
phenyl-2-oxa-6-azabicyclo[6.1.0]nonan-7-one (147i):  
Typical procedure:  A flame dried 25 mL round-
bottom flask equipped with a drying tube and magnetic stir bar was charged with 1-
bromo-2-methyl-2-phenylcyclopropanecarboxylic acid (+)-136a (127.5 mg, 0.50 mmol, 
1.00 equiv), DMF (3 drops) and 10 mL of CH2Cl2. The mixture was then treated with 
oxalyl chloride (65 µL, 0.75 mmol, 1.5 equiv) at 0 ̊C, stirred for 15 min, then warmed to 
room temperature and additionally stirred for 2 hours. The solvent was then removed in 
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vacuum and the crude acyl chloride was dissolved in 10 mL of dry THF and added 
dropwise to a solution of 3-((furan-2-ylmethyl)amino)propan-1-ol (93 mg, 0.6 mmol, 
1.20 equiv) and triethyl amine (209 µL, 1.50 mmol, 3.00 equiv.) in 10 mL of THF. The 
reaction mixture was stirred overnight. After the reaction was complete, the solvent was 
removed in vacuum and the resulting residue was partitioned between 10 mL of EtOAc 
and 10 mL of water.  The organic phase was separated; the aqueous layer was extracted 
with EtOAc (2 x 20 mL). The combined organic phases were dried (MgSO4) and 
concentrated. The residue was filtered through a short plug of Silica gel, eluting with 
EtOAc to afford (1S,2R)-1-bromo-N-(furan-2-ylmethyl)-N-(3-hydroxypropyl)-2-methyl-
2-phenylcyclopropane-1-carboxamide 145i  as a colorless oil. Yield 136 mg (0.345 
mmol, 69%), Rf 0.30 (hexanes/EtOAc 1:1). The crude material was used without further 
purification. An oven‐dried 10 mL Weaton vial was charged with obtained 
bromocyclopropane (136 mg, 0.345 mmol, 1.0 equiv.), 18-crown‐6 (9.1 mg, 34 µmol, 
10 mol%), t-BuOK (232 mg, 2.07 mmol, 6.00 equiv), and anhydrous DMSO (8.0 mL). 
The reaction mixture was stirred overnight at 40 oC, and then the reaction mixture was 
poured into a separatory funnel and was partitioned between 10 mL of water and 100 mL 
of ethyl acetate. Organic layers were washed with water (3 x 10 mL) and brine (10 mL). 
Organic extract was dried over MgSO4, filtered and evaporated. Flash column 
chromatography on Silica gel afforded the title compound as a colorless oil Rf 0.31 
(hexanes/EtOAc 2:1). Yield 86 mg (0.276 mmol 80%), dr 1:0.  [α]D= -28.5° (c 0.280, 
CH2Cl2). 1H NMR (500 MHz, CDCl3) δ 7.37 (ddd, J = 5.1, 2.6, 1.1 Hz, 3H), 7.29 (t, J = 
7.7 Hz, 2H), 7.25–7.08 (m, 1H), 6.33 (dt, J = 9.4, 2.5 Hz, 2H), 4.95 (d, J = 15.2 Hz, 1H), 
4.23 (d, J = 15.2 Hz, 1H), 4.20 (dd, J = 12.1, 4.6 Hz, 1H), 4.04 (dd, J = 15.5, 10.4 Hz, 
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1H), 3.73 (td, J = 12.7, 3.1 Hz, 1H), 3.62 (d, J = 6.3 Hz, 1H), 3.42 (dd, J = 15.5, 7.2 Hz, 
1H), 1.97–1.89 (m, 1H), 1.88 (d, J = 6.2 Hz, 1H), 1.77–1.57 (m, 1H), 1.48 (s, 3H); 13C 
NMR (126 MHz, CDCl3) δ 167.8, 151.4, 146.0, 142.2 (+), 128.6 (+, 2C), 127.9 (+, 2C), 
126.5 (+), 110.6 (+), 108.7 (+), 72.8 (-), 68.5 (+), 46.9 (-), 42.0 (-), 31.3 (+), 30.7 (-), 
30.1, 17.9 (+); FT IR (KBr, cm-1): 2963, 2927, 1637, 1473, 1436, 1425, 1261, 1149, 
1012, 761, 702; HRMS (TOF ES): found 311.1521, calculated for C19H21NO3 (M+) 
311.1521 (0.3 ppm). 
 
(1S,8S,9R)-6-(4-methoxybenzyl)-9-methyl-9-
phenyl-2-oxa-6-azabicyclo[6.1.0]nonan-7-one (147h): 
A flame dried 25 mL round-bottom flask 
equipped with a drying tube and magnetic stir bar was charged with 1-bromo-2-methyl-2-
phenylcyclopropanecarboxylic acid (+)-136a (127.5 mg, 0.50 mmol, 1.00 equiv), DMF 
(3 drops) and 10 mL of CH2Cl2. The mixture was then treated with oxalyl chloride (65 
µL, 0.75 mmol, 1.5 equiv) at 0 ̊C, stirred for 15 min, then warmed to room temperature 
and additionally stirred for 2 hours. The solvent was then removed in vacuum and the 
crude acyl chloride was dissolved in 10 mL of dry THF and added dropwise to a solution 
of 3	  3-((4-methoxybenzyl)amino)propan-1-ol (117mg, 0.6 mmol, 1.20 equiv) and triethyl 
amine (209 µL, 1.50 mmol, 3.00 equiv.) in 10 mL of THF. The reaction mixture was 
stirred overnight. After the reaction was complete, the solvent was removed in vacuum 
and the resulting residue was partitioned between 10 mL of EtOAc and 10 mL of water.  
The organic phase was separated; the aqueous layer was extracted with EtOAc (2 x 20 
O
N
O
O
	   154	  
mL). The combined organic phases were dried (MgSO4) and concentrated. The residue 
was filtered through a short plug of Silica gel, eluting with EtOAc to afford (1R,2S)-1-
bromo-N-(3-hydroxypropyl)-N-(4-methoxybenzyl)-2-methyl-2-phenylcyclopropane-1-
carboxamide 145h as a colorless oil. Yield 113 mg (0.260 mmol, 52%), Rf 0.23 
(hexanes/EtOAc 1:1) The crude material was used without further purification. An oven‐
dried 10 mL Weaton vial was charged with obtained bromocyclopropane (113 mg, 0.46 
mmol, 1.0 equiv.), 18-crown‐6 (6.8 mg, 26 µmol, 10 mol%), t-BuOK (174 mg, 2.07 
mmol, 6.00 equiv), and anhydrous DMSO (6.0 mL). The reaction mixture was stirred 
overnight at 40 oC, and then the reaction mixture was poured into a separatory funnel and 
was partitioned between 10 mL of water and 100 mL of ethyl acetate. Organic layers 
were washed with water (3 x 10 mL) and brine (10 mL). Organic extract was dried over 
MgSO4, filtered and evaporated. Flash column chromatography on Silica gel afforded the 
title compound as a colorless oil. Rf 0.33 (hexanes/EtOAc 2:1).  Yield 59 mg (0.169 
mmol 65%), dr 1:0.  [α]D= -28.5° (c 0.280, CH2Cl2). 1H NMR (500 MHz, CDCl3) δ 7.40 
(dd, J = 8.0, 1.0 Hz, 2H), 7.34–7.24 (m, 4H), 7.20 (t, J = 7.3 Hz, 1H), 6.86 (d, J = 8.6 Hz, 
2H), 5.14 (d, J = 14.5 Hz, 1H), 4.21 (dd, J = 12.6, 5.2 Hz, 1H), 3.98 (d, J = 14.5 Hz, 1H), 
4.00–3.90 (m, 1H), 3.80 (s, 3H), 3.72 (td, J = 12.7, 3.0 Hz, 1H), 3.63 (d, J = 6.3 Hz, 1H), 
3.25 (dd, J = 15.4, 7.1 Hz, 1H), 1.98 (dd, J = 7.6, 5.1 Hz, 1H), 1.91 (d, J = 6.3 Hz, 1H), 
1.70–1.57 (m, 1H), 1.52 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 168.0, 159.1, 146.1, 
129.9, 129.8 (+, 2C), 128.6 (+, 2C), 127.9 (+, 2C), 126.5 (+), 114.1 (+, 2C), 72.8 (-), 68.5 
(+), 55.4 (+), 48.3 (-), 46.2 (-), 31.5 (+), 30.6 (-), 30.1 (+), 17.9 (+); FT IR (KBr, cm-1): 
3406, 1631, 1512, 1477, 1440, 1245, 1222, 927, 883, 815, 802, 761,702, 630, 609; 
HRMS (TOF ES): found 350.1759, calculated for C19H21NO3 (M+) 350.1756 (0.3 ppm). 
	   155	  
 
(1R,8R,9S)-6-(furan-2-ylmethyl)-9-methyl-9-(p-
tolyl)-2-oxa-6-azabicyclo[6.1.0]nonan-7-one (147g): 
A flame dried 25 mL round-bottom flask equipped 
with a drying tube and magnetic stir bar was charged with 1-bromo-2-methyl-2-
phenylcyclopropanecarboxylic acid (-)-132b (134.5 mg, 0.50 mmol, 1.00 equiv), DMF (3 
drops) and 10 mL of CH2Cl2. The mixture was then treated with oxalyl chloride (65 µL, 
0.75 mmol, 1.5 equiv) at 0 ̊C, stirred for 15 min, then warmed to room temperature and 
additionally stirred for 2 hours. The solvent was then removed in vacuum and the crude 
acyl chloride was dissolved in 10 mL of dry THF and added dropwise to a solution of 3-
((furan-2-ylmethyl)amino)propan-1-ol (93 mg, 0.6 mmol, 1.20 equiv) and triethyl amine 
(209 µL, 1.50 mmol, 3.00 equiv.) in 10 mL of THF. The reaction mixture was stirred 
overnight. After the reaction was complete, the solvent was removed in vacuum and the 
resulting residue was partitioned between 10 mL of EtOAc and 10 mL of water.  The 
organic phase was separated; the aqueous layer was extracted with EtOAc (2 x 20 mL). 
The combined organic phases were dried (MgSO4) and concentrated. The residue was 
filtered through a short plug of Silica gel, eluting with EtOAc to afford (1S,2R)-1-bromo-
N-(furan-2-ylmethyl)-N-(3-hydroxypropyl)-2-methyl-2-(p-tolyl)cyclopropane-1-
carboxamide 145g as a colorless oil. Yield 82 mg (0.20 mmol, 40%), Rf 0.25 
(hexanes/EtOAc 2:1) The crude material was used without further purification. An oven‐
dried 10 mL Weaton vial was charged with obtained bromocyclopropane (82 mg, 0.20 
mmol, 1.0 equiv.), 18-crown‐6 (5.38 mg, 20 µmol, 10 mol%), t-BuOK (134 mg, 1.2 
mmol, 6.00 equiv), and anhydrous DMSO (5.0 mL). The reaction mixture was stirred 
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overnight at 40 oC, and then the reaction mixture was poured into a separatory funnel and 
was partitioned between 10 mL of water and 100 mL of ethyl acetate. Organic layers 
were washed with water (3 x 10 mL) and brine (10 mL). Organic extract was dried over 
MgSO4, filtered and evaporated. Flash column chromatography on Silica gel afforded the 
title compound as a colorless oil. Rf 0.4 (hexanes/EtOAc 2:1).  Yield 54 mg (0.166 mmol 
83%), dr 1:0.  [α]D= -26.8° (c 0.340, CH2Cl2). 1H NMR (500 MHz, CDCl3) δ 7.23–7.12 
(m, 3H), 7.01 (d, J = 7.8 Hz, 2H), 6.33–5.89 (m, 2H), 4.85 (d, J = 15.2 Hz, 1H), 4.12 (d, J 
= 15.3 Hz, 1H), 4.10 (dd, J = 12.6, 5.3 Hz, 1H), 3.93 (dd, J = 15.5, 10.4 Hz, 1H), 3.62 
(td, J = 12.7, 3.1 Hz, 1H), 3.50 (d, J = 6.2 Hz, 1H), 3.32 (dd, J = 15.5, 7.1 Hz, 1H), 2.21 
(s, 3H), 1.82 (ddd, J = 11.7, 4.8, 2.2 Hz, 1H), 1.75 (d, J = 6.2 Hz, 1H), 1.63–1.44 (m, H), 
1.36 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 167.9, 151.4, 143.2, 142.2(+), 136.2, 129.3 
(+, 2C), 127.8 (+, 2C), 110.6 (+), 108.8 (+), 72.8 (-), 68.6 (+), 46.9 (-), 42.0 (-), 31.3 (+), 
30.7 (-), 21.1 (+), 18.0 (+); FT IR (KBr, cm-1): 3386, 1639, 1477, 1421, 1380, 929, 883, 
817, 779, 723, 703, 665, 648, 626, 599; HRMS (TOF ES): found 326.1762, calculated for 
C20H24NO3 (M+H) 326.1756 (1.8 ppm).  
 
(1S,8S,9R)-9-(4-ethylphenyl)-6-(furan-2-ylmethyl)-
9-methyl-2-oxa-6-azabicyclo[6.1.0]nonan-7-one (147j): 
A flame dried 25 mL round-bottom flask equipped 
with a drying tube and magnetic stir bar was charged with 1-bromo-2-methyl-2-
phenylcyclopropanecarboxylic acid (-)-136d (141.5 mg, 0.50 mmol, 1.00 equiv), DMF (3 
drops) and 10 mL of CH2Cl2. The mixture was then treated with oxalyl chloride (65 µL, 
O
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0.75 mmol, 1.5 equiv) at 0 ̊C, stirred for 15 min, then warmed to room temperature and 
additionally stirred for 2 hours. The solvent was then removed in vacuum and the crude 
acyl chloride was dissolved in 10 mL of dry THF and added dropwise to a solution of 3-
((furan-2-ylmethyl)amino)propan-1-ol (93 mg, 0.6 mmol, 1.20 equiv) and triethyl amine 
(209 µL, 1.50 mmol, 3.00 equiv.) in 10 mL of THF. The reaction mixture was stirred 
overnight. After the reaction was complete, the solvent was removed in vacuum and the 
resulting residue was partitioned between 10 mL of EtOAc and 10 mL of water.  The 
organic phase was separated; the aqueous layer was extracted with EtOAc (2 x 20 mL). 
The combined organic phases were dried (MgSO4) and concentrated. The residue was 
filtered through a short plug of Silica gel, eluting with EtOAc to afford (1R,2S)-1-bromo-
2-(4-ethylphenyl)-N-(furan-2-ylmethyl)-N-(3-hydroxypropyl)-2-methylcyclopropane-1-
carboxamide 145j as a colorless oil. Yield 138 mg (0.33 mmol, 65%), Rf 0.36 
(hexanes/EtOAc 2:1) The crude material was used without further purification. An oven‐
dried 10 mL Weaton vial was charged with obtained bromocyclopropane (138 mg, 0.33 
mmol, 1.0 equiv.), 18-crown‐6 (9.7 mg, 33 µmol, 10 mol%), t-BuOK (221 mg, 1.98 
mmol, 6.00 equiv), and anhydrous DMSO (7.0 mL). The reaction mixture was stirred 
overnight at 40 oC, and then the reaction mixture was poured into a separatory funnel and 
was partitioned between 10 mL of water and 100 mL of ethyl acetate. Organic layers 
were washed with water (3 x 10 mL) and brine (10 mL). Organic extract was dried over 
MgSO4, filtered and evaporated. Flash column chromatography on Silica gel afforded the 
title compound as a colorless oil. Rf 0.48 (hexanes/EtOAc 2:1).  Yield 106 mg (0.310 
mmol 94%), dr 1:0.  [α]D= +30.0° (c 0.400, CH2Cl2). 1H NMR (500 MHz, CDCl3) δ 7.36 
(dd, J = 1.8, 0.8 Hz, 1H), 7.30 (d, J = 8.2 Hz, 2H), 7.13 (d, J = 8.2 Hz, 2H), 6.39–6.26 
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(m, 2H), 4.95 (d, J = 15.2 Hz, 1H), 4.23 (d, J = 15.3 Hz, 1H), 4.20 (dd, J = 13.6, 4.1 Hz, 
1H), 4.03 (dd, J = 15.5, 10.4 Hz, 1H), 3.72 (td, J = 12.7, 3.1 Hz, 1H), 3.60 (d, J = 6.2 Hz, 
1H), 3.42 (dd, J = 15.5, 7.1 Hz, 1H), 2.61 (q, J = 7.6 Hz, 2H), 2.00–1.87 (m, 1H), 1.87 (d, 
J = 6.2 Hz, 1H), 1.71–1.60 (m, 1H), 1.46 (s, 3H), 1.22 (t, J = 7.6 Hz, 3H); 13C NMR (126 
MHz, CDCl3) δ 167.9, 151.4, 143.3 (+), 142.5, 142.2, 128.1 (+, 2C), 127.9 (+, 2C), 110.6 
(+), 108.7 (+), 72.8 (-), 68.6 (+), 46.9 (-), 42.0 (-), 31.3 (+), 30.7 (-), 29.8, 28.5 (-), 18.0 
(+), 15.7 (+); FT IR (KBr, cm-1): 2962, 2931, 2871, 2079, 1992, 1643, 1633, 1514, 1477, 
1421, 1380, 1353, 1336, 1301, 1263, 1242, 1211, 1147, 1108, 1089, 1012, 931, 883, 831, 
813, 779, 732, 702, 665, 646, 624, 599; HRMS (TOF ES): found 339.1835, calculated for 
C21H25NO3 (M+) 339.1834 (0.3 ppm). . 
	  (1R,8R,9S)-6,9-dimethyl-9-phenyl-2-oxa-6-
azabicyclo[6.1.0]nonan-7-one (147l): 
A flame dried 25 mL round-bottom flask equipped with a 
drying tube and magnetic stir bar was charged with 1-bromo-2-methyl-2-
phenylcyclopropanecarboxylic acid (+)-136a (127.5 mg, 0.50 mmol, 1.00 equiv), DMF 
(3 drops) and 10 mL of CH2Cl2. The mixture was then treated with oxalyl chloride (65 
µL, 0.75 mmol, 1.5 equiv) at 0 ̊C, stirred for 15 min, then warmed to room temperature 
and additionally stirred for 2 hours. The solvent was then removed in vacuum and the 
crude acyl chloride was dissolved in 10 mL of dry THF and added dropwise to a solution 
of 3-methylamino-1-propanol  (57 µL, 0.6 mmol, 1.20 equiv) and triethyl amine (209 µL, 
1.50 mmol, 3.00 equiv.) in 10 mL of THF. The reaction mixture was stirred overnight. 
After the reaction was complete, the solvent was removed in vacuum and the resulting 
residue was partitioned between 10 mL of EtOAc and 10 mL of water.  The organic 
O
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phase was separated; the aqueous layer was extracted with EtOAc (2 x 20 mL). The 
combined organic phases were dried (MgSO4) and concentrated. The residue was filtered 
through a short plug of Silica gel, eluting with EtOAc to afford (1S,2R)-1-bromo-N-(3-
hydroxypropyl)-N,2-dimethyl-2-phenylcyclopropane-1-carboxamide 145l as a colorless 
oil. Yield 90 mg (0.27 mmol, 52%), Rf 0.22 (hexanes/EtOAc 1:1). The crude material 
was used without further purification. An oven‐dried 10 mL Weaton vial was charged 
with obtained bromocyclopropane (90 mg, 0.27 mmol, 1.0 equiv.), 18-crown‐6 (7.1 mg, 
27 µmol, 10 mol%), t-BuOK (201 mg, 1.8 mmol, 6.00 equiv), and anhydrous DMSO (7.0 
mL). The reaction mixture was stirred overnight at 40 oC, and then the reaction mixture 
was poured into a separatory funnel and was partitioned between 10 mL of water and 100 
mL of ethyl acetate. Organic layers were washed with water (3 x 10 mL) and brine (10 
mL). Organic extract was dried over MgSO4, filtered and evaporated. Flash column 
chromatography on Silica gel afforded the title compound as a colorless oil. Rf 0.44 
(CH2Cl2/MeOH 10:1).  Yield 41 mg (0.165 mmol 61%), dr 1:0.  [α]D= +3.2° (c 0.380, 
CH2Cl2). 1H NMR (500 MHz, CDCl3) δ  7.42–7.34 (m, 2H), 7.29 (t, J = 7.7 Hz, 2H), 
7.22–7.10 (m, 1H), 4.35–4.07 (m, 2H), 3.74 (td, J = 12.7, 3.2 Hz, 1H), 3.61 (d, J = 6.3 
Hz, 1H), 3.19 (dd, J = 15.3, 7.2 Hz, 1H), 2.99 (s, 3H), 2.12–1.98 (m, 1H), 1.87 (d, J = 6.2 
Hz, 1H), 1.76–1.63 (m, 1H), 1.46 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 167.8, 146.1, 
128.6 (+, 2C), 127.8 (+, 2C), 126.5 (+), 72.7 (-), 68.5 (+), 49.5(-), 33.7 (+), 31.3 (+), 30.4 
(-), 30.0, 17.8 (+); FT IR (KBr, cm-1): 2958, 2929, 1633, 1494, 1456, 1444, 1400, 1380, 
1352, 1294, 1263, 1218, 1151, 1130, 1091, 1064, 1024, 1010, 931, 763, 702, 684.; 
HRMS (TOF ES): found 244.1340, calculated for C15H18NO2 (M-H) 244.1338 (0.8 ppm).  
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(1S,8S,9R)-9-(3,4-dimethylphenyl)-6,9-dimethyl-2-
oxa-6-azabicyclo[6.1.0]nonan-7-one (147n): 
A flame dried 25 mL round-bottom flask equipped with 
a drying tube and magnetic stir bar was charged with 1-bromo-2-methyl-2-
phenylcyclopropanecarboxylic acid (-)-136c (141.5 mg, 0.50 mmol, 1.00 equiv), DMF (3 
drops) and 10 mL of CH2Cl2. The mixture was then treated with oxalyl chloride (65 µL, 
0.75 mmol, 1.5 equiv) at 0 ̊C, stirred for 15 min, then warmed to room temperature and 
additionally stirred for 2 hours. The solvent was then removed in vacuum and the crude 
acyl chloride was dissolved in 10 mL of dry THF and added dropwise to a solution of 3-
methylamino-1-propanol  (57 µL, 0.6 mmol, 1.20 equiv) and triethyl amine (209 µL, 1.50 
mmol, 3.00 equiv.) in 10 mL of THF. The reaction mixture was stirred overnight. After 
the reaction was complete, the solvent was removed in vacuum and the resulting residue 
was partitioned between 10 mL of EtOAc and 10 mL of water.  The organic phase was 
separated; the aqueous layer was extracted with EtOAc (2 x 20 mL). The combined 
organic phases were dried (MgSO4) and concentrated. The residue was filtered through a 
short plug of Silica gel, eluting with EtOAc to afford (1R,2S)-1-bromo-2-(3,4-
dimethylphenyl)-N-(3-hydroxypropyl)-N,2-dimethylcyclopropane-1-carboxamide 145n 
as a colorless oil. Yield 92 mg (0.26 mmol, 52%), Rf 0.33 (hexanes/EtOAc 1:1) The 
crude material was used without further purification. An oven‐dried 10 mL Weaton vial 
was charged with obtained bromocyclopropane (92 mg, 0.26 mmol, 1.0 equiv.), 18-
crown‐6 (6.8 mg, 26 µmol, 10 mol%), t-BuOK (174 mg, 1.56 mmol, 6.00 equiv), and 
anhydrous DMSO (7.0 mL). The reaction mixture was stirred overnight at 40 oC, and 
then the reaction mixture was poured into a separatory funnel and was partitioned 
O
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between 10 mL of water and 100 mL of ethyl acetate. Organic layers were washed with 
water (3 x 10 mL) and brine (10 mL). Organic extract was dried over MgSO4, filtered and 
evaporated. Flash column chromatography on Silica gel afforded the title compound as a 
colorless oil. Rf 0.40 (CH2Cl2/MeOH 10:1). Yield 48 mg (0.174 mmol 67%), dr 1:0.  
[α]D= +7.5° (c 0.320, CH2Cl2). 1H NMR (500 MHz, CDCl3) δ 7.16 (s, 1H), 7.10 (dd, J = 
7.8, 1.8 Hz, 1H), 7.06 (d, J = 7.8 Hz, 1H), 4.41–4.06 (m, 2H), 3.73 (td, J = 12.7, 3.2 Hz, 
1H), 3.58 (d, J = 6.2 Hz, 1H), 3.19 (dd, J = 15.3, 7.2 Hz, 1H), 2.99 (s, 3H), 2.23 (s, 3H), 
2.22 (s, 3H), 2.10–1.99 (m, 1H), 1.84 (d, J = 6.3 Hz, 1H), 1.74–1.63 (m, 1H), 1.43 (s, 
3H); 13C NMR (126 MHz, CDCl3) δ 168.0, 143.7, 136.8, 134.8, 129.9 (+), 129.3 (+), 
125.2 (+), 72.7 (-), 68.6 (+), 49.5 (-), 33.7 (+), 31.2 (+), 30.4 (-), 29.7, 19.8 (+), 19.4 (+), 
17.9 (+) ;FT IR (KBr, cm-1): 2960, 2933, 2869, 2071, 1633, 1502, 1487, 1454, 1434, 
1398, 1382, 1292, 1261, 1222, 1124, 1089, 1022 , 929, 873, 819, 783, 717, 705, 634, 
595; HRMS (TOF ES): found 273.1730, calculated for C17H23NO2 (M+) 273. 1730 (0.4 
ppm).  
(1R,8R,9S)-6-benzyl-9-methyl-9-phenyl-2-oxa-6-
azabicyclo[6.1.0]nonan-7-one (147b):  
A flame dried 25 mL round-bottom flask equipped with a 
drying tube and magnetic stir bar was charged with 1-bromo-2-methyl-2-
phenylcyclopropanecarboxylic acid (+)-136a (127.5 mg, 0.50 mmol, 1.00 equiv), DMF 
(3 drops) and 10 mL of CH2Cl2. The mixture was then treated with oxalyl chloride (65 
µL, 0.75 mmol, 1.5 equiv) at 0 ̊C, stirred for 15 min, then warmed to room temperature 
and additionally stirred for 2 hours. The solvent was then removed in vacuum and the 
crude acyl chloride was dissolved in 10 mL of dry THF and added dropwise to a solution 
O
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of 3-(benzylamino)propan-1-ol (99 mg, 0.6 mmol, 1.20 equiv) and triethyl amine (209 
µL, 1.50 mmol, 3.00 equiv.) in 10 mL of THF. The reaction mixture was stirred 
overnight. After the reaction was complete, the solvent was removed in vacuum and the 
resulting residue was partitioned between 10 mL of EtOAc and 10 mL of water.  The 
organic phase was separated; the aqueous layer was extracted with EtOAc (2 x 20 mL). 
The combined organic phases were dried (MgSO4) and concentrated. The residue was 
filtered through a short plug of Silica gel, eluting with EtOAc to afford (1S,2R)-N-
benzyl-1-bromo-N-(3-hydroxypropyl)-2-methyl-2-phenylcyclopropane-1-carboxamide 
145b as a colorless oil. Yield 110 mg (0.27 mmol, 54%), Rf 0.28 (hexanes/EtOAc 2:1). 
The crude material was used without further purification. An oven‐dried 10 mL Weaton 
vial was charged with obtained bromocyclopropane (110 mg, 0.27 mmol, 1.0 equiv.), 18-
crown‐6 (7.1 mg, 27 µmol, 10 mol%), t-BuOK (183 mg, 1.62 mmol, 6.00 equiv), and 
anhydrous DMSO (7.0 mL). The reaction mixture was stirred overnight at 40 oC, and 
then the reaction mixture was poured into a separatory funnel and was partitioned 
between 10 mL of water and 100 mL of ethyl acetate. Organic layers were washed with 
water (3 x 10 mL) and brine (10 mL). Organic extract was dried over MgSO4, filtered and 
evaporated. Flash column chromatography on Silica gel afforded the title compound as a 
colorless oil. Rf 0.34 (hexanes/EtOAc 3:1).  Yield 74 mg (0.229 mmol 85%), dr 1:0.  
[α]D= -88.2° (c 0.660, CH2Cl2). 1H NMR (500 MHz, CDCl3) δ 7.44–7.07 (m, 10H), 5.16 
(d, J = 14.7 Hz, 1H), 4.15 (dd, J = 12.6, 5.3 Hz, 1H), 3.97 (d, J = 14.7 Hz, 1H), 3.98–3.89 
(m, 1H), 3.67 (td, J = 12.7, 3.1 Hz, 1H), 3.58 (d, J = 6.3 Hz, 1H), 3.19 (dd, J = 15.5, 7.2 
Hz, 1H), 1.99–1.89 (m, 1H), 1.87 (d, J = 6.3 Hz, 1H), 1.57 (ddd, J = 9.2, 6.6, 2.0 Hz, 
1H), 1.46 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 168.1, 146.0, 137.8, 128.7 (+, 2C), 
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128.6 (+, 2C), 128.4 (+, 2C), 127.9 (+, 2C), 127.5 (+), 126.5 (+), 72.7 (-), 68.5 (+), 48.9 
(-), 46.4 (-), 31.4 (+), 30.6 (-), 30.1, 17.9 (+); FT IR (KBr, cm-1): 3031, 1635, 1477, 1419, 
1263, 1147, 1110, 1091, 1014, 933, 916, 883, 761, 730, 700, 617; HRMS (TOF ES): 
found 321.1720, calculated for C21H23NO2 (M+) 321.1729 (2.8 ppm).  
 
 (1R,8R,9S)-6-benzyl-9-methyl-9-phenyl-2-oxa-6-
azabicyclo[6.1.0]nonan-7-one (147e):  
A flame dried 25 mL round-bottom flask equipped with a 
drying tube and magnetic stir bar was charged with 1-bromo-2-methyl-2-
phenylcyclopropanecarboxylic acid (+)-136a (127.5 mg, 0.50 mmol, 1.00 equiv), DMF 
(3 drops) and 10 mL of CH2Cl2. The mixture was then treated with oxalyl chloride (65 
µL, 0.75 mmol, 1.5 equiv) at 0 ̊C, stirred for 15 min, then warmed to room temperature 
and additionally stirred for 2 hours. The solvent was then removed in vacuum and the 
crude acyl chloride was dissolved in 10 mL of dry THF and added dropwise to a solution 
of 3-(benzylamino)-2,2-dimethylpropan-1-ol (116 mg, 0.6 mmol, 1.20 equiv) and triethyl 
amine (209 µL, 1.50 mmol, 3.00 equiv.) in 10 mL of THF. The reaction mixture was 
stirred overnight. After the reaction was complete, the solvent was removed in vacuum 
and the resulting residue was partitioned between 10 mL of EtOAc and 10 mL of water.  
The organic phase was separated; the aqueous layer was extracted with EtOAc (2 x 20 
mL). The combined organic phases were dried (MgSO4) and concentrated. The residue 
was filtered through a short plug of Silica gel, eluting with EtOAc to afford (1S,2R)-N-
benzyl-1-bromo-N-(3-hydroxy-2,2-dimethylpropyl)-2-methyl-2-phenylcyclopropane-1-
O
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carboxamide 145e as a colorless oil. Yield 90 mg (0.209 mmol, 54%), Rf 0.26 
(hexanes/EtOAc 5:1). The crude material was used without further purification. An oven‐
dried 10 mL Weaton vial was charged with obtained bromocyclopropane (90 mg, 0.209 
mmol, 1.0 equiv.), 18-crown‐6 (5.5 mg, 21 µmol, 10 mol%), t-BuOK (140 mg, 1.25 
mmol, 6.00 equiv), and anhydrous DMSO (6.0 mL). The reaction mixture was stirred 
overnight at 40 oC, and then the reaction mixture was poured into a separatory funnel and 
was partitioned between 10 mL of water and 100 mL of ethyl acetate. Organic layers 
were washed with water (3 x 10 mL) and brine (10 mL). Organic extract was dried over 
MgSO4, filtered and evaporated. Flash column chromatography on Silica gel afforded the 
title compound as a colorless oil. Rf 0.36 (hexanes/EtOAc 5:1).  Yield 27 mg (0.077 
mmol 37%), dr 1:0.  [α]D= -150.8° (c 0.240, CH2Cl2). 1H NMR (500 MHz, CDCl3) δ 
7.43–6.98 (m, 10H), 5.58 (d, J = 14.9 Hz, 1H), 3.88 (d, J = 15.6 Hz, 1H), 3.64 (dd, J = 
19.1, 8.0 Hz, 2H), 3.59–3.48 (m, 1H), 3.41 (d, J = 12.3 Hz, 1H), 2.83 (d, J = 15.6 Hz, 
1H), 1.99–1.69 (m, 1H), 1.44 (s, 3H), 1.14 (s, 3H), 0.72 (s, 3H); 13C NMR (126 MHz, 
CDCl3) δ 169.1, 145.8, 137.6, 128.7 (+, 2C), 128.6 (+, 2C), 128.2 (+, 2C), 127.8 (+, 2C), 
127.5 (+), 126.5 (+), 84.6 (-), 68.6 (+), 56.1 (-), 51.6 (-), 38.2, 31.6 (+), 29.3, 25.3(+), 
23.0(+), 17.9 (+); FT IR (KBr, cm-1): 3388, 2088, 1643, 1633, 1556, 1519, 1473, 1421, 
1394, 1355, 1282, 1265, 1249, 1228, 1207, 1143, 1093, 1081, 1062, 1027, 993, 700; 
HRMS (TOF ES): found 348.1963, calculated for C23H26NO2 (M-H) 348.1964 (0.3 ppm).  
 (1R,8R,9S)-6-benzyl-9-methyl-9-phenyl-2-oxa-6-
azabicyclo[6.1.0]nonan-7-one (147f):  
A flame dried 25 mL round-bottom flask equipped with a 
drying tube and magnetic stir bar was charged with 1-bromo-2-methyl-2-
O
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phenylcyclopropanecarboxylic acid (+)-136a (127.5 mg, 0.50 mmol, 1.00 equiv), DMF 
(3 drops) and 10 mL of CH2Cl2. The mixture was then treated with oxalyl chloride (65 
µL, 0.75 mmol, 1.5 equiv) at 0 ̊C, stirred for 15 min, then warmed to room temperature 
and additionally stirred for 2 hours. The solvent was then removed in vacuum and the 
crude acyl chloride was dissolved in 10 mL of dry THF and added dropwise to a solution 
2-ethyl-2-((methylamino)methyl)butan-1-ol (87 mg, 0.6 mmol, 1.20 equiv) and triethyl 
amine (209 µL, 1.50 mmol, 3.00 equiv.) in 10 mL of THF. The reaction mixture was 
stirred overnight. After the reaction was complete, the solvent was removed in vacuum 
and the resulting residue was partitioned between 10 mL of EtOAc and 10 mL of water.  
The organic phase was separated; the aqueous layer was extracted with EtOAc (2 x 20 
mL). The combined organic phases were dried (MgSO4) and concentrated. The residue 
was filtered through a short plug of Silica gel, eluting with EtOAc to afford (1S,2R)-1-
bromo-N-(2-ethyl-2-(hydroxymethyl)butyl)-N,2-dimethyl-2-phenylcyclopropane-1-
carboxamide 145f as a colorless oil. Yield 168 mg (0.44 mmol, 88%), Rf 0.34 
(hexanes/EtOAc 5:1). The crude material was used without further purification. An oven‐
dried 10 mL Weaton vial was charged with obtained bromocyclopropane (168 mg, 0.44 
mmol, 1.0 equiv.), 18-crown‐6 (11 mg, 44 µmol, 10 mol%), t-BuOK (299 mg, 2.64 
mmol, 6.00 equiv), and anhydrous DMSO (10.0 mL). The reaction mixture was stirred 
overnight at 40 oC, and then the reaction mixture was poured into a separatory funnel and 
was partitioned between 10 mL of water and 100 mL of ethyl acetate. Organic layers 
were washed with water (3 x 10 mL) and brine (10 mL). Organic extract was dried over 
MgSO4, filtered and evaporated. Flash column chromatography on Silica gel afforded the 
title compound as a colorless oil. Rf 0.22 (hexanes/EtOAc 5:1).  Yield 41 mg (0.136 
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mmol 31%), dr 3:1.  [α]D= -8.6° (c 0.30, CH2Cl2). 1H NMR (500 MHz, CDCl3) δ 7.30 
(dd, J = 8.2, 1.2 Hz, 2H), 7.22 (dd, J = 10.7, 4.6 Hz, 2H), 7.15–7.09 (m, 1H), 4.03 (d, J = 
15.4 Hz, 1H), 3.90 (dd, J = 12.6, 1.8 Hz, 1H), 3.54 (d, J = 6.2 Hz, 1H), 3.22 (dd, J = 12.6, 
0.9 Hz, 1H), 2.95 (s, 3H), 2.88 (dd, J = 15.4, 1.9 Hz, 1H), 1.76 (d, J = 6.2 Hz, 1H), 1.61 
(ddd, J = 20.2, 13.8, 6.3 Hz, 1H), 1.37 (s, 3H), 1.32–1.24 (m, 1H), 1.06 (dt, J = 14.8, 7.4 
Hz, 1H), 0.97 (ddd, J = 21.5, 11.2, 5.0 Hz, 1H), 0.80 (td, J = 7.4, 2.5 Hz, 6H); 13C NMR 
(126 MHz, CDCl3) δ 169.1, 146.0, 128.6 (+, 2C), 127.9 (+, 2C), 126.5 (+), 78.9 (-), 68.6 
(+), 58.2 (-), 42.8, 38.4 (+), 31.4 (+), 25.4 (-), 22.3 (-), 17.8, 7.6 (+), 6.9 (+); FT IR (KBr, 
cm-1): 2964, 2933, 2088, 1633, 1382, 1271, 1242, 1195, 1143, 869, 796, 761, 700, 648, 
615; HRMS (TOF ES): found 301.2041, calculated for C19H27NO2 (M+) 301.2042 (0.3 
ppm).  
(1S,1aR,9aR)-3-benzyl-1-methyl-1-phenyl-
1a,3,4,9a-tetrahydrobenzo[b]cyclopropa[g][1,5]oxazocin-
2(1H)-one (147o): 
A solution of Me3SiCl (76.5 µL, 0.6 mmol, 1.20 
equiv), NEt3 (244 µL, 1.75 mmol, 3.5 equiv), and 2-((benzylamino)methyl)phenol (98 
mg, 0.55 mmol, 1.10 equiv) was stirred in dry THF (10 mL) overnight under a nitrogen 
atmosphere. Then 2-bromocyclopropanecarbonyl chloride obtained according to a typical 
protocol from 1-bromo-2-methyl-2-phenylcyclopropanecarboxylic acid (+)-136a (127.5 
mg, 0.50 mmol, 1.00 equiv), was added and allowed to stir for 3 hours.  The solvent was 
removed by rotary evaporation and then partitioned between 10 mL 5% HCl & 10 mL 
EtOAc.  The organic layer was washed with 5% HCl (3 x 15 mL) then dried with 
MgSO4, filtered, and concentrated which afforded (1S,2R)-N-benzyl-1-bromo-N-(2-
O
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hydroxybenzyl)-2-methyl-2-phenylcyclopropane-1-carboxamide 145o as a viscous oil Rf 
0.5 (hexanes/EtOAc 5:1). The obtained material was pure enough for the following 
transformation with no additional purification.  Yield 191 mg (0.46 mmol, 92%). An 
oven‐dried 10 mL Weaton vial was charged with obtained bromocyclopropane (191 mg, 
0.46 mmol, 1.0 equiv.), 18-crown‐6 (12 mg, 46 µmol, 10 mol%), t-BuOK (309 mg, 2.76 
mmol, 6.00 equiv), and anhydrous DMSO (10.0 mL). The reaction mixture was stirred 
overnight at 40 oC, and then the reaction mixture was poured into a separatory funnel and 
was partitioned between 10 mL of water and 100 mL of ethyl acetate. Organic layers 
were washed with water (3 x 10 mL) and brine (10 mL). Organic extract was dried over 
MgSO4, filtered and evaporated. Flash column chromatography on Silica gel afforded the 
title compound as a colorless oil. Rf 0.28 (hexanes/EtOAc 5:1).  Yield 88 mg (0.244 
mmol 31%), dr 1:0.  [α]D= -229.7° (c 0.40, CH2Cl2). 1H NMR (500 MHz, CDCl3) δ 7.44 
(dd, J = 8.3, 1.2 Hz, 2H), 7.39–7.20 (m, 9H), 7.12 (dd, J = 8.1, 1.0 Hz, 1H), 7.05–6.93 
(m, 2H), 5.45 (d, J = 16.4 Hz, 1H), 5.17 (d, J = 14.7 Hz, 1H), 4.00 (d, J = 6.0 Hz, 1H), 
3.81 (dd, J = 29.3, 15.6 Hz, 2H), 2.44 (d, J = 5.9 Hz, 1H), 1.71 (s, 3H); 13C NMR (126 
MHz, CDCl3) δ 168.0, 157.1, 145.3, 137.4, 131.3 (+), 129.5 (+), 128.8 (+, 2C), 128.7 (+, 
2C), 128.6 (+, 2C), 128.0 (+, 2C), 127.6 (+), 126.9 (+), 125.9, 123.3 (+), 121.7 (+), 63.7 
(+), 50.0 (-), 47.9 (-), 32.0 (+), 30.7, 16.9 (+); FT IR (KBr, cm-1): 2972, 1649, 1604, 
1488, 1429, 1269, 1224, 1209, 858, 823, 796, 761, 736, 700, 648, 617; HRMS (TOF ES): 
found 369.1731, calculated for C25H23NO2 (M+) 369.1729 (0.5 ppm).  
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  (1R,9R,10S)-7-benzyl-10-methyl-10-phenyl-2-oxa-7-
azabicyclo[7.1.0]decan-8-one (147c): A flame dried 25 mL round-
bottom flask equipped with a drying tube and magnetic stir bar was 
charged with 1-bromo-2-methyl-2-phenylcyclopropanecarboxylic acid (+)-136a (127.5 
mg, 0.50 mmol, 1.00 equiv), DMF (3 drops) and 10 mL of CH2Cl2. The mixture was then 
treated with oxalyl chloride (65 µL, 0.75 mmol, 1.5 equiv) at 0 ̊C, stirred for 15 min, then 
warmed to room temperature and additionally stirred for 2 hours. The solvent was then 
removed in vacuum and the crude acyl chloride was dissolved in 10 mL of dry THF and 
added dropwise to a solution 4-(benzylamino)butan-1-ol (107 mg, 0.6 mmol, 1.20 equiv) 
and triethyl amine (209 µL, 1.50 mmol, 3.00 equiv.) in 10 mL of THF. The reaction 
mixture was stirred overnight. After the reaction was complete, the solvent was removed 
in vacuum and the resulting residue was partitioned between 10 mL of EtOAc and 10 mL 
of water.  The organic phase was separated; the aqueous layer was extracted with EtOAc 
(2 x 20 mL). The combined organic phases were dried (MgSO4) and concentrated. The 
residue was filtered through a short plug of Silica gel, eluting with EtOAc to afford 
(1S,2R)-N-benzyl-1-bromo-N-(4-hydroxybutyl)-2-methyl-2-phenylcyclopropane-1-
carboxamide 145c as a colorless oil. Yield 155 mg (0.37 mmol, 74%), Rf 0.37 
(hexanes/EtOAc 1:1). The crude material was used without further purification. An oven‐
dried 10 mL Weaton vial was charged with obtained bromocyclopropane (155 mg, 0.37 
mmol, 1.0 equiv.), 18-crown‐6 (10 mg, 37 µmol, 10 mol%), t-BuOK (250 mg, 2.22 
mmol, 6.00 equiv), and anhydrous DMSO (10.0 mL). The reaction mixture was stirred 
overnight at 40 oC, and then the reaction mixture was poured into a separatory funnel and 
O
N
O
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was partitioned between 10 mL of water and 100 mL of ethyl acetate. Organic layers 
were washed with water (3 x 10 mL) and brine (10 mL). Organic extract was dried over 
MgSO4, filtered and evaporated. Flash column chromatography on Silica gel afforded the 
title compound as a colorless oil. Rf 0.36 (hexanes/EtOAc 3:1).  Yield 26 mg (0.077 
mmol 21%), dr 1:0.  [α]D= -27.7° (c 0.36, CH2Cl2). 1H NMR (500 MHz, CDCl3) δ 7.52 – 
6.94 (m, 10H), 5.35 (d, J = 14.7 Hz, 1H), 4.29 (dd, J = 12.8, 7.5 Hz, 1H), 4.23–4.11 (m, 
1H), 3.86 (d, J = 14.7 Hz, 1H), 3.52 (d, J = 6.4 Hz, 1H), 3.42 (ddd, J = 12.8, 7.8, 1.0 Hz, 
1H), 3.17 (ddd, J = 14.8, 4.9, 1.7 Hz, 1H), 1.96 (d, J = 6.4 Hz, 1H), 2.00–1.87 (m, 1H), 
1.81 (ddd, J = 15.0, 7.3, 3.6 Hz, 1H), 1.61 (s, 3H), 1.59–1.49 (m, 1H), 1.46–1.33 (m, 1H); 
13C NMR (126 MHz, CDCl3) δ 168.3, 146.6, 137.7, 128.7 (+, 2C), 128.6 (+, 2C), 128.5 
(+, 2C), 127.9 (+, 2C), 127.4 (+), 126.5 (+), 72.2 (-), 66.7 (+), 45.8 (-), 43.5 (-), 31.4 (+), 
29.9, 27.6 (-), 25.0 (-), 17.3 (+); FT IR (KBr, cm-1): 2927, 1643, 1633, 1444, 1429, 1151, 
1091, 810, 763, 734, 700, 648, 599, 559; HRMS (TOF ES): found 334.1807, calculated 
for C22H24NO2 (M-H) 334.1807 (1.5 ppm).  
(1S,8S,9R)-6-benzyl-9-ethyl-9-phenyl-2-oxa-6-
azabicyclo[6.1.0]nonan-7-one (147k):  
A flame dried 25 mL round-bottom flask equipped with a 
drying tube and magnetic stir bar was charged with 1-bromo-2-methyl-2-
phenylcyclopropanecarboxylic acid (-)-136f (134.5 mg, 0.50 mmol, 1.00 equiv), DMF (3 
drops) and 10 mL of CH2Cl2. The mixture was then treated with oxalyl chloride (65 µL, 
0.75 mmol, 1.5 equiv) at 0 ̊C, stirred for 15 min, then warmed to room temperature and 
additionally stirred for 2 hours. The solvent was then removed in vacuum and the crude 
acyl chloride was dissolved in 10 mL of dry THF and added dropwise to a solution of 3-
O
N
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(benzylamino)propan-1-ol (99 mg, 0.6 mmol, 1.20 equiv) and triethyl amine (209 µL, 
1.50 mmol, 3.00 equiv.) in 10 mL of THF. The reaction mixture was stirred overnight. 
After the reaction was complete, the solvent was removed in vacuum and the resulting 
residue was partitioned between 10 mL of EtOAc and 10 mL of water.  The organic 
phase was separated; the aqueous layer was extracted with EtOAc (2 x 20 mL). The 
combined organic phases were dried (MgSO4) and concentrated. The residue was filtered 
through a short plug of Silica gel, eluting with EtOAc to afford (1R,2S)-N-benzyl-1-
bromo-2-ethyl-N-(3-hydroxypropyl)-2-phenylcyclopropane-1-carboxamide 145k as a 
colorless oil. Yield 200 mg (0.48 mmol, 96%), Rf 0.30 (hexanes/EtOAc 2:1). The crude 
material was used without further purification. An oven‐dried 10 mL Weaton vial was 
charged with obtained bromocyclopropane (200 mg, 0.48 mmol, 1.0 equiv.), 18-crown‐
6 (12.7 mg, 48 µmol, 10 mol%), t-BuOK (324 mg, 2.88 mmol, 6.00 equiv), and 
anhydrous DMSO (10.0 mL). The reaction mixture was stirred overnight at 40 oC, and 
then the reaction mixture was poured into a separatory funnel and was partitioned 
between 10 mL of water and 100 mL of ethyl acetate. Organic layers were washed with 
water (3 x 10 mL) and brine (10 mL). Organic extract was dried over MgSO4, filtered and 
evaporated. Flash column chromatography on Silica gel afforded the title compound as a 
colorless oil. Rf 0.38 (hexanes/EtOAc 3:1).  Yield 127 mg (0.379 mmol 79%), dr 1:0.  
[α]D= +9.1° (c 0.780, CH2Cl2). 1H NMR (500 MHz, CDCl3) δ 7.60–7.04 (m, 10H), 5.28 
(d, J = 14.7 Hz, 1H), 4.23 (dd, J = 12.6, 5.3 Hz, 1H), 3.99 (d, J = 14.8 Hz, 1H), 3.99–3.92 
(m, 1H), 3.77–3.62 (m, 2H), 3.23 (dd, J = 15.5, 7.2 Hz, 1H), 2.12–1.93 (m, 2H), 1.88 (d, 
J = 6.2 Hz, 1H), 1.77 (dq, J = 14.6, 7.3 Hz, 1H), 1.64 (ddd, J = 15.0, 6.6, 1.9 Hz, 1H), 
0.88 (t, J = 7.4 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 168.2, 143.9, 137.8, 129.4 (+, 
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2C), 128.7 (+, 2C), 128.4 (+, 2C), 128.4 (+, 2C), 127.5 (+), 126.6 (+), 72.9 (-), 68.3 (+), 
48.8 (-), 46.3 (-), 35.2, 32.4 (+), 30.6 (-), 24.9 (-), 11.4 (+); FT IR (KBr, cm-1): 3056, 
2966, 2935, 1633, 1477, 1421, 1357, 1265, 1247, 1357, 1265, 1247, 1220, 114, 1105, 
1014, 935, 887, 763, 736, 702, 682, 659, 617, 595; HRMS (TOF ES): found 335.1891, 
calculated for C22H25NO2 (M+) 335.1885 (1.8 ppm).  
(1R,8R,9S)-6-benzyl-9-methyl-9-(naphthalen-2-yl)-
2-oxa-6-azabicyclo[6.1.0]nonan-7-one (147m): 
A flame dried 25 mL round-bottom flask equipped 
with a drying tube and magnetic stir bar was charged with 1-bromo-2-methyl-2-
phenylcyclopropanecarboxylic acid (+)-136g (88 mg, 0.20 mmol, 1.00 equiv), DMF (3 
drops) and 3 mL of CH2Cl2. The mixture was then treated with oxalyl chloride (26 µL, 
0.30 mmol, 1.5 equiv) at 0 ̊C, stirred for 15 min, then warmed to room temperature and 
additionally stirred for 2 hours. The solvent was then removed in vacuum and the crude 
acyl chloride was dissolved in 10 mL of dry THF and added dropwise to a solution of 3-
(benzylamino)propan-1-ol (40 mg, 0.24 mmol, 1.20 equiv) and triethyl amine (84 µL, 
0.60 mmol, 3.00 equiv.) in 10 mL of THF. The reaction mixture was stirred overnight. 
After the reaction was complete, the solvent was removed in vacuum and the resulting 
residue was partitioned between 10 mL of EtOAc and 10 mL of water.  The organic 
phase was separated; the aqueous layer was extracted with EtOAc (2 x 10 mL). The 
combined organic phases were dried (MgSO4) and concentrated. The residue was filtered 
through a short plug of Silica gel, eluting with EtOAc to afford (1S,2R)-N-benzyl-1-
bromo-N-(3-hydroxypropyl)-2-methyl-2-(naphthalen-2-yl)cyclopropane-1-carboxamide 
145m as a colorless oil. Yield 70 mg (0.155 mmol, 78%), Rf 0.28 (hexanes/EtOAc 3:1). 
O
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The crude material was used without further purification. An oven‐dried 10 mL Weaton 
vial was charged with obtained bromocyclopropane (70 mg, 0.155 mmol, 1.0 equiv.), 18-
crown‐6 (4.1 mg, 48 µmol, 10 mol%), t-BuOK (113 mg, 2.88 mmol, 6.00 equiv), and 
anhydrous DMSO (4.0 mL). The reaction mixture was stirred overnight at 40 oC, and 
then the reaction mixture was poured into a separatory funnel and was partitioned 
between 10 mL of water and 100 mL of ethyl acetate. Organic layers were washed with 
water (3 x 10 mL) and brine (10 mL). Organic extract was dried over MgSO4, filtered and 
evaporated. Flash column chromatography on Silica gel afforded the title compound as a 
colorless oil. Rf 0.27 (hexanes/EtOAc 3:1).  Yield 28 mg (0.076 mmol 49%), dr 1:0.  
[α]D= +25.8° (c 0.60, CH2Cl2). 1H NMR (500 MHz, CDCl3) δ 7.81 (ddd, J = 7.8, 7.1, 2.0 
Hz, 4H), 7.57 (dd, J = 8.5, 1.8 Hz, 1H), 7.51–7.41 (m, 2H), 7.35 (d, J = 4.4 Hz, 4H), 
7.32–7.27 (m, 1H), 5.27 (dd, J = 14.7, 0.7 Hz, 1H), 4.25 (dd, J = 12.6, 5.2 Hz, 1H), 4.05 
(d, J = 14.8 Hz, 1H), 4.06–3.98 (m, 1H), 3.78 (dd, J = 12.7, 3.1 Hz, 1H), 3.74 (d, J = 6.3 
Hz, 1H), 3.27 (dd, J = 15.5, 7.2 Hz, 1H), 2.05 (d, J = 6.2 Hz, 1H), 2.04 (dd, J = 10.4, 7.6 
Hz, 1H), 1.66 (ddd, J = 13.2, 5.6, 1.8 Hz, 1H), 1.60 (s, 3H); 13C NMR (126 MHz, CDCl3) 
δ 168.2, 143.4, 137.8, 133.6, 132.3, 128.7 (+, 2C), 128.5 (+, 2C), 127.8 (+), 127.7 (+), 
127.5 (+), 126.6 (+), 126.2 (+), 125.8 (+), 72.8 (-), 68.5 (+), 49.0 (-), 46.5 (-), 31.5 , 30.6 
(+), 30.4 (-), 17.9 (+); FT IR (KBr, cm-1): 3058, 1633, 1475, 1421, 1261, 858, 819, 748, 
734, 702, 676, 659, 648, 609; HRMS (TOF ES): found 372.1966, calculated for 
C25H26NO2 (M+H) 372.1964 (0.5 ppm).  
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Appendix 
A1. 1H and 13C Specta for 121aa 
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A2. 1H and 13C Specta for 117da 
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A3. NOE Data for 117da 
Figure	  8. 1D NOEDIFF spectra of xx. Chemical shifts of the irradiated multiplets are listed at the 
right side of each chart. 
	  
	  
Figure	  9	  Observed NOEs upon irradiation at 3.36 ppm (green), 1.32 ppm (teal), 1.77 ppm 
(purple) for compound xx. For color-coded spectral charts corresponding to these 
experiments, see Figure 8.	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A4. NOE Data for 147o 
Figure	  101D NOEDIFF spectra of 147o. Chemical shifts of the irradiated multiplets are listed at 
the right side of each chart.
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Figure	  11	  Observed NOEs upon irradiation at 1.71 ppm (red), 2.44 ppm (green), , 4.00 
ppm (blue), 5.17 ppm (purple), 5.45 ppm (brown) for compound 147o. For color-coded 
spectral charts corresponding to these experiments, see Figure 10.	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A5. 1H and 13C Specta for 147k 
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A6. Crystallographic Data for 121bk 
Figure	  12	  ORTEP	  drawing	  of	  cyclopropylazole	  121bk	  molecule,	  showing	  the	  atom	  
numbering	  scheme;	  50%	  probability	  amplitude	  displacement	  ellipsoids	  are	  shown.	  
	  
	  
Figure	  13	  Packing	  of	  121bk	  molecules	  in	  the	  crystalline	  lattice	  cell.	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A7. Crystallographic Data for 134aaf 
Figure	  14	  ORTEP	  drawing	  of	  cyclopropylazole	  134aaf	  molecule,	  showing	  the	  atom	  
numbering	  scheme;	  50%	  probability	  amplitude	  displacement	  ellipsoids	  are	  shown.	  
	  
 
Figure	  15	  Packing	  of	  134aaf	  molecules	  in	  the	  crystalline	  lattice	  cell	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A8. Crystallographic Data for (-)-136aCD 
Figure	  16	  ORTEP	  drawing	  of	  cyclopropylazole	  (-­‐)-­‐136aCD	  molecule,	  showing	  the	  atom	  
numbering	  scheme;	  50%	  probability	  amplitude	  displacement	  ellipsoids	  are	  shown.	  
	  
Figure	  17	  Packing	  of	  (-­‐)-­‐136aCD	  molecules	  in	  the	  crystalline	  lattice	  cell	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A9. Crystallographic Data for (-)-136bCD 
Figure	  18	  ORTEP	  drawing	  of	  cyclopropylazole	  (-­‐)-­‐136bCD	  molecule,	  showing	  the	  atom	  
numbering	  scheme;	  50%	  probability	  amplitude	  displacement	  ellipsoids	  are	  shown	  
	  
	  
Figure	  19	  Packing	  of	  (-­‐)-­‐136bCD	  molecules	  in	  the	  crystalline	  lattice	  cell	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A10. Crystallographic Data for (+)-132ac 
	  
Figure	  20	  ORTEP	  drawing	  of	  cyclopropylazole	  (+)-­‐132ac	  molecule,	  showing	  the	  atom	  
numbering	  scheme;	  50%	  probability	  amplitude	  displacement	  ellipsoids	  are	  shown	  
	  
	  
Figure	  21	  Packing	  of	  (+)-­‐132ac	  molecules	  in	  the	  crystalline	  lattice	  cell	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A11. Crystallographic Data for 134baa 
	  
Figure	  22	  ORTEP	  drawing	  of	  cyclopropylazole	  134baa	  molecule,	  showing	  the	  atom	  
numbering	  scheme;	  50%	  probability	  amplitude	  displacement	  ellipsoids	  are	  shown	  
	  
	  
Figure	  23	  Packing	  of	  134baa	  molecules	  in	  the	  crystalline	  lattice	  cell	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